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ABSTRACT	Although	 reductions	 in	 cerebral	blood	 flow	 (CBF)	may	be	 implicated	 in	 the	development	of	central	 fatigue	during	environmental	stress,	 the	contribution	 from	hypocapnia-induced	reductions	in	CBF	versus	reductions	in	CBF	per	se	has	yet	to	be	isolated.	 The	 current	 research	 program	 examined	 the	 influence	 of	 CBF,	 with	 and	without	 consequent	hypocapnia,	 on	neuromuscular	 responses	during	hypoxia	 and	passive	 heat	 stress.	 To	 this	 end,	 neuromuscular	 responses,	 as	 indicated	 by	motor	evoked	potentials	(MEP),	maximal	M-wave	(Mmax)	and	cortical	voluntary	activation	(cVA)	of	the	flexor	carpi	radialis	muscle	during	isometric	wrist	flexion,	was	assessed	in	three	separate	projects:	1)	hypocapnia,	independent	of	concomitant	reductions	in	CBF;	 2)	 altered	 CBF	 during	 severe	 hypoxia	 and;	 3)	 thermal	 hyperpnea-mediated	reductions	in	CBF,	independent	of	hypocapnia.	All	projects	employed	a	custom-built	dynamic	end-tidal	forcing	system	to	control	end-tidal	PCO2	(PETCO2),	independent	of	the	 prevailing	 environmental	 conditions,	 and	 cyclooxygenase	 inhibition	 using	indomethacin	 (Indomethacin,	 1.2	 mg·Kg-1)	 to	 selectively	 reduce	 CBF	 (estimated	using	 transcranial	 Doppler	 ultrasound)	 without	 changes	 in	 PETCO2.	 A	 primary	finding	of	the	present	research	program	is	that	the	excitability	of	the	corticospinal	tract	is	inherently	sensitive	to	changes	in	PaCO2,	as	demonstrated	by	a	12%	increase	in	MEP	amplitude	 in	response	 to	moderate	hypocapnia.	Conversely,	CBF	mediated	reductions	 in	 cerebral	O2	delivery	 appear	 to	decrease	 corticospinal	 excitability,	 as	indicated	by	a	51-64%	and	4%	decrease	 in	MEP	amplitude	in	response	to	hypoxia	and	 passive	 heat	 stress,	 respectively.	 The	 collective	 evidence	 from	 this	 research	program	suggests	 that	 impaired	voluntary	activation	 is	associated	with	reductions	in	CBF;	however,	it	must	be	noted	that	changes	in	cVA	were	not	linearly	correlated	with	changes	in	CBF.	Therefore,	other	factors	independent	of	CBF,	such	as	increased	perception	of	effort,	distress	or	discomfort,	may	have	contributed	to	the	reductions	in	 cVA.	 Despite	 the	 functional	 association	 between	 reductions	 in	 CBF	 and	hypocapnia,	 both	 variables	 have	 distinct	 and	 independent	 influence	 on	 the	neuromuscular	system.	Therefore,	future	studies	should	control	or	acknowledge	the	separate	mechanistic	influence	of	these	two	factors.	 	
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GLOSSARY	
Central	nervous	system	(CNS)	—	Nerve	 tissues	 that	controls	 the	activities	of	 the	body,	comprises	the	brain	and	the	spinal	cord.		
Cortical	 silent	 period	 (cSP)	—	 Interruption	 of	 voluntary	 muscle	 contraction	 by	transcranial	stimulation	of	the	contralateral	motor	cortex.		
Cortical	voluntary	activation	(cVA)	—	The	percentage	of	motor	units	that	can	be	activated	by	the	brain	during	a	voluntary	muscle	contraction,	assessed	using	transcranial	magnetic	stimulation	of	the	motor	cortex.	
End-tidal	partial	pressure	—	The	partial	pressure	of	respiratory	gas	at	the	end	of	the	exhaled	breath	(exhalation).		
End-Tidal	Forcing	—	A	technique	in	which	the	delivery	of	inspired	compressed	gas	mixtures	 (O2,	N2,	CO2)	are	delivered	 to	a	participant	based	on	an	algorithm	designed	 “force”	 end-tidal	 partial	 pressure	 of	 respiratory	 gases	 (PETO2	 and	PETCO2)	to	a	desired	level.	
Hyperpnea	—	Increased	depth	of	breathing.	
Hyperthermia	—	Increased	body	core	temperature.	
Hypocapnia	—	The	state	of	reduced	carbon	dioxide	in	the	arterial	blood.	Typically	estimated	using	measurements	of	end-tidal	PCO2.	
Hypoxia	—	The	state	of	 reduced	oxygen	 in	 the	arterial	blood.	Typically	estimated	using	measurements	of	end-tidal	PO2.		
Indomethacin	—	 A	 non-steroidal	 anti-inflammatory	 drug	 that	 is	 used	 to	 reduce	cerebral	 blood	 flow	 independent	 of	 arterial	 gas	 concentration.	 The	mechanism	of	action	is	blocking	prostaglandin	via	non-selective	inhibition	of	cyclooxygenase	enzymes.	
Isocapnia	—	A	state	in	which	the	arterial	carbon	dioxide	pressure	remains	constant	or	unchanged.	
		 xiv	
Maximal	voluntary	contraction	(MVC)	—	The	maximum	torque	produced	during	a	voluntary	contraction.		
Motor	 evoked	 potential	 (MEP)	 —	 The	 electromyography	 response	 of	 the	peripheral	muscle	 to	 transcranial	magnetic	stimulation	of	 the	motor	cortex.	Representative	of	the	excitability	cortico-spinal	tract.		
Mwave	—	The	 electromyography	 response	 of	 the	 peripheral	muscle	 in	 response	 to	supra-maximal	 electrical	 stimulation	 of	 the	 peripheral	 motor	 nerve.	Representative	of	the	excitability	of	the	motor	neuron	pool.	
Peripheral	voluntary	activation	(pVA)	—	The	percentage	of	motor	units	that	cant	be	 activated	 by	 the	 brain	 during	 a	 voluntary	 muscle	 contraction,	 assessed	using	electrical	stimulation	of	the	peripheral	motor	nerve.	
Poikilocapnia	—	The	state	in	which	arterial	carbon	dioxide	pressure	is	allowed	to	vary	naturally.		
Resting	motor	threshold	(RMT)	—	The	 lowest	 transcranial	magnetic	stimulation	intensity	 required	 to	 elicit	 a	motor	 evoked	potential	 of	 at	 least	 0.05	mV	 in	peak-to-peak	amplitude,	in	at	least	one	half	of	a	given	number	of	stimuli	in	a	relaxed	muscle.		
Transcranial	Doppler	ultrasound	(TCD)	—	A	non-invasive	technique	that	uses	a	pulsed	 Doppler	 transduced	 for	 assessing	 intracranial	 cerebral	 blood	 flow	velocity.			
Transcranial	 Magnetic	 Stimulator	 (TMS)	 —	 A	 non-invasive	 technique	 used	 to	stimulate	small	regions	of	the	motor	cortex	using	a	magnetic	field	generator	(i.e.,	a	coil).	
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Environmental	stress,	such	as	high	ambient	temperature	(hyperthermia)	and	low	 oxygen	 availability	 (hypoxia),	 has	 been	 associated	 with	 impaired	neuromuscular	 response;	 however,	 the	 mechanisms	 associated	 with	 these	decrements	 and	 their	 potential	 synergies	 remain	 unclear.	 While	 the	 majority	 of	research	suggests	that	the	observed	fatigue	is	related	to	the	central	nervous	system,	the	 influence	 of	 changes	 in	 cerebral	 blood	 flow	 (CBF)	 and	 associated	 changes	 in	arterial	 PCO2	 (PaCO2)	 remains	 unexamined.	 In	 response	 to	 hyperthermia,	 humans	hyperventilate	as	means	of	heat	dissipation,	resulting	in	hyperventilation-mediated	hypocapnia	 and	 subsequent	 decrease	 in	 CBF.	 Likewise,	 during	 periods	 of	 hypoxic	stress,	 humans	 hyperventilate	 to	 maintain	 oxygen	 consumption,	 resulting	 in	 a	similar	 hyperventilation-mediated	 hypocapnia	 and	 blunting	 of	 the	 cerebral	vasodilator	 effect	 of	 reduced	 arterial	 PO2	 (PaO2).	 Previous	 research	 suggests	 that	hyperventilation	 induces	 changes	 in	neural	 excitability	 and	 synaptic	 transmission;	however,	 it	 remains	 unclear	 if	 these	 changes	 are	 related	 to	 hypocapnia	mediated	decrease	in	CBF	or	PaCO2	or	both.	The	purpose	of	the	proposed	research	program	is	to	examine	the	individual	and	 synergistic	 influences	 of	 CBF	 and	 PaCO2	 on	 neuromuscular	 responses.	Furthermore,	 a	 secondary	 purpose	 is	 to	 examine	 whether	 hypoxia	 and	hyperthermia	 both	 affect	 neuromuscular	 responses	 primarily	 by	 the	 similar	mechanism	of	CBF/	PaCO2	 alteration,	 or	 factors	 specific	 to	hypoxia	 and	 specific	 to	hyperthermia.	 The	 research	 program	 will	 consist	 of	 3	 separate	 projects,	summarized	 below	 in	 Table	 3-1	 outlining	 the	 proposed	 protocols	 and	 resultant	physiological	manipulations.	 During	 each	manipulation,	 neuromuscular	 responses	
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will	 be	 evaluated	 and	 compared	 to	 baseline	 (normoxic/normothermic)	 conditions	using	a	repeated	measures	design.	All	 projects	 will	 use	 an	 indomethacin	 and	 end-tidal	 PCO2	 (PETCO2)	manipulation	 to	 independently	 control	 CBF	 and	 PETCO2.	 Indomethacin	 is	 a	 non-steroidal	 anti-inflammatory	drug	 that	 causes	a	30%	reduction	 in	CBF	without	any	changes	 in	 cerebral	metabolism	 or	 pH,	making	 it	 an	 ideal	 tool	 for	 evaluating	 CBF	independent	 of	 confounders,	 such	 as	 environmental	 stress.	 PETCO2	manipulations,	via	 controlled	 hyperventilation	 or	 dynamic	 end-tidal	 forcing	 (a	 process	 in	 which	isocapnia	 is	 achieved	 by	 adjusting	 inspired	 PCO2	 such	 that	 end-tidal	 gas	concentrations	remain	constant),	allows	for	control	of	CBF	and	PaCO2	 independent	of	hypoxia	or	hyperthermia	induced	hyperventilation.			 	
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2 REVIEW	OF	LITERATURE		 	
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Environmental	 stress,	 such	 as	 high	 ambient	 temperature	 (Morrison	 et	 al.	2004;	 Morrison	 et	 al.	 2009;	 Ross	 et	 al.	 2012;	 Todd	 et	 al.	 2005)	 and	 low	 oxygen	availability	 (Garner	 et	 al.	 1990;	 Szubski	 et	 al.	 2007),	 has	 been	 associated	 with	impaired	neuromuscular	response;	however,	the	mechanisms	associated	with	these	decrements	 and	 their	 potential	 synergies	 remain	 unclear.	 While	 the	 majority	 of	research	suggests	that	the	observed	fatigue	is	related	to	the	central	nervous	system	(Amann	et	al.	2006;	Millet	et	al.	2009;	Peltonen	et	al.	1997),	the	influence	of	changes	in	 cerebral	 blood	 flow	 (CBF)	 and	 subsequent	 changes	 in	 cerebral	 pH	 remains	unexamined.	In	response	to	hyperthermia,	humans	hyperventilate	as	means	of	heat	dissipation,	 resulting	 in	 a	 hypocapnia	mediated	 decrease	 in	 CBF.	 Likewise	 during	periods	of	hypoxic	stress,	humans	hyperventilate	to	maintain	oxygen	consumption,	resulting	 in	 a	 similar	 hypocapnia	 mediated	 decrease	 in	 CBF.	 Previous	 research	suggests	 that	 hyperventilation	 induces	 changes	 in	 neural	 excitability	 and	 synaptic	transmission	(Sparing	et	al.	2007);	however,	it	remains	unclear	if	these	changes	are	related	to	hypocapnia	mediated	decrease	in	CBF	or	PaCO2	or	both.	The	focus	of	this	literature	review	is	to	summarize	the	present	knowledge	of	neuromuscular	impairment	during	environmental	stress,	with	a	particular	focus	on	the	role	of	CBF.	Specifically,	the	literature	review	will	examine	CBF,	the	mechanisms	of	 regulation	 and	 measurement	 considerations;	 cerebral,	 cardiorespiratory	 and	peripheral	 tissue	 effects	 of	 hypoxia;	 the	 anatomy	 and	 associated	 models	 of	thermoregulation;	 cardiovascular,	 central	 and	 peripheral	 effects	 of	 hyperthermia;	and	physiological	and	methodological	principles	of	electromyography.	
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2.1 Cerebral	blood	flow	The	regulation	of	CBF	is	required	to	maintain	normal	brain	and	consequently,	systemic	 function.	 Emphasizing	 the	 importance	 of	 adequate	 CBF	 is	 the	disproportionate	 metabolic	 rate	 and	 therefore,	 distribution	 of	 cardiac	 output	towards	cerebral	tissue.	Specifically,	cerebral	tissue	receives	approximately	15%	of	total	 cardiac	 output	 and	 represents	 approximately	 20%	 of	 overall	 oxygen	consumption;	 however,	 only	 represents	 2-3%	 of	 total	 body	 mass.	 The	 following	section	 will	 focus	 on	 the	 mechanisms	 of	 CBF	 regulation	 and	 a	 discussion	 of	 CBF	measurement	considerations.		
2.1.1 Mechanisms	of	regulation	Cerebral	 hemodynamics	 is	 tightly	 controlled	 by	 a	 variety	 of	 mechanisms,	with	the	ultimate	goal	of	providing	adequate	supply	of	oxygen	and	other	nutrients	to	the	local	tissue	without	causing	over	perfusion	of	the	sensitive	cerebral	vasculature.	Although	 cerebral	 vasomotor	 activity	 is	 highly	 sensitive	 to	 arterial	 blood	 gases,	specifically	 the	 partial	 pressure	 of	 carbon	 dioxide	 (PCO2),	 other	 factors	 such	 as	cerebral	auto-regulation,	sympathetic	nerve	activity,	cerebral	metabolism,	systemic	factors	 (cardiac	 output,	 heart	 rate	 and	 blood	 pressure)	 and	 pharmacological	supplementation	will	influence	CBF	as	well.	
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	Figure	2-1.	Schematic	of	cerebral	blood	flow	control	(Ainslie	&	Duffin	2009).	The	influence	of	PCO2	on	CBF	has	been	well	established	and	the	importance	of	this	homeostatic	control	is	tightly	linked	with	cerebral	pH,	central	chemoreceptor	stimulus	and	consequently,	ventilatory	control.	Hypercapnia	triggers	vasodilation	of	the	 cerebral	 vasculature,	 causing	 concomitant	 increases	 in	 CBF	 and	 subsequent	washout	 of	 carbon	dioxide	 (CO2)	 from	 cerebral	 tissue.	 In	 response	 to	 hypocapnia,	CBF	decreases	 as	 a	 consequence	of	 cerebral	 vasoconstriction,	 thereby	 slowing	 the	rate	 of	%&'	washout	 and	maintenance	of	 cerebral	 pH	 (Ainslie	&	Duffin	2009).	The	mechanisms	 involved	 in	 CO2-mediated	 cerebral	 vasomotor	 activity	 are	 linked	 to	activation	of	potassium	(K+)	channels	in	vascular	smooth	muscle.	It	is	suggested	that	ATP-sensitive	 K+	 and	 voltage-gated	 K+	 channels	 are	 activated	 in	 response	 to	decrease	 pH	 (via	 increased	 PCO2),	 causing	 K+	 efflux	 and	 subsequent	 sarcolemma	membrane	 hyperpolarization.	 Hyperpolarizing	 currents	 propagate	 throughout	vascular	 smooth	 muscle	 tissue	 via	 myoendothelial	 gap	 junctions,	 resulting	 in	 the	
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closing	 calcium	 (Ca2+)	 channels,	 reduction	 in	 intracellular	 Ca2+	 and	 ultimately,	vasodilation	due	to	vascular	smooth	muscle	relaxation.		An	alternative	mechanism	of	PCO2	cerebrovascular	regulation	suggests	 that	increased	 CBF	 is	 mediated	 by	 a	 shear	 stress	 induced	 release	 of	 vasoactive	substances,	 such	 as	 nitric	 oxide	 (NO).	 NO	 causes	 an	 increase	 in	 Ca2+	 uptake	 by	 a	signaling	 cascade	 that	 involves	 the	 formation	 of	 cyclic	 guanosine	monophosphate	and	 subsequent	 activation	 of	 protein	 kinase	 G.	 Therefore,	 the	 decrease	 in	 Ca2+	prevents	 myosin	 phosphorylation	 and	 cross	 bridge	 cycling,	 resulting	 in	 smooth	muscle	relaxation	and	vasodilation.	Regardless	of	the	mechanism,	the	hemodynamic	response	 to	 changes	 in	 partial	 pressure	 of	 carbon	 dioxide	 (	()*+)	 is	 very	 rapid;	changes	in	CBF	are	observed	within	10	seconds	of	changes	in	arterial	()*+ .	The	 influence	 of	 partial	 pressure	 of	 oxygen	 (PO2)	 in	 the	 regulation	 of	 CBF	appears	to	be	minor	in	comparison	to	PCO2.	Although	a	threshold	of	PO2	<	60	mmHg	is	 required	 to	 elicit	 increases	 in	 CBF,	 hypoxia	 is	 accompanied	 naturally	 by	hyperventilation,	resulting	in	a	hypocapnic	mediated	decrease	in	CBF.	Therefore,	it	is	difficult	to	isolate	the	specific	influence	of	partial	pressure	of	oxygen	((*+)	on	the	regulation	 of	 CBF.	 Using	 advanced	 techniques,	 such	 as	 the	 breath-by-breath	manipulation	 of	 inspired	 gas	 concentration,	 research	 suggests	 that	 isocapnic	hypoxia	 alone	 is	 a	 cerebral	 vasodilator	 and	 may	 be	 of	 interest	 in	 pathological	conditions,	 such	 as	 chronic	 obstructive	 pulmonary	 disorder	 and	 heart	 failure	(Ainslie	&	Duffin	2009;	Ainslie	&	Ogoh	2010).	The	 ability	 of	 CBF	 to	 remain	 constant	 over	 a	 range	 of	 blood	 pressure	 is	termed	cerebral	autoregulation.	Impaired	cerebral	autoregulation	poses	the	risk	of	
	 	
	
9	
ischemic	damage	to	local	tissue	during	periods	of	 low	blood	pressure	and	cerebral	hemorrhage	during	periods	of	high	blood	pressure.	Cerebral	autoregulation	can	be	classified	 as	 either	 static	 or	 dynamic.	 Static	 cerebral	 autoregulation	 is	 the	maintenance	 of	 CBF	 over	 gradual	 and	 progressive	 changes	 in	 blood	 pressure.	Dynamic	 cerebral	 autoregulation	 is	 the	 CBF	 response	 to	 rapid	 changes	 in	 blood	pressure	that	occur	in	seconds,	such	as	those	observed	during	postural	changes	and	during	the	Valsalva	maneuver.	Although	the	traditional	view	that	autoregulation	will	control	 CBF	 over	 a	 range	 of	 blood	 pressure,	 recent	 research	 (Lucas	 et	 al.	 2010)	suggests	 that	 changes	 in	 CBF	 closely	 parallel	 changes	 in	 mean	 arterial	 pressure,	findings	 that	 are	 in	 conflict	 with	 the	 classic	 definition	 of	 cerebral	 autoregulation.	Therefore,	 further	 attention	 to	 systemic	 factors,	 such	 as	 cardiac	 output,	 blood	pressure	 and	 heart	 rate,	 should	 be	 examined	 as	 potential	 mechanisms	 of	 CBF	regulation.	Although	it	is	commonly	accepted	that	CBF	is	maintained	over	a	wide	rage	of	blood	pressure,	evidence	suggests	that	changes	in	cardiac	output	will	influence	the	magnitude	of	CBF	(Secher	et	al.	2008).	Theoretically,	changes	in	sympathetic	nerve	activity	and	heart	 rate	 that	occur	during	CO2	 reactivity	 testing	would	 suggest	 that	changes	in	cardiac	output	would	influence	CBF;	however,	it	remains	unclear	if	these	changes	occur	independently	of	blood	pressure	(Ainslie	&	Duffin	2009).	Data	using	techniques	 that	 clamp	 blood	 pressure	 and	 end-tidal	 carbon	 dioxide	 (PETCO2)	illustrate	a	positive	relationship	between	cardiac	output	and	CBF	during	both	rest	and	 exercise	 (Ide	 et	al.	 2003).	 Mechanisms	 explaining	 a	 cardiac	 output	 mediated	change	in	CBF	remain	unclear;	however,	a	non-neural	mechanism(s),	such	as	release	
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of	vasoactive	substances	from	the	endothelium	during	shear	stress,	remain	a	likely	candidate	(Rubanyi	et	al.	1986).	The	 effect	 of	 sympathetic	 nerve	 activity	 (SNA)	 on	 cerebral	 vascular	 tone	remains	equivocal;	however,	the	consensus	view	is	that	SNA	has	little	effect,	or	may	be	masked	by	other	more	powerful	regulatory	mechanisms,	on	CBF	(Strandgaard	&	Sigurdsson	 2008).	 Data	 from	 animal	 studies	 (Cassaglia	 et	 al.	 2008)	 illustrate	 an	increase	 in	 SNA	 of	 fibres	 innervating	 cerebral	 vasculature	 exclusively	 during	hypertension.	 The	 authors	 suggest	 that,	 rather	 than	 a	 direct	 regulator	 of	 CBF,	increased	SNA	may	serve	as	a	protective	mechanism,	preventing	over	perfusion	of	the	 cerebral	 vasculature.	 Indirectly,	 SNA	 may	 influence	 CBF	 by	 modifying	 the	cerebral	 CO2	 reactivity	 (D'Alecy	 et	al.	 1979;	 Jordan	 et	al.	 2000),	 thereby	 altering	cerebral	vasomotor	response	to	changes	in	()*+ .	Neurovascular	coupling,	or	the	association	between	cerebral	hemodynamics	and	neural	activity,	is	a	mechanism	by	which	CBF	is	increased	to	meet	the	demands	of	 cerebral	 metabolism.	 The	 cellular	 mechanism(s)	 underlying	 neurovascular	coupling	 remains	 poorly	 understood.	 One	 plausible	 theory	 suggest	 that	 calcium	release	 from	 local	 astrocytes	 during	 synaptic	 activity	 causes	 the	 release	 of	vasoactive	 substances,	 such	 as	 adenosine,	 NO	 and	 prostaglandins,	 resulting	 in	vascular	 smooth	muscle	 relaxation	 and	 subsequent	 increase	 in	 CBF	 (Jakovcevic	&	Harder	 2007).	 Therefore,	 neurovascular	 coupling	 may	 provide	 a	 method	 of	evaluating	 CBF	 in	 patients	 who	 suffer	 from	 pathologies	 that	 disrupt	 cognitive	 or	sensorimotor	stimulation	(Willie	et	al.	2011).		
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Pharmacological	 manipulation	 of	 CBF	 can	 be	 achieved	 via	 indomethacin	supplementation	(Fan	et	al.	2010;	Fan	et	al.	2011;	Xie	et	al.	2006).	Indomethacin	is	a	prescription	 non-steroidal	 anti-inflammatory	 drug	 that	 is	 commonly	 used	 to	 treat	pain,	stiffness	and	inflammation,	and	has	a	profound	effect	on	vasoactive	properties	of	 the	 cerebral	 vasculature.	 Acute	 indomethacin	 supplementation	 (approximately	100	mg	or	1.2	mg⋅kg-1	body	mass)	causes	a	reduction	in	CBF	and	CO2	reactivity	with	little	influence	on	metabolic	rate	(Hohimer	et	al.	1985;	Kraaier	et	al.	1992),	cerebral	pH,	 or	 catecholamine	 concentration	 (Green	 et	 al.	 1987;	 Staessen	 et	 al.	 1984;	Wennmalm	 et	 al.	 1984),	 making	 it	 an	 ideal	 tool	 for	 evaluating	 cerebrovascular	hemodynamics.	 Mechanistically,	 indomethacin	 is	 a	 non-selective	 cyclooxygenase	(COX)	inhibitor	that	blocks	the	production	of	prostaglandins	from	arachidonic	acid.	Animal	research	suggests	that	mammals	contain	two	distinct	COX	enzymes:	COX-2	is	involved	 in	 the	 inflammation-signaling	 cascade,	 whereas	 COX-1	 is	 the	 more	generally	 expressed	enzyme.	Prostaglandins	produce	vasodilation	via	 a	paracrine-signaling	 cascade	 that	 involves	 the	 activation	 of	 cyclic	 AMP	 and	 protein	 kinase	A,	resulting	in	myosin	phosphorylation	and	vascular	smooth	muscle	relaxation.	When	prostaglandin	 synthesis	 is	 blocked	 via	 COX	 inhibition,	 the	 basal	 vasodilator	(Yoshimoto	 et	 al.	 1990)	 effect	 is	 removed	 causing	 increased	 cerebrovascular	resistance	and	concomitant	decrease	in	CBF.	
2.1.2 Measurement	considerations	The	gold	 standard	method	 for	quantifying	CBF	 is	 the	Kety-Schmidt	method	(Kety	&	 Schmidt	 1948),	whereby	 an	 inert	 tracer,	 such	 as	 nitrous	 oxide,	 is	 infused	into	the	cerebral	circulation.	Founded	on	the	Fick	principle,	simultaneous	areterio-
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venous	 samples	 are	 drawn	 and	 the	 resultant	 difference	 in	 tracer	 concentration	 is	proportional	to	the	volume	of	blood	flow	through	the	brain	vasculature.	Global	CBF	can	then	be	calculated	using	the	Kety-Schmid	equation:	
%,- = 100	 ∙ 3 ∙ %45 6789:9;<98=%45 > ∙ ?>@AB@AC − %E > ∙ ?>@AB@AC 	where	 %45 	and	 %E 	represent	 the	 jugular	 and	 arterial	 tracer	 concentration,	respectively,	t	represents	tracer	time	in	minutes,	and	λ	 is	the	brain-blood	partition	coefficient	in	=: ∙ FGH.	Alternatively,	 transcranial	 Doppler	 ultrasound	 (TCD)	 provides	 a	 safe,	 non-invasive	and	relatively	inexpensive	method	for	quantifying	CBF	(Willie	et	al.	2011).	Consistent	with	Doppler	technology,	the	TCD	probe	emits	sound	waves	that	reflect	moving	 red	blood	 cells	 and	 return	 to	 the	probe.	The	 time	delay	 is	 then	 calculated	and	 resultant	 Doppler-shift	 is	 proportional	 to	 the	 blood	 flow	 velocity.	 A	 key	assumption	 of	 the	 TCD	 technique	 of	 measuring	 CBF	 is	 that	 the	 diameter	 of	 the	insonated	vessel	remains	constant	and	therefore,	CBF	velocity	can	be	assumed	as:	%,-I ∝ <K	where	CBFv	 represents	cerebral	blood	 flow	velocity	and	r	 represents	 the	radius	of	the	 insonated	 vessel.	 Although	 there	 are	 numerous	 studies	 to	 validate	 this	assumption	(Bishop	et	al.	1986;	Nuttall	et	al.	1996;	Peebles	et	al.	2008;	Serrador	et	
al.	2000;	ter	Minassian	et	al.	1998;	Valdueza	et	al.	1996),	the	possibility	of	changes	in	cerebral	vasomotor	tone	require	that	data	collected	using	the	TCD	are	interpreted	only	as	CBF	velocity	(Willie	et	al.	2011).	
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Recent	research	(Willie	et	al.	2012)	suggests	that	 increases	 in	blood	flow	in	the	 internal	carotid	artery	and	vertebral	artery,	supplying	the	middle	cerebral	and	posterior	 cerebral	 intracranial	 arteries,	 respectively,	 change	 disproportionately	during	CO2	reactivity	testing.	These	findings	suggest	that	the	cerebral	vasculature	is	vasoactive,	 despite	 previous	 research	 that	 suggests	 otherwise	 (Bishop	et	al.	 1986;	Nuttall	 et	al.	 1996;	 Peebles	 et	al.	 2008;	 Serrador	 et	al.	 2000;	 ter	 Minassian	 et	al.	1998;	 Valdueza	 et	 al.	 1996).	 To	 supplement	 TCD	 data,	 recent	 research	 has	incorporated	volumetric	measures	of	blood	flow	in	the	feed	arteries	that	supply	the	intracranial	 arteries,	 namely	 the	 internal	 carotid,	 external	 carotid	 and	 vertebral	arteries.	 Using	 duplex	 ultrasonography,	 simultaneous	 B-mode	 imaging	 and	 pulse-wave	 velocity	 measures	 can	 be	 combined,	 such	 that	 volumetric	 flow	 can	 be	calculated	using	the	following	equation:	
,- = ,-5 ∙ L ∙ ∅2 ' ∙ 60	where	 BF	 represents	 blood	 flow	 (=: ∙ =9OGH),	 BFv	represents	 blood	 flow	 velocity	(cm∙s-1)	 and	∅ 	represents	 vessel	 diameter	 (cm).	 Therefore,	 quantification	 of	volumetric	 blood	 flow	 of	 neck	 vessels	 supplying	 the	 brain,	 coupled	 with	 TCD	quantification	 of	 blood	 flow	 velocity	 of	 intracranial	 vessels	 may	 provide	 a	 more	accurate	representation	of	CBF.	
2.1.3 Cerebral	blood	flow,	carbon	dioxide	and	neuromuscular	responses	To	date,	there	are	no	peer-reviewed	articles	that	specifically	examine	changes	in	CBF	on	corticospinal	excitability	or	neuromuscular	responses.	However,	given	the	association	between	decreased	PETCO2	and	CBF	(Wollman	et	al.	1968),	it	is	logical	to	
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examine	 changes	 in	 motor	 cortex	 excitability	 in	 response	 to	 changes	 in	 PETCO2.	Hyperventilation	 is	 often	 used	 to	 induce	 respiratory	 alkalosis,	 as	 there	 is	 a	 close	relationship	between	PETCO2	and	ventilation	rate.	Animal	model	research	(Somjen	et	
al.	 1987)	 has	 illustrated	 increase	 excitability	 of	 neurons	 located	 in	 hippocampal	formation	 in	 response	 to	 hyperventilation.	 In	 humans,	 hyperventilation	 modifies	visual	evoked	potentials	in	patients	with	multiple	sclerosis	(Davies	et	al.	1986)	and	has	 been	 shown	 to	 modulate	 electroencephalograph	 discharges	 in	 patients	 with	absence	seizures	(Davis	et	al.	1970).	The	 influence	 of	 changes	 in	 PaCO2	 on	 motor	 cortex	 excitability	 remains	debated;	 however,	 it	 is	 generally	 accepted	 that	 hypocapnia	 has	 an	 excitatory	influence	on	neurons	of	the	motor	cortex.	For	example,	Seyal	el	al.	(1998)	report	an	increase	in	motor	evoked	potential	(MEP)	amplitude	when	PETCO2	is	reduced	by	15	mmHg	during	controlled	hyperventilation,	suggesting	that	motor	cortex	excitability	is	enhanced	 in	response	to	hypocapnia.	Furthermore,	a	concomitant	 increase	 in	F-wave	amplitude	was	observed,	suggesting	that	spinal	motor	neuron	excitability	was	increased,	 either	 by	 enhanced	 descending	 central	 activation	 or	 changes	 in	 the	intrinsic	properties	of	 the	motoneuron.	Similarly,	Sparing	et	al.	 (2007)	observed	a	significant	decrease	in	the	transcranial	magnetic	stimulation	(TMS)	threshold	for	a	MEP	responses	and	an	enhancement	of	 the	MEP	 to	TMS-response	curve	 following	hyperventilation-induced	 hypocapnia	 (PETCO2	 15	 mmHg	 below	 eucapnia),	suggesting	increased	motor	cortex	excitability.	The	mechanistic	influence	of	hypocapnia	on	motor	cortex	excitability	has	been	elucidated	in	rat	hippocampal	slice	preparations	(Dulla	et	al.	2005).	The	increase	in	
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extracellular	 pH	 associated	 with	 hypocapnia	 inhibits	 ecto-ATPase	 activity	 (a	trans-membrane	 enzyme	 that	 is	 involved	 in	 the	 hydrolysis	 of	 extracellular	 ATP),	causing	 the	 accumulation	 of	 extracellular	 ATP	 and	 the	 decrease	 in	 extracellular	adenosine.	 Increased	 extracellular	 ATP	 concentrations	 enhance	 purinergic	receptors,	 causing	 an	 increase	 in	 excitatory	 inputs	 on	 interneurons	 (Khakh	 et	al.	2003),	modulation	of	excitatory	post-synaptic	potentials	(Pankratov	et	al.	1998)	and	facilitation	 of	 long-term	 potentiation	 (Almeida	 et	al.	 2003).	 Conversely,	 decreased	extracellular	concentrations	of	adenosine	decrease	A1	receptor	activity,	reducing	the	tonic	 inhibition	 of	 glutamate,	 a	 neurotransmitter	 that	 is	 responsible	 mediating	excitatory	signals	(Johansson	et	al.	2001).	Collectively,	these	changes	are	associated	with	increase	neuronal	excitability	and	therefore,	enhancement	of	the	MEP.	Despite	 a	mechanistic	 explanation	 for	 increased	motor	 cortex	 excitability	 in	response	 to	 hypocapnia,	 similar	 research	 (Kong	 et	 al.	 1994;	 Priori	 et	 al.	 1995)	suggests	that	reductions	in	PETCO2	have	no	significant	influence	on	the	supraspinal	nervous	system.	For	example,	Kong	et	al.	(1994)	examined	motor	cortex	excitability	in	response	to	hypo-	and	hypercapnia	and	found	that	post-stimulus	time	histograms	were	 insensitive	 to	 changes	 in	 PETCO2.	 The	 authors	 suggest	 that	 the	motor	 cortex	may	 compensate	 for	 changes	 in	 PCO2	 by	 altering	 CBF,	 or	 perhaps	 a	 synchronized	change	 in	motor	 unit	 firing	 rate;	 however,	 this	 explanation	 remains	 unlikely	 as	 it	implies	 a	 close	 relationship	 between	 motor	 unit	 firing	 rates	 and	 motor	 cortex	excitability.	 A	 more	 plausible	 explanation	 is	 that	 there	 is	 a	 threshold	 for	hyperventilation-mediated	changes	in	motor	cortex	excitability.	Specifically,	Kong	et	al.	(1994)	observed	no	changes	in	motor	cortex	excitability	when	mean	PETCO2	was	
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22	mmHg,	whereas	Seyal	et	al.	(1998)	observed	enhanced	motor	cortex	excitability	when	mean	PETCO2	was	further	reduced	to	15	mmHg.	
2.2 Hypoxia	Decreased	 arterial	 oxygen	 content,	 achieved	 by	 changes	 in	 inspired	 oxygen	concentration	 (FiO2)	 or	 impaired	 oxygen	 transport,	 is	 associated	 with	 impaired	exercise	performance	(Amann	et	al.	2006;	Amann	et	al.	2007;	Katayama	et	al.	2007;	Millet	 et	al.	 2009;	 Peltonen	 et	al.	 1995;	 Peltonen	 et	al.	 1997;	 Romer	 et	al.	 2007).	Although	 well	 documented,	 the	 mechanism(s)	 that	 explain	 decrements	 in	 the	resultant	 hypoxia	 remain	 unclear.	 Possible	 loci	 of	 fatigue	 may	 be	 central	 or	peripheral	 in	 origin;	 however,	 it	 is	 likely	 a	 combination	 of	 mechanisms	 that	contribute	 to	 the	 observed	 decrements.	 The	 following	 section	 examines	 the	physiological	 effects	 of	 hypoxia,	 focusing	 specifically	 on	 cerebral	 (Ainslie	 &	 Ogoh	2010;	Cohen	et	al.	1967;	Nybo	&	Rasmussen	2007;	Verges	et	al.	2012;	Wilson	et	al.	2009),	 cardio-pulmonary	 (Calbet	 et	 al.	 2009;	 Katayama	 et	 al.	 2001;	 Teppema	 &	Dahan	2010),	peripheral	(Lundby	et	al.	2009)	and	neuromuscular	effects	(Amann	et	
al.	2006;	Amann	et	al.	2007;	Katayama	et	al.	2007)	respectively.		
2.2.1 Cerebral	effects	The	 cerebral	 vasculature	 is	 highly	 sensitive	 to	 changes	 in	 arterial	 gas	concentrations	 (Ainslie	 &	 Duffin	 2009),	 specifically	(*+ 	and	()*+ .	 In	 response	 to	severe	isocapnic	hypoxia	((*+ 	<	40	mmHg),	cerebral	blood	flow	(CBF)	increases	as	a	result	of	cerebral	pial	vessel	relaxation.	Although	hypoxia	alone	 is	considered	as	a	vasodilator,	 exposure	 to	 low	(*+ 	is	 associated	 with	 marked	 hyperventilation	 and	
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concomitant	 decrease	 in	()*+ .	 Since	 hypocapnia	 is	 a	 potent	 vasoconstrictor,	increased	 CBF	 during	 poikilocapnic	 hypoxic	 is	 often	 counteracted	 by	 a	()*+ 	mediated	cerebral	vasoconstriction.	Therefore,	overall	changes	in	CBF	during	acute	hypoxia	at	rest	are	relatively	minor	(Ainslie	&	Poulin	2004;	Nishimura	et	al.	2010;	Peltonen	et	al.	2007).	The	CBF	response	during	acute	hypoxia	with	combined	exercise	continues	to	be	debated.	 Ainslie	 et	 al.	 (2007)	 provide	 evidence	 of	 increase	middle	 cerebral	 artery	velocity	 (MCAv)	 –	 or	 increased	 CBF	 -	 during	 hypoxic	 exercise,	 an	 observation	associated	with	increase	neuronal	activity,	 increased	cerebral	metabolism	(Ogoh	&	Ainslie	2009)	and	a	decreased	sensitivity	to	hypocapnia	(Ogoh	et	al.	2005).	Others	(Ainslie	 et	al.	 2007;	 Huang	 et	al.	 1991;	 Peltonen	 et	al.	 2009;	 Subudhi	 et	al.	 2008)	have	reported	similar	MCAv	between	normoxic	and	hypoxic	exercise,	due	in	part	to	hypocapnic-mediated	 vasoconstriction	 blunting	 the	 neuronal	 increase	 in	 CBF	associate	 with	 exercise.	 Conflicting	 results	 may	 be	 attributed	 to	 measurement	issues,	as	asymmetric	venous	draining	from	the	brain	may	cause	an	underestimation	of	 CBF	when	using	 the	Kety-Schmit	method	or	 radioisotope	 inhalation	 techniques	(Ogoh	&	Ainslie	2009).	Cerebral	autoregulation,	 the	 intrinsic	ability	of	cerebral	vasculature	 to	regulate	CBF	 in	 response	 to	 changes	 in	blood	pressure,	 is	 impaired	 in	 response	 to	hypoxia	(Iwasaki	 et	 al.	 2007).	 Mechanisms	 that	 contribute	 to	 this	 impairment	 include	increased	 sympathetic	 nervous	 activity	 mediated	 by	 peripheral	 chemoreceptor	stimulation	 (Hughson	 et	 al.	 1994;	 Saito	 et	 al.	 1988)	 and	 an	 up-regulation	 in	 NO	release	 causing	 cerebrovascular	 smooth	 muscle	 relaxation	 (White	 et	al.	 2000).	 A	
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loss	in	cerebral	autoregulation	may,	in	part,	contribute	to	the	development	of	acute	mountain	sickness	when	at	altitude	(Wilson	et	al.	2009).		 Cerebral	 oxygenation,	 in	 contrast	 to	 muscle	 tissue,	 is	 reduced	 at	 rest	 in	hypoxia	(Ainslie	et	al.	2007;	Peltonen	et	al.	2007).	As	measured	using	near-infrared	spectroscopy	 (NIRS),	 decreased	 tissue	 oxygenation	 suggests	 that	 there	 is	 a	mismatch	 in	 oxygen	 delivery	 and	 oxygen	 utilization	 in	 brain	 tissue	 (Verges	 et	al.	2012).	 Increased	 cerebral	 metabolic	 rate	 and	 associated	 O2	 consumption	 in	comparison	to	muscle	tissue	may	explain	the	disparity	between	cerebral	and	muscle	oxygenation	 during	 whole	 body	 exercise	 in	 hypoxia	 (Subudhi	 et	 al.	 2008).	Remarkably,	 the	 lack	 of	 correlation	 between	 deoxyhemoglobin	 accumulation	 and	MCAv	 suggests	 that	 the	mechanism	 that	 regulate	 cerebral	 oxygenation	 and	 blood	flow	are	 independent	(Peltonen	et	al.	2007).	During	exercise,	cerebral	oxygenation	is	reduced	during	submaximal	and	maximal	exercise,	when	compared	to	normoxic	conditions	 (Ainslie	 et	al.	 2007;	 Peltonen	 et	al.	 2007).	 Studies	 (Imray	 et	al.	 2005;	Subudhi	et	al.	2008)	 in	which	CBF	 is	artificially	enhanced	 fail	 to	maintain	cerebral	oxygenation,	therefore	further	emphasize	the	dissociation	between	blood	flow	and	oxygenation.	An	elevated	cerebral	metabolic	rate,	however,	may	explain	changes	in	cerebral	oxygenation	during	exercise	in	hypoxia	(Subudhi	et	al.	2008).		 A	 sensitive	 indicator	 of	 brain	 function	 is	 the	 concentration	 and	 rate	 of	turnover	 of	 cerebral	 neurotransmitters.	 The	 rate-limiting	 step	 of	 serotonin,	dopamine	 and	 norepinephrine	 is	 oxygen	 dependent	 (Gibson	 et	 al.	 1981);	consequently,	 metabolism	 of	 these	 neurotransmitters	 are	 impaired	 with	 mild	hypoxia	 (Peltonen	 et	al.	 2007).	 Perturbations	 in	 cerebral	 neurotransmitters	 have	
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been	 associated	with	hyperthermia	 and	 fatigue	 (Davis	&	Bailey	1997;	Heyes	et	al.	1985;	Romanowski	&	Grabiec	1974);	therefore,	it	is	plausible	that	hypoxia	may	limit	response	by	similar	neurotransmitter	mediated	mechanisms.	
2.2.2 Cardiorespiratory	effects	Changes	 in	 systemic	 oxygen	 availability	 have	 profound	 effects	 on	cardiovascular	function	and	have	been	shown	to	alter	heart	rate,	vascular	resistance	and	 cardiac	 output	 with	 respect	 to	 normoxic	 values	 (Thomson	 et	 al.	 2006).	 The	vascular	response	during	hypoxia	may	be	mediated	by	several	mechanisms	such	as	changes	 in	 L-type	 calcium	 channels	 (Welsh	 et	al.	 1998),	 ATP-sensitive	 potassium	channels	 (Daut	 et	al.	 1990)	 and	 voltage-gated	 potassium	 channels	 (Coppock	 et	al.	2001).	 Hypoxia	 is	 associated	 with	 changes	 in	 vasoactive	 substances,	 such	 as	endothelin-1	 prostaglandins,	 adenosine,	 NO	 (Thomson	 et	 al.	 2006)	 and	 the	formation	 of	 reactive	 oxygen	 species	 that	 damage	 cell	 functions	 (Liu	 et	al.	 2003).	Furthermore,	the	autonomic	balance	is	altered	with	hypoxia	as	sympathetic	activity	is	increased	causing	excitatory	cardiovascular	changes	(Xie	et	al.	2001).	Acute	 hypoxic	 exposure	 is	 associated	 with	 hemodynamic	 changes	 (Naeije		2010)	and	may	occur	regardless	of	end-tidal	carbon	dioxide	tension	(Thomson	et	al.	2006).	 As	 an	 immediate	 response	 to	 hypoxia,	 cardiac	 output	 (P)	 increases	 as	 a	consequence	of	 increased	heart	rate.	 It	 is	 interesting	to	note	that	the	increase	in	P	parallels	 the	decrease	 in	(*+ 	such	 that	 oxygen	delivery	 is	maintained	during	 acute	hypoxia.	With	chronic	exposure	to	hypoxia,	 the	 initial	 increase	 in	P	is	abolished	as	values	 return	 to	normoxic	values	 (Pugh	et	al.	 1964).	Regardless	of	 acclimatization	
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status,	 the	 relationship	 between	P,	 work	 rate	 and	 oxygen	 consumption	 is	 similar	during	 hypoxia	 and	 normoxic	 exposure	 (Boussuges	 et	al.	 2000;	 Pugh	 et	al.	 1964;	Vogel	et	al.	1974).	As	mentioned	previously,	heart	rate	increases	with	altitude,	both	at	rest	and	at	 a	 given	 exercise	 intensity.	 Acute	 hypoxia	 exposure	 at	 simulated	 altitudes	 of	approximately	4000	m	((*+ 	of	40-45	mmHg)	cause	increases	in	resting	heart	rate	of	40-50%	 when	 compared	 to	 normoxia,	 then	 return	 to	 baseline	 values	 following	acclimatization	 (Vogel	 &	 Harris	 1967).	 During	 submaximal	 exercise,	 heart	 rate	 is	disproportionally	 higher	 during	 hypoxia	 at	 a	 given	 workload	 or	 oxygen	consumption;	 however,	maximal	 heart	 rate	 during	 exercise	 is	 reduced	 in	 subjects	with	chronic	hypoxia	exposure	(Pugh	et	al.	1964).	For	example,	maximal	heart	rates	decrease	progressively	with	 increasing	altitude	 from	160	bpm	at	 sea	 level,	 to	137	bpm	at	6100	m,	 to	123	bpm	at	7620	m	and	 to	118	bpm	at	8848	m	 (Reeves	et	al.	1987).	Decreased	maximal	 cardiac	 output	 (PQER)	 and	maximal	 heart	 rate	 (HRmax)	suggest	 that	 myocardial	 contractility	 may	 be	 down	 regulated,	 acting	 as	 a	 cardio-protective	mechanism	during	hypoxia.	Evidence	of	decreased	cardiac	β-adrenergic	receptor	and	autonomic	nervous	activity	may	represent	a	physiological	adaptation	to	protect	the	heart	from	excessive	strain	that	occurs	when	exercise	and	hypoxia	are	combined	 (Richalet	 	 1990).	 Alternatively,	 reduced	PQER	and	 HRmax	 may	 simply	reflect	the	reduced	work	rate	that	occurs	during	hypoxia.	During	acute	hypoxia	exposure,	stroke	volume	remains	unchanged	compared	to	 normoxic	 values	 due	 to	 the	 linear	 increase	 in	 both	P	and	 heart	 rate.	 More	interesting,	however,	 is	 the	reduction	 in	stroke	volume	 that	occurs	during	chronic	
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hypoxia	exposure	when	P	returns	to	normoxic	level,	but	heart	rate	remains	elevated	(Alexander	 et	 al.	 1967).	 The	 mechanisms	 that	 explain	 the	 reduction	 in	 stroke	volume	 with	 chronic	 hypoxia	 remain	 unclear;	 however,	 myocardial	 hypoxia	 and	resultant	decrease	 in	contractility	(Alexander	et	al.	1967)	or	 fall	 in	plasma	volume	(Boussuges	et	al.	2000)	both	provide	possible	explanations.		When	exercise	 is	coupled	with	hypoxia,	 increases	 in	Qm 	and	absolute	oxygen	consumption	 are	 no	 different	 than	 baseline	 measures;	 however,	 maximal	 oxygen	consumption	(S*+QER),	PQER	and	HRmax	are	significantly	 lower.	S*+QER ,	 regarded	as	the	 best	 indicator	 of	 cardio-respiratory	 capacity	 during	 exercise,	 represents	 the	ability	 of	 the	 circulatory	 system	 to	 transport	 and	 utilize	 oxygen	 (Östrand	 	 2003).	During	ascents	to	high	altitude,	S*+QER	decreases	linearly	as	a	function	of	decreased	oxygen	 availability	 (Wehrlin	 &	 Hallen	 2006).	 Wagner	 (2010)	 examined	 the	mechanisms	of	reduced	S*+QER	at	altitude	through	analysis	of	data	collected	during	the	 Operation	 Everest	 II	 project.	 In	 the	 study,	 participants	 were	 progressively	subjected	 to	 hypobaric	 hypoxia	 over	 a	 40-day	 period	 to	 a	 simulated	 altitude	equivalent	 to	 the	summit	of	Everest	 (8848	m).	Using	 the	Four	Principal	Transport	Processes	model	(Weibel		1984),	oxygen	consumption	can	be	examined	as	4	distinct	processes:	 alveolar	ventilation,	pulmonary	diffusion,	oxygen	profusion	and	muscle	diffusion.	 Using	 this	 model,	 Wagner	 determined	 that	 decreased	S*+QER 	during	Operation	Everest	 II	was	explained	by	a	 impaired	diffusion	capacity	 in	pulmonary	and	muscle	tissues	(Wagner		2010).	Fick’s	law	of	diffusion	supports	this	conclusion	as	 the	(*+ 	gradient	 between	 the	 local	 tissue	 and	 environment	 is	 abolished	 with	hypoxia.	
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Although	 there	 are	 very	 little	 changes	 in	 mean	 systemic	 arterial	 blood	pressure	with	acute	hypoxia	exposure,	chronic	hypoxia	elicits	an	increase	in	blood	pressure	that	can	persist	for	several	weeks	(Kontos	et	al.	1967).	This	blood	pressure	response	 to	 hypoxia,	 which	 may	 be	 mediated	 by	 increased	 sympathetic	 activity	(Wolfel	et	al.	1994),	 is	reversed	upon	return	to	normoxia	(Kamat	&	Banerji	1972).	Interestingly,	people	who	are	exposed	to	hypoxia	for	several	years	(greater	than	1	year)	have	a	decrease	in	both	systolic	and	diastolic	blood	pressure	(Marticorena	et	
al.	 1969).	 As	 such,	 evidence	 suggest	 that	 individuals	 who	 suffer	 from	 systemic	hypertension	 benefit	 from	 improved	 symptoms	 when	 residing	 in	 the	 hypoxic	conditions	 of	 high	 altitude	 (Peñaloza	&	 Sime	 1971).	 The	 systemic	 blood	 pressure	response	 to	exercise	 is	higher	during	hypoxia	when	compared	 to	normoxia	and	 is	similar	regardless	of	acclimatization	status	(Vogel	et	al.	1974).	Acute	exposure	to	hypoxia	precipitates	an	increase	in	ventilation	via	in	part	by	stimulation	of	peripheral	chemoreceptors	located	in	the	carotid	artery	(Ainslie	&	Duffin	 2009).	 Once	 a	 threshold	 of	 hypoxia	 is	 surpassed	 ((*+ 	of	 approximately	 60	mmHg),	 chemoreceptor	 discharge	 rates	 increase	 and	 subsequently,	 stimulate	 the	medullary	 inspiratory	neurons.	Known	as	 the	hypoxic	ventilatory	response	(HVR),	this	 resultant	 increase	 in	 ventilation	 maintains	 the	 alveolar-arterial	(*+ 	gradient	during	 hypoxic	 conditions	 (Teppema	 &	 Dahan	 2010);	 however,	 this	 results	 in	 a	hypocapnic	mediated	 decrease	 in	 CBF,	which	 is	 associated	with	 reduced	 cerebral	oxygenation	 and	 neurobehavioral	 impairment	 (Peltonen	 et	al.	 2007).	 The	 HVR	 is	subject	to	high	inter-individual	variability	as	athletes	have	been	observed	to	exhibit	blunted	 responses	 while	 experienced	 alpinists	 show	 vigorous	 chemosensitivity	
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responses	to	hypoxia	(Schoene		1982).	Chronic	(Powell	et	al.	1998)	or	intermittent	(Katayama	et	al.	2001)	exposure	to	hypoxia	is	associated	with	increased	ventilation	mediated	by	an	increased	sensitivity	to	(*+ .	Although	the	mechanisms	remain	to	be	elucidated,	possible	explanations	 include	 increase	oxygen	sensitivity	of	 the	carotid	body	 chemoreceptor	 (Powell	 et	 al.	 1998)	 and	 plasticity	 of	 the	 central	 nervous	system	respiratory	centres	(Wilkinson	et	al.	2010).		Pulmonary	 hypertension,	 a	 cardiovascular	 adaptation	 that	 occurs	 in	response	to	hypoxia,	 is	characterized	by	an	 increase	 in	 the	pulmonary	vasculature	blood	 pressure.	 This	 phenomenon	 is	 observable	 during	 both	 acute	 and	 chronic	hypoxia.	Mean	pulmonary	artery	pressure	has	been	observed	to	increase	by	13-23	mmHg	 when	 breathing	 air	 containing	 10%	 oxygen	 for	 10	 minutes	 (Motley	 et	al.	1947).	The	stimulus-response	curve	relating	pulmonary	circulation	and	(*+ 	is	non-linear;	very	little	change	in	vascular	resistance	is	observed	when	(*+ 	is	greater	than	100	 mmHg	 (Barer	 et	 al.	 1970).	 Although	 the	 mechanisms	 remain	 unclear,	 the	occurrence	 of	 vasoconstriction	 in	 isolated	 blood	 vessels	 during	 hypoxia	 suggests	that	 this	 response	 is	 locally	mediated	 (Lloyd	 	 1965).	 Possible	 chemical	mediators	include	 catecholamines,	 histamine,	 angiotensin,	 prostaglandins	 (Fishman	 	 1985)	and	 more	 recently,	 NO	 (Ignarro	 et	 al.	 1987).	 NO	 inhibitors	 have	 been	 shown	 to	augment	the	pulmonary	hypertension	response	observed	during	hypoxia	(Archer	et	
al.	 1989)	 -	 the	 pathway	 in	 which	 NO	 inhibition	 causes	 an	 increase	 in	 vascular	resistance	will	 be	 discussed	 later	 in	 this	 review	of	 literature.	 Regional	 pulmonary	hypertension	may	provide	some	benefit,	albeit	trivial,	during	hypoxia	as	blood	flow	is	 redistributed	 to	 regions	 of	 the	 lung	 with	 higher	(*+ ,	 therefore,	 improving	 the	
	 	
	
24	
ventilation/perfusion	 relationship	 (WEST	 	 1962).	 The	 deleterious	 effect	 of	pulmonary	 hypertension	 is	 far	 more	 consequential	 as	 it	 is	 responsible	 for	 high	altitude	pulmonary	oedema.		
2.2.3 Peripheral	tissue	effects	Diffusion	 of	 oxygen	 from	 peripheral	 capillaries	 to	 the	 mitochondria	represents	 the	 final	 step	 in	 the	 oxygen	 transport	 cascade.	 The	 diffusion	 distance	between	the	capillary	and	the	mitochondria,	chief	in	oxygen	transport,	is	modified	in	response	 to	 hypoxia	 via	 changes	 in	 capillary	 density,	 muscle	 fibre	 size	 and	 the	volume	of	mitochondria.	Myoglobin	and	intracellular	enzymes	involved	in	oxidative	metabolism	 are	 modified	 in	 response	 to	 hypoxia	 and	 will	 also	 influence	 oxygen	diffusion	in	peripheral	tissues.	A	 mechanism	 to	 increase	 oxygen	 transport	 to	 peripheral	 tissue	 during	conditions	 of	 hypoxia	 is	 to	 increase	 capillary	 density.	 Early	 evidence	 (Mercker	 &	Schneider	 1949)	 suggests	 that	 there	 is	 increased	 capillarization	 in	 animal	 brain,	retina,	 liver	and	skeletal	muscle	tissue	 in	response	to	chronic	hypoxia,	resulting	 in	increased	 gas	 transport	 (Tenney	 &	 Ou	 1970).	 More	 recently,	 these	 observations	have	 been	 challenged	 by	 research	 (Banchero	 	 1982)	 suggesting	 that	 capillary-volume	density	 increases	during	hypoxic	 exposure	and	 furthermore,	 the	observed	increase	 occurs	 as	 a	 result	 from	 decreased	muscle	 fibre	 diameter	 rather	 than	 an	absolute	increase	in	capillary	content.	These	latter	observations	were	confirmed	in	human	 studies	 (Boutellier	 et	 al.	 1983;	 Cerretelli	 et	 al.	 1984)	 as	 capillary-volume	density	increased	in	biopsied	skeletal	muscle	as	a	function	of	decreased	muscle	fibre	size.	 Alternatively,	 Appell	 (1978)	 proposed	 that	 capillary	 configuration	 changed	
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with	 exposure	 to	 hypoxia	 such	 that	 greater	 tortuosity	 increases	 vascular	 surface	area	 and	 enhanced	 gas	 diffusion;	 however,	 these	 measures	 are	 abolished	 when	standardized	by	sarcomere	length	(Mathieu-Costello		1989).	As	 mentioned	 previously,	 diminished	 muscle	 fibre	 diameter	 is	 likely	 the	primary	mechanism	responsible	 for	 increase	 in	capillary-volume	density	observed	in	 response	 to	 hypoxia.	 The	 mechanisms	 for	 this	 muscle	 atrophy	 remain	 poorly	understood.	Initially,	it	was	believed	that	reduced	muscular	activity	during	hypoxic	exposure	was	 responsible	 for	 the	 decrements	 in	muscle	 fibre	 diameter;	 however,	further	 analysis	 revealed	 that	muscle	 wasting	 occurred	 despite	 vigorous	 exercise	during	 a	Himalayan	mountaineering	 expedition	 (Pugh	et	al.	 1964).	More	plausible	explanations	of	muscle	atrophy	during	hypoxia	 include	reduced	appetite,	 impaired	gastrointestinal	 absorption	 and	 changed	 protein	 metabolism	 that	 results	 in	 the	breakdown	of	muscle	protein.	The	mitochondria	 represent	 the	major	 site	 of	 oxygen	 utilization	 in	 human	tissue.	 The	 density	 of	 skeletal	 muscle	 mitochondria	 is	 related	 to	S*+QER 	and	therefore,	increases	in	response	to	physical	training.	With	chronic	hypoxia	exposure,	the	decline	in	S*+QER	is	paralleled	by	a	decrease	in	mitochondrial	volume.	Although	the	skeletal	muscle	atrophy	that	occurs	with	chronic	hypoxia	exposure	will	reduce	the	absolute	mitochondrial	density,	data	collected	 from	muscle	biopsies	(Hoppeler	
et	al.	 1990)	 indicates	 that	 a	 30%	decrease	 in	 relative	mitochondrial	 content	 does	occur,	suggesting	that	mitochondrial	volume	changes	occur	independent	of	changes	in	 skeletal	muscle.	 It	 is	 interesting	 to	 note	 that	 regional	 changes	 in	mitochondrial	
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content	 also	 occur,	 with	 greater	 decreases	 in	 subsarcolemmal	 mitochondria	compared	to	interfibrillar	mitochondria	(Desplanches	et	al.	1993).	Myoglobin,	 an	 iron	 and	 oxygen	 binding	 protein	 found	 in	 muscle	 tissue,	 is	found	to	increase	in	response	to	chronic	hypoxia	in	both	animal	and	human	models.	High	altitude	natives	have	significantly	higher	myoglobin	concentrations	(7.03	mg⋅g-
1	tissue)	compared	to	sea	level	controls	(6.07	mg⋅g-1	tissue),	irrespective	of	hypoxia	induced	changes	 in	muscle	mass	(Reynafarje	 	1962).	The	functional	significance	of	increased	 myoglobin	 content	 in	 high	 altitude	 natives	 may	 be	 to	 assist	 in	 oxygen	diffusion	through	muscle	cells	and	to	buffer	regional	differences	in	tissue	(*+ 	during	periods	of	severe	hypoxia.	Intracellular	 enzymes	 involved	 in	 the	 metabolic	 pathways	 responsible	 for	energy	production	are	modified	in	response	to	chronic	hypoxia.	Reynadarje	(1962)	observed	 that	 activities	 of	 NADH-oxidase,	 NADPH-cytochrome	 c-reductase	 and	NAD[P]+	 transhydrogenase,	 enzymes	 involved	 in	 the	 electron	 transport	 chain	 of	oxidative	metabolism,	increased	in	high	altitude	(4400	m)	residents.	The	enhanced	enzymatic	 activity	 observed	 at	 high	 altitude	 (4000	 –	 5000	 m)	 may	 not	 occur	 at	extreme	 altitudes	 (above	 6000	m).	 Data	 from	 both	 field	 studies	 conduced	 during	expeditions	 to	 Lhotse	 Shar	 (Cerretelli	 	 1987)	 and	 Mount	 Everest	 (Howald	 et	 al.	1990)	 and	 simulated	 altitude	 exposure	 during	 Operation	 Everest	 II	 (Green	 et	 al.	1989)	indicate	that	oxidative	enzyme	activity	decreases	in	response	to	extreme	high	altitude.	 The	mechanisms	 explaining	 the	 deleterious	 effect	 of	 extreme	 altitude	 on	enzyme	activity	remain	unknown.	
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2.2.4 Hypoxia	and	central	neuromuscular	responses	Peltonen	et	al.	(1995)	provided	some	of	the	preliminary	data	suggesting	that	fatigue	during	exercise	 in	hypoxia	 is	mediated	by	central	mechanisms.	Specifically,	they	 examined	 rowing	 performance	 in	 response	 to	 various	 levels	 of	 oxygen	availability	(FiO2	=	0.62,	0.21,	0.15)	and	found	a	linear	relationship	between	exercise	performance	 and	 inspired	 oxygen	 content.	 The	 significant	 finding,	 however,	 was	that	exercise	performance	was	not	associated	with	changes	in	lactate	accumulation	or	relative	oxygen	consumption	and	therefore,	must	be	related	to	factors	other	than	changes	 in	 anaerobic	 metabolism.	 To	 advance	 these	 findings,	 further	 research	examined	changes	 in	electromyography	(EMG)	activity	during	rowing	(Peltonen	et	
al.	 1997)	 and	 cycling	 (Tucker	 et	 al.	 2007)	 and	 found	 that	 there	 was	 a	 positive	relationship	 between	 oxygen	 availability	 and	 descending	 neural	 drive.	 These	findings	precipitated	the	concept	of	an	anticipatory	regulation	of	exercise	intensity,	in	 which	 descending	 neural	 activity	 is	 regulated	 based	 of	 afferent	 feedback	 to	 a	central	governor.	Goodall	 el	 al.	 (2010)	 examined	 changes	 in	 supraspinal	 fatigue	 during	repetitive	isometric	contractions	to	fatigue	in	hypoxia	(FiO2	=	0.16/0.10)	and	found	that	 decreases	 in	 maximal	 voluntary	 force	 production	 were	 associated	 with	 an	increase	in	twitch	force	elicited	by	TMS.	Changes	in	voluntary	activation	were	most	affect	after	exercise	in	severe	hypoxia	and	least	in	normoxia,	which	confirm	findings	from	 previous	 research	 (Amann	 et	 al.	 2007),	 suggesting	 that	 central	 fatigue	predominates	 when	 the	 severity	 of	 hypoxia	 increases.	 Using	 complete	 vascular	occlusion	 of	 the	 working	 muscle,	 Millet	 et	 al.	 (2012)	 confirmed	 that	 supraspinal	
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fatigue	 during	 severe	 hypoxia	 (FiO2	 =	 0.09)	 occurred	 independently	 of	 afferent	feedback	 from	 working	 muscle,	 suggesting	 that	 performance	 was	 limited	 by	decreased	oxygenation	of	the	brain.		More	recently,	motor	cortex	excitability	has	been	examined	following	1	and	3-hours	of	hypoxic	(FiO2	=	0.12)	exposure.	The	results	demonstrate	that	hypoxia	has	a	 time-dependent	 effect	 on	 motor	 cortex	 excitability,	 as	 motor	 evoked	 potentials	and	 cortical	 silent	 periods	 were	 observed	 to	 increase	 only	 following	 3-hours	 of	exposure.	 These	 findings	 suggest	 an	 increase	 in	 motor	 cortex	 excitability	 and	intracortical	 inhibition	 following	 prolonged	 hypoxia;	 however,	 these	 changes	 did	not	correspond	with	changes	 in	maximal	 force	production	or	voluntary	activation.	Further	 research	 is	 required	 to	 fully	 elucidate	 the	 influence	 of	 motor	 cortex	excitability	 and	 resultant	 changes	 in	 neuromuscular	 responses	 in	 response	 to	hypoxic	stress.	
2.2.5 Hypoxia	and	peripheral	neuromuscular	responses	Reduced	oxygen	availability	 contributes	 to	peripheral	neuromuscular	 fatigue	by	changes	in	relative	exercise	intensity	and/or	changes	in	intracellular	metabolism	that	 ultimately	 impair	 excitation	 contraction	 coupling.	 The	 increased	 rate	 of	metabolite	 accumulation	 caused	 by	 hypoxia	 can	 directly	 inhibit	 the	 mechanical	processes	of	the	contractile	apparatus	or	impair	calcium	release	and	re-uptake	from	the	 sarcoplasmic	 reticulum	 (Amann	 &	 Calbet	 2008).	 There	 appears	 to	 be	 a	 dose	dependent	 relationship	 between	 the	 magnitude	 of	 the	 hypoxic	 stress	 and	 the	peripheral	contributions	to	neuromuscular	fatigue;	peripheral	fatigue	predominates	
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during	 periods	 of	 moderate	 hypoxic	 stress	 whereas	 central	 mechanism	 are	more	dominate	during	periods	of	sever	hypoxic	stress	(Amann	et	al.	2007).	Changes	 in	 inspired	 oxygen	 content	 during	 exercise	 cause	 a	 change	 in	 both	maximal	 oxygen	 uptake	 and	 peak	 workload,	 therefore	 causing	 a	 shift	 in	 relative	exercise	 intensity	 at	 a	 given	 absolute	workload	 (Amann	 et	al.	 2006;	 Amann	 et	al.	2007;	Amann	et	al.	2006).	An	increase	in	relative	exercise	intensity	associated	with	hypoxia	causes	a	greater	percentage	of	type	II	fibre	to	be	activated	during	exercise	(Merletti	et	al.	1990),	possibly	mediated	by	a	hypoxia-induced	blunting	of	type	III/IV	muscle	 afferent	 sensitivity.	 Collectively,	 this	 evidence	 suggests	 that	 the	 increased	reliance	 of	 type	 II	 fibre	 during	 hypoxia	 results	 in	 a	 greater	 accumulation	 of	metabolites	that	are	attributed	to	neuromuscular	fatigue	(Amann	&	Calbet	2008).	In	addition	to	changes	in	muscle	fiber	recruitment,	hypoxia	induces	changes	in	intracellular	 metabolism	 that	 results	 in	 the	 increased	 rate	 of	 metabolite	accumulation	 (Adams	 &	 Welch	 1980;	 Fitts	 	 1994;	 Hogan	 et	 al.	 1994).	 Although	traditional	understanding	suggests	that	an	increase	in	hydrogen	ion	concentration	is	the	primary	contributor	to	peripheral	muscle	fatigue,	more	recent	evidence	suggests	that	inorganic	phosphate	may	be	the	largest	contributor	to	peripheral	fatigue	during	high-intensity	exercise	(Westerblad	et	al.	2002).	Therefore,	given	the	greater	rate	of	inorganic	 phosphate	 accumulation	 during	 exercise	 in	 hypoxia,	 more	 calcium	precipitate	(the	chemical	binding	of	calcium	and	inorganic	phosphate)	is	formed	in	the	sarcoplasmic	reticulum,	thereby	decreasing	the	amount	of	calcium	ions	available	for	excitation	contraction	coupling	(Dutka	et	al.	2005).	
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The	 severity	 of	 hypoxic	 stress	 may	 influence	 the	 relative	 contributions	 of	peripheral	versus	central	 fatigue	during	exercise.	To	examine	 this	dose-dependent	relationship,	Amann	et	al.	(2007)	examined	potentiated	quadriceps	twitch	pre-	and	post-	 constant-load	exercise	at	various	magnitudes	of	hypoxic	 stress	 (FiO2	of	0.21,	0.15,	 and	 0.10).	 At	 the	 point	 of	 task-failure,	 participants	 inhaled	 a	 hyperoxic	 gas	mixture	 (FiO2	 =	 0.30)	 and	 were	 encouraged	 to	 continue	 exercising	 as	 long	 as	possible.	 Following	 exercise	 in	 normoxia	 and	 moderate	 hypoxia	 (FiO2	 =	 0.15),	hyperoxic	 gas	 inhalation	 did	 not	 result	 in	 increased	 exercise	 time,	 despite	 the	instantaneous	restoration	of	muscle	and	cerebral	oxygenation	(as	indicated	by	near-infrared	spectroscopy),	whereas	inhalation	of	a	hyperoxic	gas	mixture	during	severe	hypoxic	 stress	 allowed	 participants	 to	 significantly	 prolong	 their	 exercise	 time.	Furthermore,	 levels	 of	 peripheral	 fatigue,	 assessed	 using	 potentiated	 twitch	response,	 were	 identical	 following	 exercise	 in	 normoxia	 and	 moderate	 hypoxia;	however,	 were	 significantly	 lower	 following	 exercise	 in	 severe	 hypoxia.	Interpretation	 of	 these	 results	 suggest	 that	 peripheral	 fatigue	 is	 the	 regulated	variable	 during	 exercise,	 and	 once	 a	 threshold	 of	 peripheral	 fatigue	 is	 surpassed,	known	as	the	 ‘sensory	tolerance	 limit’	 (Bigland-Ritchie	et	al.	1986;	Enoka	&	Stuart	1992),	 central	 mechanisms	 predominate.	 Theses	 findings	 (Amann	 et	 al.	 2007)	support	previous	research	(Goodall	et	al.	2010;	Romer	et	al.	2007)	that	suggest	that	the	 relative	 contributions	of	 central	 versus	peripheral	mechanisms	are	dependent	on	the	magnitude	of	hypoxic	stress.	
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2.3 Hyperthermia	Hyperthermia,	 the	state	of	elevated	body	core	temperature,	 is	detrimental	 to	human	performance,	as	 illustrated	by	decreased	exercise	 tolerance	during	various	modes	of	exercise	(Galloway	&	Maughan	1997;	Todd	et	al.	2005;	Tucker	et	al.	2006).	To	 combat	hyperthermia	during	passive	heating	 and	exercise	 induced	heat	 stress,	the	 body	 relies	 on	 a	 complex	 and	 well-coordinated	 system	 comprised	 of	thermosensors	and	thermoeffectors.	When	body	core	temperature	increases	above	the	 thermoneutral	 threshold,	 direct	 effects	 of	 hyperthermia	 can	 be	 observed	 on	peripheral	 (such	 as	 in	 the	 muscle	 tissue	 and	 motor	 unit	 apparatus)	 and	 central	systems	 (such	 as	 neural	 drive,	 spinal	 modulation,	 and	 neurotransmitter	concentration).	
2.3.1 Hyperthermia	and	cardiovascular	responses	During	periods	of	environmental	stress,	the	human	body	has	the	capability	to	withstand	 significant	 changes	 in	 core	 temperature.	 In	 response	 to	 heat	 stress,	elevations	in	skin	blood	flow	and	the	initiation	of	sweating	are	primary	mechanisms	that	prevent	heat	related	injuries	(Crandall		2008).	Theoretical	calculations	suggest	that	 if	 increases	 in	 skin	 blood	 flow	 did	 not	 occur	 during	moderate	 exercise,	 core	temperature	 would	 reach	 unsafe	 values	 within	 10	 minutes	 (Kenney	 &	 Johnson	1992).	 Therefore,	 certain	 cardiovascular	 adjustments	 during	 both	 passive	 and	exercise	induced	heat	stress	must	occur	to	maintain	physiological	homeostasis.		Although	exercise	is	the	primary	mechanism	that	instigates	increases	in	core	temperature,	 heat	 related	 injuries	 can	 occur	 during	 passive	 heat	 exposure,	especially	when	 underlying	 cardiovascular	 conditions	 are	 present	 (Semenza	 et	al.	
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1996).	During	passive	heat	stress,	skin	blood	flow	increases	from	~300	mL⋅min-1	to	~7500	mL⋅min-1	(Rowell	et	al.	1969)	to	promote	heat	loss	mechanisms.	In	response	to	 the	 drastic	 increase	 in	 vascular	 conductance	 associated	 with	 peripheral	vasodilation,	 cardiac	 output	 increases	 such	 that	 mean	 arterial	 pressure	 is	maintained.	Research	(Rowell	et	al.	1969)	indicates	that	cardiac	output	can	increase	to	values	as	high	as	13	L⋅min-1,	50%	of	which	is	directed	towards	cutaneous	tissue.	The	 mechanism	 mediating	 this	 increase	 in	 cardiac	 output	 is	 heart	 rate,	 whereas	stroke	volume	remains	unchanged	during	passive	heat	 stress.	During	passive	heat	stress,	 the	 redistribution	of	 blood	 volume	 from	 splanchnic	 and	 renal	 tissue	 to	 the	periphery	results	in	a	decrease	in	central	venous	pressure	and	in	turn,	a	decrease	in	left	 ventricular	 filling	 pressure	 (Rowell	 et	 al.	 1971).	 Baroreflex	 function	 may	 be	impaired	during	heat	stress,	as	orthostatic	intolerance	during	hyperthermia	cannot	be	 explained	 exclusively	 by	 venous	 pooling	 (Crandall	 &	 González-Alonso	 2010).	Research	 (Crandall	 	 2008)	 suggests	 that	 the	 baroreflex	 curve	 is	 reset	 to	 the	prevailing	heart	rate	and	blood	pressure	to	accommodate	for	the	changes	in	blood	pressure.	The	combined	effects	of	heat	stress	and	exercise	impose	significant	stress	on	the	 cardiovascular	 system,	 as	 blood	 flow	 to	 the	muscle	 is	 required	 to	 sustain	 the	metabolic	 demands	 of	 active	 musculature	 and	 blood	 flow	 to	 cutaneous	 tissue	 is	required	 to	 meet	 thermoregulatory	 demands.	 During	 exercise,	 even	 in	normothermic	 conditions,	 there	 is	 a	 significant	 disparity	 between	 the	 demand	 for	muscle	blood	flow	and	the	capacity	of	the	heart	to	meet	that	demand.	Therefore,	a	complex	neural	network	 involving	 the	baroreflex	and	metaboreflexes	 limit	muscle	
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vasculature	 vasodilation,	 such	 that	 blood	 pressure	 is	 maintained	 during	 exercise.	During	exercise	in	heat	stress,	the	increased	afferent	thermal	loading	causes	further	vasoconstriction	 of	 splenic	 and	 renal	 vasculature;	 however,	 muscle	 blood	 flow	remains	unchanged	in	comparison	to	normothermic	conditions	(Nielsen	et	al.	1993).	Therefore,	 exercise	 performed	 in	 the	 heat	 causes	 a	 competition	 between	 both	muscle	and	cutaneous	blood	flow,	with	muscle	blood	flow	dominating	and,	therefore	limiting	 skin	 blood	 flow	 and	 compromising	 the	 capacity	 of	 the	 thermoregulatory	system	 (Gonzalez-Alonso	 et	 al.	 2008).	 To	 further	 exacerbate	 cardiovascular	challenge	during	exercise	in	the	heat,	plasma	volume	decreases	as	a	result	of	plasma	filtration	(via	increases	in	blood	pressure)	and	dehydration.	The	resultant	decrease	in	 central	 blood	 volume	 impairs	 end-diastolic	 filling	 and	 consequently	 decreases	stroke	 volume.	 When	 exercise	 is	 performed	 at	 near	 maximal	 levels,	 increases	 in	heart	 rate	 are	 not	 enough	 to	 offset	 the	 decrease	 in	 stroke	 volume,	 ultimately	resulting	in	fatigue.	
2.3.2 Hyperthermia	and	central	neuromuscular	fatigue	Traditionally,	 investigations	examining	hyperthermia-mediated	fatigue	have	focused	 on	 peripheral	 mechanisms,	 with	 little	 attention	 to	 the	 central	 nervous	system	 (CNS).	 Central	 fatigue,	 defined	 as	 the	 “progressive	 reduction	 in	 muscle	activation	by	the	CNS”	(Abbiss	&	Laursen	2005),	has	received	increasing	attention	as	performance	 decrements	 are	 observed	 in	 the	 absence	 of	 any	 peripheral	 fatigue	indicators	(Tucker	et	al.	2006;	Tucker	et	al.	2004).	Central	fatigue	can	be	examined	as	changes	in	the	electrical	activity	sent	from	the	brain	to	the	muscles	(neural	drive),	
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the	 spinal	 modulation	 of	 neural	 drive,	 and	 changes	 in	 cerebral	 neurotransmitter	concentration	that	occur	during	heat	stress.	Changes	in	neural	drive	during	heat	stress,	observed	in	response	to	dynamic	whole	 body	 exercise	 (Tucker	 et	 al.	 2006;	 Tucker	 et	 al.	 2004)	 and	 static	 isolated	contractions	 (Morrison	 et	 al.	 2004;	 Nybo	 &	 Nielsen	 2001;	 Thomas	 et	 al.	 2006),	suggest	 that	 fatigue	 occurs	 as	 a	 result	 of	 changes	 in	 the	 CNS.	 In	 a	 series	 of	experiments	(Tucker	et	al.	2006;	Tucker	et	al.	2004)	designed	to	examine	voluntary	pacing	strategies	during	thermal	stress,	 it	was	observed	that	decrements	 in	power	output	coincided	with	decreased	EMG	activity	while	cycling	in	the	heat.	Collectively,	the	results	suggest	that	while	exercising	in	the	heat,	the	brain	(or	another	centrally	located	 governor	 of	 exercise	 intensity)	 reduces	 neural	 drive	 such	 that	 thermal	homeostasis	is	persevered.	Results	 from	 isolated	muscle	contractions	suggest	 that	reductions	 in	neural	drive	during	heat	stress	can	occur	independent	of	exercise.	For	example,	Nybo	and	Nielsen	(2001b)	report	that	voluntary	activation	of	non-exercising	muscle	decrease	following	cycling	to	exhaustion	in	a	hot	environment,	confirming	that	modulation	in	neural	drive	occurs	in	response	to	changes	in	core	temperature.	Furthermore,	Todd	el	al.	(2005)	used	TMS	techniques	to	isolate	the	source	of	impairment	at	the	level	of	the	 motor	 cortex	 or	 higher.	 Decrements	 in	 voluntary	 activation	 and	 maximal	voluntary	 force	 production	 correspond	 to	 increases	 in	 core	 temperature,	 not	 skin	temperature,	 during	 a	 protocol	 in	which	 participants	were	 passively	 heated	 from	thermoneutral	 to	 hyperthermia	 (~39.5°C)	 then	 cooled	 back	 to	 thermoneutral	(Morrison	et	al.	2004;	Thomas	et	al.	2006).		
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Once	 initiated	 by	 the	 motor	 cortex,	 descending	 neural	 drive	 can	 be	modulated	via	 reflex	pathways,	 either	 facilitating	or	 inhibiting	 force	production	 in	the	 muscle.	 In	 response	 to	 elevated	 temperatures,	 pre-synaptic	 inhibition	 of	temperature	sensitive	group	 III	and	 IV	afferents	causes	a	decrease	 in	 spinal	 reflex	amplitude	(Racinais	et	al.	2008).	This	theory	is	supported	by	evidence	of	decreased	H-reflex	amplitude	(indicative	of	the	modulation	of	the	monosynaptic	reflex	activity	of	the	spinal	cord)	following	passive	hyperthermia	(Racinais	et	al.	2008),	suggesting	inhibition	of	the	post-synaptic	element,	namely	the	motor	neuron.	Changes	in	cerebral	neurotransmitters,	specifically	changes	in	serotonin	and	dopamine,	 have	 been	 associated	with	 central	 fatigue	 in	 normothermic	 conditions.	Activity	 and	 sensitivity	 of	 these	 neurotransmitters	 may	 be	 influenced	 by	 high	ambient	 temperatures	 and	 therefore,	 have	 been	 the	 focus	 of	 extensive	 research	(Meeusen	 &	 Roelands	 2010).	 The	 serotonin	 hypothesis	 (Meeusen	 et	 al.	 2006)	suggests	 that	 changes	 in	 arousal,	 motivation	 and	 perceived	 effort	 are	 associated	with	an	increase	in	intracellular	serotonin	concentration.	Pharmacological	inhibition	of	accumulation	via	serotonin	antagonists	enhances	endurance	performance	(Davis	&	Bailey	1997);	however,	the	role	in	hyperthermia	induced	fatigue	remains	unclear.	Another	 neurotransmitter	 that	 is	 likely	 to	 play	 a	 role	 in	 central	 fatigue	 during	hyperthermia	 is	dopamine.	 Initial	 research	using	amphetamines,	a	classification	of	psycho-stimulant	drugs	known	to	release	dopamine,	show	significant	performance	improvements	during	exercise	(Wyndham	et	al.	1971).	Concentrations	of	dopamine	rise	with	 the	 initiation	of	exercise,	whereas	 the	sudden	 fall	 in	dopamine	coincides	with	 early	 fatigue	 (Davis	 &	 Bailey	 1997).	 Pharmacological	 manipulation	 of	
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dopamine	 using	 a	 reuptake	 inhibitor,	 bupropion,	 may	 only	 provide	 performance	benefits	 during	 exercise	 in	 the	 heat.	 Watson	 et	 al.	 (2005)	 found	 that	 bupropion	supplementation	improved	time-trial	performance	by	9%	while	cycling	in	the	heat,	whereas	 supplementation	 had	 no	 performance	 enhancing	 effect	 in	 normothermic	conditions.	 Furthermore,	 dopamine	 re-uptake	 inhibition	 was	 associated	 with	 an	increased	 capacity	 to	 increase	 core	 temperature	 during	 exercise	 without	 any	changes	 in	 subjective	 thermal	 ratings	 (Watson	 et	al.	 2005).	 This	 finding	 suggests	that	dopamine	plays	an	integral	role	in	cessation	of	exercise	during	hyperthermia.	
2.3.3 	Hyperthermia	and	peripheral	neuromuscular	fatigue	The	effects	of	hyperthermia	on	peripheral	muscle	responses	are	complex	as	muscle	 contractile	 properties	 improve	 with	 increased	 temperature	 while	descending	 neural	 drive	 from	 the	 motor	 cortex	 decreases	 with	 hyperthermia.	Hyperthermia	 can	 impair	 the	 ability	 of	 an	 action	potential	 to	 propagate	 along	 the	sarcolemma	 membrane	 and	 furthermore,	 cause	 detrimental	 changes	 to	 the	 non-contractile	elements	of	the	muscle.		Decrements	in	EMG	activity	observed	during	heat	stress	are	often	attributed	to	decreased	supraspinal	mechanisms;	however,	impairment	of	neural	transmission	throughout	 the	 periphery	 (i.e.,	 spinal	 cord	 and	 sarcolemma	 membrane)	 can	 be	observed	with	 hyperthermia	 as	well	 (Racinais	 &	 Oksa	 2010).	 There	 is	 a	 negative	linear	relationship	between	temperature	and	the	latency,	amplitude	and	duration	of	an	action	potential,	as	 there	 is	a	 temperature	dependence	of	 the	 ion	channels	 that	cause	 action	 potentials	 to	 propagate	 along	 the	 sarcolemma	 membrane.	 At	 high	temperatures,	voltage-gated	sodium	channels	open	and	close	quickly	in	comparison	
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to	 normal	 and	 low	 temperatures,	 resulting	 in	 smaller	 ion	 fluctuations	 and	consequently,	 lower	 amplitude,	 duration	 and	 latency	 of	 the	 action	 potential	(Racinais	 &	 Oksa	 2010).	 Furthermore,	 the	 conduction	 velocity	 of	 motor	 nerves	increase	 non-linearly	 with	 increased	 temperature	 (Todnem	 et	 al.	 1989),	 thereby	reducing	 the	 duration	 of	 the	 action	 potential.	 Decrements	 in	 compound	 muscle	action	potential	(M-wave)	amplitude	at	rest	and	during	contraction	suggest	that	for	a	 given	 amount	 of	 neural	 drive,	 hyperthermia	 results	 in	 a	 smaller	 sarcolemmal	action	potential	 (Racinais	et	al.	2008).	Furthermore,	quantal	 failures	 increase	with	increasing	 temperature,	 suggesting	 that	 synaptic	 transmission	 is	 impaired	 with	increasing	temperature	as	well.	Increased	 temperature	 has	 effects	 on	 non-contractile	 elements	 within	 the	muscle	 and	 related	 structures.	 From	 a	 mechanical	 perspective,	 increased	temperature	 decreases	 fluid	 resistance	 within	 a	 joint,	 thereby	 improving	neuromuscular	 function	 (Racinais	 &	 Oksa	 2010).	 Increased	 temperature	 has	 a	positive	 influence	 on	 peripheral	 oxygen	 delivery	 as	 unloading	 from	 haemoglobin	and	 myoglobin	 is	 facilitated.	 Another	 important	 metabolic	 adaptation	 associated	with	 increased	temperature	 is	 improved	substrate	utilization	during	exercise;	ATP	utilization,	 anaerobic	 glycolysis	 and	 creatine	 phosphate	 hydrolysis	 are	 increased	while	 exercising	 in	 the	 heat.	 As	 mentioned	 previously,	 a	 hyperthermia	 induced	increase	in	blood	flow	improves	the	local	metabolic	environment.	 	
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3 OBJECTIVES	AND	HYPOTHESES		 	
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To	examine	neuromuscular	responses	 in	response	to	changes	 in	CBF,	PaCO2	during	 environmental	 stress	 (hypoxia	 and	 hyperthermia).	 The	 following	 series	 of	three	experiments	have	been	designed	with	the	following	objectives:	1. To	 examine	 neuromuscular	 responses	 in	 response	 to	 changes	 in	 CBF	 with	and	 without	 concomitant	 changes	 in	 PaCO2.	 It	 is	 hypothesized	 that	neuromuscular	 response	 will	 be	 impaired	 in	 response	 decreased	 PaCO2,	independent	of	CBF.	2. To	examine	whether	hypoxia	affects	neuromuscular	responses	primarily	by	the	 similar	mechanism	of	CBF/PaCO2	alteration	 (see	objective	1),	 or	 factors	specific	to	reduced	oxygen	availability.	It	is	hypothesized	that	neuromuscular	impairments	observed	during	hypoxia	will	be	mediated	primarily	by	changes	in	PaCO2,	independent	of	changes	in	CBF	and	the	direct	affects	of	low	oxygen	availability.		3. To	 examine	 whether	 hyperthermia	 affects	 neuromuscular	 responses	primarily	 by	 the	 similar	mechanism	 of	 CBF/PaCO2	 alteration	 (see	 objective	1),	or	 factors	specific	 to	 increased	core	temperature.	 It	 is	hypothesized	that	neuromuscular	 impairments	 observed	 during	 hypoxia	 will	 be	 mediated	primarily	by	changes	in	PaCO2,	independent	of	changes	in	CBF	and	the	direct	affects	of	hyperthermia.	
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Table	3-1.	Experimental	protocol	and	expected	physiological	manipulation	for	each	of	the	three	projects		 Protocol	 Physiological	Manipulation	
Project	1		 Indomethacin	 ↓	CBF;		 n/c	PETCO2			 Hypocapnia	 ↓	CBF;			 ↓	PETCO2		 Isocapnic	hyperventilation	 n/c	CBF	 n/c	PETCO2	
Project	2		 Poikilocapnic	hypoxia	 ↓	PETO2;	 n/c	CBF;	 ↓	PETCO2		 Isocapnic	hypoxia	 ↓	PETO2;	 ↑	CBF;	 n/c	PETCO2		 Isocapnic	hypoxia	+	indomethacin	 ↓	PETO2;	 ↓	CBF;	 n/c	PETCO2	
Project	3		 Poikilocapnic	hyperthermia	 ↑	Tc;	 ↓	CBF;	 ↓	PETCO2		 Isocapnic	hyperthermia	 ↑	Tc;	 n/c	CBF;	 n/c	PETCO2		 Isocapnic	hyperthermia	+	indomethacin	 ↑	Tc;	 ↓	CBF;	 n/c	PETCO2	Increase	(↑);	decrease	(↓);	no	change	(n/c);	cerebral	blood	flow	(CBF);	end-tidal	PCO2	(PETCO2);	end-tidal	PO2	(PETO2);	core	temperature	(Tc)			 	
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4 GENERAL	METHODS		 	
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4.1 Participants	The	experimental	protocol	and	procedures	were	approved	by	 the	Bioscience	Research	Ethics	Board	at	Brock	University	(BREB	12-167	and	12-271,	Appendix	B),	and	conformed	to	the	latest	revision	of	the	Declaration	of	Helsinki.	The	participants	for	this	series	of	studies	consisted	of	healthy	male	volunteers,	who	were	free	from	cardiovascular,	 respiratory	 and	 neurological	 disorders,	 recruited	 from	 the	university	 and	 local	 community.	 After	 an	 explanation	 of	 the	 experimental	procedures	and	associated	risks,	all	participants	were	screened	by	a	physician	and	provided	written	informed	consent.	
4.2 Experimental	Design	Participants	 were	 given	 the	 opportunity	 to	 practice	 experimental	 protocols	and	 acquaint	 themselves	 with	 the	 apparatus	 during	 a	 familiarization	 session.	Subsequently,	participants	reported	 to	 the	 laboratory	on	 three	separate	occasions,	separated	 by	 a	minimum	 of	 48	 hours,	 and	were	 asked	 to	 abstain	 from	 strenuous	exercise	and	the	consumption	of	alcohol	for	24	hours	and	caffeine	for	12	hours	prior	to	each	session.		Upon	arrival	 to	 the	 laboratory,	participants’	height	and	mass	were	measured	using	 standard	 laboratory	 equipment.	 Participants	 were	 positioned	 in	 a	 semi-recumbent	 position	 on	 an	 examination	 table	 with	 their	 back	 through	 neck	supported	by	a	backrest	and	their	right	forearm	supported	on	a	side	table	(hip	and	elbow	 angle	 ~135°).	 Following	 instrumentation	 (~20	 min),	 participants	 rested	quietly	prior	to	data	collection.	
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4.3 Physiological	Manipulations	4.3.1 Dynamic	end-tidal	forcing	A	custom-made	end-tidal	forcing	system	(	
	Figure	4-1)	was	used	to	control	PETO2	(50	–	55	mmHg	during	all	conditions)	and	PETCO2	(eucapnia	during	Iso	and	Indo)	throughout	all	conditions.	Using	solenoid	valves	 (S-ET-3M,	Clippard,	 Cincinnati,	OH,	USA)	 to	 independently	 control	 gas	 flow	from	 cylinders	 of	 compressed	 medical	 grade	 breathing	 air	 (21%	 O2,	 0.03%	 CO2,	balance	N2),	100%	N2	and	100%	CO2,	inspired	air	volumes	were	delivered	to	an	air	reservoir	(~5	L)	via	a	humidification	chamber	(~500	mL).	Inspired	air	volumes	and	gas	fractions	were	determined	using	an	algorithm	(Koehle	et	al.	2009)	incorporating	tidal	 volume,	 PETO2	 and	 PETCO2	 error	 (i.e.,	 the	 difference	 between	 desired	 and	measured	 end-tidal	 partial	 pressures)	 to	 “force”	 PETO2	 and	 PETCO2	 towards	 the	desired	 values.	 Expired	 air	 was	 collected	 in	 a	 ~2	 L	 air	 reservoir	 and	was	 vented	from	 the	 system	 using	 a	 low	 resistance	 one-way	 valve.	 In	 the	 event	 that	 the	 air	
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volume	in	the	inspired	reservoir	was	lower	than	tidal	volume,	the	negative	pressure	(created	 by	 the	 complete	 emptying	 of	 the	 inspired	 reservoir)	would	 cause	 a	 high	resistance	one-way	valve	 (connecting	 the	expired	 reservoir)	 to	open,	 allowing	 the	participant	 to	 re-breathe	expired	air.	Re-breathing	prevents	 excessive	 fluctuations	in	PETO2	and	PETCO2	values	while	ensuring	that	the	inspired	air	volume	is	sufficient	during	situations	of	irregular	tidal	volume.	
	Figure	4-1.	Schematic	depicting	the	end	tidal	forcing	system	4.3.2 Indomethacin	Supplementation		To	reduce	CBF	independent	of	PETCO2,	participants	ingested	a	1.2	mg⋅kg-1	dose	of	indomethacin	along	with	150	mg	of	ranitidine	to	reduce	the	possibility	of	gastro-intestinal	 irritation.	 Participants	 then	 rested	 for	 90	 minutes	 to	 allow	 for	 drug	concentrations	 to	peak	within	 the	bloodstream	 (Xie	et	al.	 2006).	During	 this	 time,	participants	rested	quietly	in	the	laboratory.	
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4.4 Neuromuscular	Measurements	The	 neuromuscular	 testing	 consisted	 of	 eliciting	 six	 maximal	 M-wave	response	 (Mmax)	 and	six	MEP	responses,	 each	 separated	by	10	 to	12	 s	 (the	 timing	between	 stimulation	was	 randomized	 to	minimize	 any	 confounds	 of	 a	 participant	anticipating	 the	 stimulus).	 Subsequently,	 participants	 performed	 three	 sets	 of	voluntary	 contractions;	 each	 contraction	 was	 three	 seconds	 in	 duration	 and	consisted	of	a	maximal	voluntary	contraction	(MVC),	followed	by	a	50%	MVC	and	a	75%	 MVC.	 Participants	 viewed	 a	 monitor	 that	 displayed	 the	 target	 torque	 for	submaximal	contractions	(i.e.,	50%	MVC	and	75%	MVC),	with	the	target	calculated	as	 a	 percentage	 of	 the	 previous	 MVC.	 Throughout	 each	 contraction,	 TMS	 was	delivered	 during	 a	 period	 of	 stable	 torque	 production	 (approximately	 one	 second	following	 contraction	 onset)	 and	 each	 contraction	 was	 separated	 by	 10	 s.	Participants	 then	 performed	 three	 MVCs,	 each	 separated	 by	 10	 s.	 For	 each	 MVC,	peripheral	 nerve	 stimulation	 was	 used	 to	 elicit	 a	 superimposed	 twitch	 during	 a	period	of	stable	torque	production	(approximately	one	second	following	contraction	onset)	 and	 a	 potentiated	 twitch	 approximately	 one	 second	 following	 each	contraction.		4.4.1 Electromyography	and	torque	measurements	Electromyography	 (EMG)	 activity	 of	 the	 flexor	 carpi	 radialis	 muscle	 was	measured	using	surface	electrodes	(Hush™	Disk	Electrodes,	Natus	Medical	Inc.,	San	Carlos,	USA).	To	ensure	low	impedance	values	(<5	MΩ),	the	skin	surface	was	shaved	and	abraded	with	electrolyte	gel	(Nuprep,	Weaver	and	Company,	Aurora,	CO,	USA)	then	cleansed	with	isopropyl	alcohol.	The	recording	electrode	was	placed	overtop	of	
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a	motor	point	and	the	reference	electrode	was	placed	10	mm	distal	to	the	recording	electrode	 in	 a	 bipolar	 configuration.	 A	 100	 mm	 circular	 self-adhesive	 ground	electrode	(Dermatorde,	Delsys,	Boston,	MA,	USA)	was	placed	overtop	the	olecranon	process.	EMG	signals	were	band-pass	filtered	between	10	and	2000	Hz	and	acquired	at	sampling	rate	of	3	kHz	using	an	analog	to	digital	converter	(KeyPoint	G4,	Dantec,	Denmark)	 and	 analyzed	 offline	 (MATLAB	 2012b,	 MathWorks,	 Natick,	 MA,	 USA).	Participants	were	positioned	with	 their	 forearm	 in	a	 custom	made	apparatus	 (hip	and	elbow	 joint	angle	~	135°)	designed	to	 isolate	 isometric	 forearm	flexion	of	 the	wrist	 (Figure	 4-2).	 A	 non-compliant	 cuff	 was	 placed	 around	 the	 participant’s	forearm,	 approximately	 10	 cm	 proximal	 to	 the	 styolid	 processes,	 and	 the	 carpals	though	 distal	 phalanges	 of	 the	 right	 hand	 placed	 between	 two	 aluminum	 plates.	These	plates	were	affixed	tangentially	to	a	calibrated	load	cell	and	the	forearm	was	positioned	 such	 that	 the	 styloid	 process	 was	 aligned	 with	 the	 axis	 of	 rotation.	Torque	 measurements	 were	 acquired	 using	 an	 analog	 to	 digital	 converter	 at	 a	sampling	rate	of	3	kHz	(LabView	2010,	National	Instruments,	Austin,	TX,	USA)	and	analyzed	offline	(MATLAB	2012b,	MathWorks,	Natick,	MA,	USA).	
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	Figure	4-2.	Custom	made	isometric	forearm	flexion	device.		4.4.2 Motor	cortex	stimulation	Stimulation	of	the	motor	cortex	was	achieved	using	a	transcranial	magnetic	stimulator	with	a	70	mm	figure-of-eight	coil	(Magstim	Rapid2,	Whitland,	Wales,	UK).	Initially,	 the	 cortical	 site	 for	 optimal	 activation	 of	 the	 flexor	 carpi	 radialis	 was	systematically	 identified	 through	 repeated	 stimulations	 (separated	 by	 ~	 10	 s)	 at	different	locations	of	the	scalp	until	the	largest	amplitude	MEP	was	recorded.	In	all	cases,	 the	optimal	site	of	activation	was	~3	–	5	cm	contralateral	 to	the	vertex,	45°	relative	to	the	sagittal	plane	and	marked	on	the	silicone	swim	cap	used	to	cover	the	participant’s	 scalp,	 allowing	 for	 easy	 identification	 and	 slight	 adhesion	 to	 the	 coil.	
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The	 resting	 motor	 threshold	 was	 estimated	 by	 constructing	 a	 stimulus	 response	curve	(Figure	4-3).	A	 M-wave	 was	 evoked	 using	 a	 handheld	 probe	 with	 anode	 and	 cathode	(inter-electrode	 distance	 of	 2	 cm)	 in	 series,	 placed	 in	 the	 bicipital	 groove	 and	proximal	to	the	cubital	space	(cathode	distal	to	the	anode).	The	anode	and	cathode	were	attached	to	a	constant	current	stimulator	(KeyPoint	G4,	Dantec,	Denmark)	that	delivered	 a	 square	 wave	 pulse	 of	 2	 ms	 in	 duration.	 The	 median	 nerve	 was	stimulated	at	0.5	mA	increments	once	every	10	s,	ranging	from	5	mA	until	reaching	the	 maximal	 M-wave	 response	 (Mmax).	 To	 ensure	 a	 supramaximal	 response,	subsequent	motor	nerve	stimulation	was	delivered	at	1.3	x	Mmax.		
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Figure	4-3.	Schematic	outlining	determination	of	stimulator	output	at	resting	motor	threshold	(i.e.,	stimulus	response	curve).	Motor	evoked	potential	(MEP);	Resting	motor	threshold	(RMT).	4.4.3 Data	analysis	Peak-to-peak	MEP	amplitude	was	normalized	to	Mmax	to	reflect	the	changes	in	 cortical	 excitability	 independent	 of	 potential	 changes	 in	 muscle	 fiber	 action	potentials	 (Gandevia	 et	al.	 1999).	MVC	 torque	was	 quantified	 as	 the	mean	 torque	over	a	100	ms	epoch	immediately	prior	to	the	stimulus;	the	maximum	torque	value	was	selected	for	analysis.	The	resultant	EMG	signal	was	analyzed	in	the	time	domain	as	 root	 mean	 square	 (RMS)	 and	 as	 median	 frequency	 (Fmedian)	 in	 the	 frequency	domain.	 The	maximum	 relaxation	 rate	 of	 the	potentiated	 twitch	 (RRTw,Pot)	 elicited	using	peripheral	nerve	stimulation	was	calculated	as	the	steepest	rate	of	decline	in	force	production	following	stimulation.	Cortical	 voluntary	 activation	 (cVA)	 was	 quantified	 using	 the	 twitch	interpolation	technique	in	which	the	torque	response	to	TMS	was	examined	during	a	 series	of	 submaximal	and	maximal	voluntary	contractions	 (Figure	4-4).	 cVA	was	quantified	using	the	equation	(Todd	et	al.	2003):	TSU % = 1 −	 WXY Z[Y ∙ 100	where	 SIT	 represents	 the	 superimposed	 twitch	 elicited	 by	 TMS	during	 a	maximal	voluntary	 contraction	 (MVC)	 and	 ERT	 represents	 the	 estimated	 resting	 twitch	response.	 Due	 to	 increased	 cortical	 and	 spinal	 excitability	 induced	 by	 muscular	activity,	ERT	was	estimated	by	determining	the	y-intercept	of	the	linear	regression	between	 the	 superimposed	 twitch	 amplitude	 and	 voluntary	 torque	 during	 MVC,	50%	MVC	and	75%	MVC	(Figure	4-4).	
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Similarly,	 peripheral	 voluntary	 activation	 (pVA)	 was	 quantified	 using	 the	interpolated	twitch	technique	in	which	the	torque	increment	elicited	by	peripheral	motor	 nerve	 stimulation	 was	 examined.	 pVA	 was	 quantified	 using	 the	 flowing	equation	(Merton		1954):	\SU % = 1 − WXY P]^,`a@ ∙ 100	where	SIT	represents	 the	superimposed	 twitch	elicited	by	peripheral	motor	nerve	stimulation	 and	 QTw,pot	 represents	 the	 potentiated	 twitch	 elicited	 ~1	 s	 following	MVC.	
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	Figure	 4-4.	 Representative	 data	 illustrating	 (A)	 torque	 increments	 caused	 by	superimposed	TMS	during	MVC,	50%	MVC	and	75%	MVC,	and	(B)	 interpolation	of	estimated	 resting	 twitch.	 Maximal	 voluntary	 contraction	 (MVC);	 Transcranial	magnetic	stimulus	(TMS).	
4.5 Respiratory	measurements	Participants	breathed	through	a	mouthpiece	attached	to	a	T-shaped	two-way	non-rebreathing	valve	 (2700,	Hans	Rudolph,	 Inc.,	Kansas,	USA).	 Inspired	 flow	rate	
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(Sb)	 was	 measured	 using	 a	 pneumotach	 (3813,	 Hans	 Rudolph,	 Inc.,	 Kansas,	 USA)	while	 inspired	and	expired	 fractions	of	O2	and	CO2	were	sampled	at	a	 flow	rate	of	200	 ml⋅min-1	 and	 analyzed	 in	 real	 time	 using	 a	 gas	 analyzer	 (ML206,	 AD	Instruments,	Colorado	Springs,	USA).	
4.6 Cerebrovascular	and	cardiovascular	measurements	Bi-lateral	middle	cerebral	artery	velocity	(MCAv)	was	assessed	using	a	2	MHz	pulsed	transcranial	Doppler	ultrasound	(TCD)	system	(Doppler-Box,	Compumedics	DWL,	Germany).	The	probes	were	positioned	over	the	temporal	window	and	were	held	in	place	using	a	secure	and	comfortable	head	frame	(M600	Headframe,	Spencer	Technologies,	 Seattle,	WA,	 USA).	 TCD	 signals	were	 identified	 and	 optimized	 using	techniques	described	by	Willie	et	al.	(2011a).	Heart	rate	(HR)	was	measured	using	a	one	lead	electrocardiogram	(MLA2340,	AD	Instruments,	Colorado	Springs,	CO,	USA)	and	 non-invasive	 measurement	 of	 oxygen	 saturation	 (SaO2)	 was	 measured	 using	pulse	 oximetry	 (ML320/F,	 AD	 Instruments,	 Colorado	 Springs,	 CO,	 USA)	 placed	 on	the	 left	 ring	 finger.	 Beat-to-beat	 blood	 pressure	 was	 measured	 by	 finger	photoplethysmography	 (Nexfin,	 Bmeye,	 Netherlands)	 and	 was	 normalized	 to	manual	 sphygmomanometer	measurements	 of	 the	 brachial	 artery.	 All	 respiratory,	cerebrovascular	 and	 cardiovascular	 data	 were	 acquired	 continuously	 at	 1	 kHz	(PowerLab	16/30,	AD	Instruments,	Colorado	Springs,	CO,	USA).	 	
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5 THE	EXPERIMENTS		 	
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5.1 Delineating	 the	 role	 of	 cerebral	 blood	 flow	 and	 hypocapnia	 on	
neuromuscular	responses	5.1.1 Introduction	Neuromuscular	 fatigue	 is	 defined	 as	 the	 inability	 of	 a	 muscle	 or	 group	 of	muscles	to	maintain	a	given	level	of	force,	regardless	of	whether	or	not	a	task	can	be	sustained	(Bigland-Ritchie	&	Woods	1984;	Gandevia	 	2001).	It	can	be	attributed	to	many	factors,	ranging	from	changes	in	cortical	excitability	to	excitation-contraction	coupling	 in	 the	 muscle	 tissue	 itself	 (Taylor	 &	 Gandevia	 2001).	 Recent	 research	suggests	 that	 central	 mechanisms	 of	 fatigue	 may	 predominate	 during	 dynamic	exercise	 (Amann	 et	 al.	 2006;	 Amann	 et	 al.	 2007)	 and	 isolated	 isometric	 muscle	contractions	(Millet	et	al.	2009;	Millet	et	al.	2012),	and	may	be	attributed	in	part	to	a	reduction	 in	cerebral	blood	 flow	(CBF)	(Nybo	&	Nielsen	2001;	Nybo	&	Rasmussen	2007;	Secher	et	al.	2008).		 Since	 Nybo	 and	 Nielsen	 (2001b)	 first	 reported	 the	 association	 between	reductions	 in	 cerebral	 blood	 flow	 (CBF)	 and	 impaired	 performance	 during	prolonged	 exercise	 in	 the	 heat,	 research	 has	 examined	 the	 influence	 of	 decreased	arterial	 PCO2	 (PaCO2),	 circulatory	 stress	 (Ide	 &	 Secher	 2000)	 and	 inadequate	cerebral	 oxygen	 delivery	 (Nybo	 &	 Rasmussen	 2007;	 Rasmussen	 et	 al.	 2007)	 as	associated	mechanisms	 contributing	 to	 fatigue.	 Rasmussen	 et	 al.	 (2010a)	 suggest	that	 impaired	 mitochondrial	 oxygen	 tension	 caused	 by	 inadequate	 CBF	 may	compromise	motor	cortical	output;	however,	the	functional	significance	of	reduced	CBF	and	neuromuscular	 fatigue	has	yet	 to	be	 systematically	 investigated	 in	detail.	Recently,	 Ross	 and	 colleagues	 (2012)	
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drive	 during	 passive	 heat	 stress	 was	 related	 to	 reductions	 in	 CBF,	 which	 was	mediated	via	hyperventilation-induced	hypocapnia.	In	this	study,	it	is	interesting	to	note	that,	at	the	point	of	thermal	intolerance,	the	restoration	of	the	partial	pressure	of	end-tidal	CO2	(PETCO2)	towards	baseline	values	restored	decrements	in	voluntary	drive	 despite	 CBF	 remaining	 below	 baseline	 levels.	 These	 findings	 are	 consistent	with	the	view	that	hypocapnia	may	independently	impact	motor	drive	and	provide	an	important	influence	on	neuromuscular	fatigue.	Decreases	 in	 PaCO2	 have	 a	 profound	 effect	 on	 the	 neuromuscular	 system,	ranging	 from	 the	motor	axons	 (Macefield	&	Burke	1991;	Mogyoros	et	al.	 1997)	 to	the	motor	cortex	(Dulla	et	al.	2005;	Kong	et	al.	1994;	Kukumberg	et	al.	1996;	Seyal	et	
al.	 1998;	 Sparing	 et	al.	 2007).	 Hyperventilation-induced	 hypocapnia	 is	 associated	with	 the	 clinical	 presentation	 of	 tetany	 and	 paresthesia,	 and	 is	 linked	 to	spontaneous	action	potentials	(Kong	et	al.	1994).	At	the	peripheral	level,	an	inverse	relationship	 is	 observed	 between	 PaCO2	and	 maximal	 M-wave	 (Mmax)	 amplitude,	presumably	due	in	part	to	a	reduction	in	plasma	calcium	concentration	(Macefield	&	Burke	 1991).	 In	 the	 central	 nervous	 system	 (CNS),	 neuronal	 cells	 in	 the	hippocampus	 increase	 in	 excitability	 during	 conditions	 of	 hypocapnia	 (Dulla	 et	al.	2005).	Similarly,	hypocapnia	has	been	shown	to	 increase	corticospinal	excitability,	causing	increased	amplitude	of	the	motor	evoked	potential	(MEP)	and	a	shortening	of	 the	 MEP	 onset	 latency	 (Kong	 et	 al.	 1994;	 Seyal	 et	 al.	 1998);	 however,	 these	findings	 are	 not	 universally	 accepted	 (Priori	 et	 al.	 1995),	 likely	 due	 in	 part	 to	methodological	differences.	
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Hyperpnea	may	modulate	both	the	cerebral	vasculature	and	neuromuscular	system	 independent	 of	 changes	 in	 PaCO2.	 For	 example,	 Neubauer	 (1983)	 report	 a	modest	 increase	 in	 total	 CBF	 (12%)	 following	 isocapnia	 hyperpnea,	 induced	 by	carotid	 sinus	 nerve	 stimulation	 in	 anesthetised	 cats.	 It	was	 hypothesized	 that	 the	increase	in	metabolic	activity	of	the	medulla	during	hyperpnea	causes	the	release	of	metabolites	 that	mediate	 local	 cerebral	 vasodilation.	 Similarly,	 hyperpnea	may	 be	associated	with	 factors,	such	as	an	external	 focus	of	attention	or	 the	perception	of	effort	(1983;	Ruge	et	al.	2014;	Sparing	et	al.	2007),	that	have	an	excitatory	affect	on	the	motor	cortex	(Ruge	et	al.	2014).	A	novel	approach	to	examine	the	independent	influence	of	CBF	on	ventilation	control	in	humans	is	pharmaceutical	inhibition	of	cyclooxygenase	(Ainslie	&	Duffin	2009).	 Indomethacin	 is	 a	 reversible	 and	 safe	 cyclooxygenase	 inhibitor	 that	 blunts	the	 prostanoid-mediated	 responses	 of	 the	 cerebral	 vasculature,	 decreasing	 CBF	(Parfenova	 et	 al.	 1995)	 without	 concomitant	 changes	 in	 cerebral	 metabolic	 rate	(Hohimer	 et	al.	 1985;	 Kraaier	 et	al.	 1992)	 or	 plasma	 catecholamines	 (Green	 et	al.	1987;	Staessen	et	al.	1984;	Wennmalm	et	al.	1984).	Additionally,	evidence	suggests	that	 indomethacin	 reduces	 cerebrovascular	 reactivity	 to	 CO2,	 causing	 enhanced	central	chemoreceptor	activation	(Fan	et	al.	2011;	Xie	et	al.	2006)	with	 little	effect	on	the	peripheral	chemoreflex	(Fan	et	al.	2011;	Hoiland	et	al.	2014).	Consequently,	indomethacin	has	been	used	successfully	to	investigate	changes	in	CBF	independent	of	changes	in	PaCO2.	The	 purpose	 of	 this	 study	was	 to	 examine	 the	 effects	 of	 reductions	 in	 CBF	with	and	without	hypocapnia	on	neuromuscular	responses.	It	was	hypothesized	that	
	 	
	
57	
hypocapnia,	independent	of	changes	in	CBF,	would	have	a	primary	role	in	mediating	changes	in	neuromuscular	responses.	5.1.2 Methods	
5.1.2.1 Participants	Ten	healthy	male	volunteers,	who	were	free	from	cardiovascular,	respiratory	and	 neurological	 disorders,	 were	 recruited	 from	 the	 university	 and	 local	community.	The	mean	(±	SD)	age,	height,	mass	and	body	mass	index	were	29	±	10	y,	1.78	±	0.06	m,	70.7	±	7.6	kg	and	22.2	±	1.3	kg⋅m-2,	respectively.	
5.1.2.2 Experimental	Design	In	 a	 repeated	measures	 design,	 baseline	 and	 experimental	 measures	 were	collected	in	the	following	conditions	in	this	order:		1) Cyclooxygenase	 inhibition	 via	 oral	 indomethacin	 (Indo;	 1.2	 mg·Kg-1)	administration	 to	 selectively	 reduce	 CBF	 (28.8±10.3%)	 without	 altering	ventilation	or	arterial	blood	gases;	2) Controlled	hyperventilation-induced	hypocapnia	(Hypo)	 to	reduce	CBF	by	a	comparable	extent	as	(1)	 in	the	presence	of	hypocapnia	(PETCO2	 	=	20.1±45	mmHg);	and,	3) Isocapnic	 hyperpnea	 (Iso)	 to	 selectively	 induce	 hyperventilation	 without	changing	PETCO2.	The	 Iso	 condition	was	 performed	 to	 examine	 possible	 confounds	 associated	with	hyperpnea	 and	 potential	 activation	 of	 the	 CNS	 respiratory	 control	 centres	(Neubauer	et	al.	 1983).	 Each	 condition	was	 presented	 in	 a	 non-randomized	 order
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such	that	the	breathing	frequency	(fbr)	utilized	in	Hypo	induced	a	matched	reduction	in	CBF	observed	during	Indo;	and	that	the	fbr	utilized	during	Iso	was	matched	with	Hypo.	The	experimental	protocol	is	illustrated	in	Figure	5-1.	
	Figure	 5-1.	 Schematic	 outlining	 the	 protocol	 for	 experiment	 5.1.	 Transcranial	magnetic	 stimulation	 (TMS);	 Maximal	 M-wave	 (Mmax);	 Motor	 evoked	 potential	(MEP);	cortical	voluntary	activation	(cVA);	peripheral	voluntary	activation	(pVA).		
5.1.2.3 Statistical	Analysis	Normal	distribution	of	data	was	confirmed	with	the	Shapiro-Wilk	normality	test.	 Two-way	 repeated	measures	 ANOVA	 analyses	 were	 conducted	 to	 assess	 the	change	 in	 respiratory,	 cerebrovascular,	 cardiovascular	 and	 neuromuscular	responses	 between	 baseline	 versus	 experimental	 measurements	 and	 across	 the	three	 conditions	 (Indo,	 Hypo	 and	 Iso).	 Sphericity	 for	 terms	 was	 assessed	 by	Mauchly's	test	of	sphericity;	if	this	was	violated	(p	<	0.05),	data	were	assessed	using	a	 Greenhouse-Geisser	 adjustment.	 Pair-wise	 comparisons,	 using	 a	 Bonferroni	correction,	were	used	to	identify	main	effects.	Significant	interactions	were	assessed	using	 separate	 repeated	 measures	 ANOVA.	 The	 relationship	 between	 MEP	amplitude	and	cortical	voluntary	activation	(cVA)	vs.	PETCO2,	middle	cerebral	artery	
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velocity	 (MCAv)	 and	 fbr	 was	 assessed	 using	 a	 Pearson	 correlation.	 All	 statistical	analyses	were	conducted	using	SPSS	20	(SPSS	Inc.,	Chicago,	IL,	USA),	with	statistical	significance	set	a	p	<	0.05.	Data	are	discussed	 in-text	as	 the	absolute	change	 from	baseline	(mean	±	SD),	whereas	data	are	presented	in	Tables	and	Figures	as	separate	baseline	and	experimental	measurements	(mean	±	SD).	5.1.3 Results	
5.1.3.1 Respiratory,	Cerebrovascular	and	Cardiovascular	Responses	Baseline	 and	 experimental	 respiratory,	 cerebrovascular	 and	 cardiovascular	data	during	Indo,	Hypo	and	Iso	conditions	are	displayed	in		Table	5-1.	No	significant	differences	(p	>	0.05)	in	baseline	measurements	between	conditions	were	observed	for	any	of	the	collected	respiratory,	cerebrovascular	or	cardiovascular	variables.	Table	5-1	Baseline	and	experimental	cardio-respiratory	data	during	Indomethacin,	Hypocapnia	and	Isocapnia	conditions.		 Indomethacin	 	 Hypocapnia	 	 Isocapnia		 Baseline	 Experimental	 	 Baseline	 Experimental	 	 Baseline	 Experimental	PETO2,	mmHg	 109.2	±	6.9	 107.3	±	5.8	 	 110.5	±	7.3	 110.0	±	9.8	 	 109.9	±	6.7	 106.0	±	8.0	PETCO2,	mmHg	 41.1	±	4.2	 40.6	±	3.0	 	 41.6	±	2.9	 30.1	±	4.5†	 	 42.1	±	3.2	 46.3	±	2.7	MCAv,	cm·s-1	 61.2	±	7.8	 43.4	±	8.1†	 	 65.3	±	9.6	 50.9	±	8.1†	 	 62.1	±	6.6	 62.1	±	5.8	
fbr,	breaths·min-1	 14.2	±	2.4	 13.9	±	2.2	 	 14.5	±	2.8	 20.5	±	4.6†	 	 13.9	±	2.9	 21.1	±	5.2†	Sb ,	L·min-1	 8.8	±	2.1	 9.0	±	1.4	 	 9.5	±	1.4	 17.1	±	6.1†	 	 9.5	±	1.6	 15.9	±	1.4†	HR,	beats·min-1	 59	±	6	 51	±	6†	 	 58	±	6	 67	±	10†	 	 61	±	8	 64	±	8*	SpO2,	%	 97.5	±	0.9	 98.3	±	0.7	 	 97.2	±	2.1	 98.7	±	0.8	 	 97.1	±	1.1	 97.2	±	1.0	MAP,	mmHg	 91	±	8	 96	±	7†	 	 93	±	14	 102	±	13†	 	 90	±	10	 97	±	12†	PETO2,	 end-tidal	 partial	 pressure	 of	 oxygen;	 PETCO2,	 end-tidal	 partial	 pressure	 of	 carbon	 dioxide;	MCAv,	middle	cerebral	artery	velocity;	fbr,	breathing	frequency,	Sb ,	inspired	flow	rate;	HR,	heart	rate;	SpO2,	oxygen	saturation;	MAP,	mean	arterial	pressure;	Values	are	mean	±	SD;	n	=	10	recordings;	*	p	<	0.05	vs.	Baseline;	†	p	<	0.01	vs.	Baseline.	
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Compared	 to	 baseline,	 significant	 increases	 in	 fbr	 (6.0±4.7	 and	 7.2±3.5	breath⋅min-1,	 p	 <	 0.01)	 and	 consequently,	Sb 	(7.52±5.17	 and	 6.40±1.74	 L⋅min-1,	p	<	0.01)	were	observed	during	Hypo	and	Iso,	respectively,	whereas	no	differences	were	observed	during	 Indo	 (-0.3±2.5	breath⋅min-1,	 p	=	0.69;	0.21±1.43	L⋅min-1,	 p	=	0.65).	By	design,	PETCO2	was	significantly	lower	during	Hypo	(-11.5±2.8	mmHg,	p	<	0.01),	 but	 not	 during	 Indo	 (-0.5±3.0	mmHg,	 p	 <	 0.63)	 or	 Iso	 (-0.2±1.3	mmHg,	 p	 <	0.72).	 PETO2	 remained	 similar	 to	 baseline	 levels	 during	 all	 conditions	 (-1.8±4.3	mmHg,	 -0.5±5.7	 mmHg,	 -3.9±5.6	 mmHg	 for	 Indo,	 Hypo	 and	 Iso,	 respectively,	 p	 =	0.10).	 MCAv	 decreased	 during	 both	 Indo	 (-17.7±7.14	 cm⋅s-1	 or	 28.8±10.3%,	 p	 <	0.01)	 and	 Hypo	 (-14.27±4.80	 cm⋅s-1	 or	 21.7±6.3%,	 p	 <	 0.01)	 conditions	 and	remained	 unchanged	 during	 Iso	 (-0.01±2.12	 cm⋅s-1	 or	 0.1±3.5%,	 p	=	0.99).	Reductions	 in	 HR	 were	 observed	 during	 Indo	 (-8±4	 beats⋅min-1,	 p	<	0.01)	 while	elevations	were	observed	in	Hypo	(9±7	beats⋅min-1,	p	<	0.01).	HR	was	unchanged	in	Iso	 (3±4	 beats⋅min-1,	 p	<	0.9).	 Significant	 increases	 in	 MAP	 were	 observed	(6.69±6.71	mmHg,	p	<	0.01)	across	all	conditions.	
5.1.3.2 Neuromuscular	Responses	Voluntary	torque	production	during	MVC	was	unchanged	(p	=	0.85)	relative	to	baseline	during	all	conditions	(-0.22±2.31	N⋅m-1,	-0.41±1.82	N⋅m-1,	0.22±1.51	Nm,	for	Indo,	Hypo	and	Iso;	Figure	5-2A).	Similarly,	there	was	no	significant	difference	in	root	mean	square	(RMS)	(21.6±34.1	mV,	8.4±34.1	mV,	22.1±34.1	mV,	p	=	0.94)	and	median	 frequency	 (Fmedian)	 (-0.1±20.8	Hz,	 -7.4±20.8	Hz,	 48.8±20.8	Hz,	 p	 =	 0.17)	 of	
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the	voluntary	torque	production	during	MVC	in	all	conditions	when	examining	the	change	from	baseline	measurements.	
	Figure	 5-2.	 Neuromuscular	 response	 to	 Indomethacin,	 Hypocapnia	 and	 Isocapnia.	Motor	 evoked	 potential	 (MEP);	 maximal	 M-wave	 (Mmax);	 cortical	 siluednt	 period	(cSP);	 cortical	 voluntary	 activation	 (cVA);	 peripheral	 voluntary	 activation	 (pVA);	Maximal	relaxation	rate	of	the	potentiated	twitch	(RRTw,Pot);	Maximal	relaxation	rate	of	the	transcranial	magnetic	stimulation	twitch	(RRTMS).	Peak	 to	 peak	 MEP	 amplitude	 (Figure	 5-2B),	 expressed	 as	 a	 percentage	 of	Mmax,	 increased	 significantly	 during	 the	 Hypo	 condition	 (11.78±9.07%,	 p	 <	 0.01);	
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however,	it	remained	unchanged	from	baseline	in	Indo	(-1.48±2.57%,	p	=	0.10)	and	Iso	 (0.16±1.96%,	 p	=	0.86)	 conditions.	 Conversely,	 cVA	 (Figure	 5-2E)	 was	significantly	lower	during	the	Indo	(-13.6±14.7	%,	p	=	0.02)	and	Hypo	(-14.9±11.8%,	p	=	0.01)	conditions	in	comparison	to	baseline,	whereas	no	significant	changes	were	observed	during	Iso	(-2.4	±6.2%,	p	=	0.26).	The	maximum	relaxation	rate	from	TMS	(RRTMS)	of	the	superimposed	twitch	(Figure	5-2H)	was	unchanged	in	all	conditions	(14.5±22.7	N⋅m-1,	-6.7±31.4	N⋅m-1,	and	-0.6±26.1	N⋅m-1;	p	=	0.128).	The	resultant	cSP	(Figure	 5-2D)	 remained	 similar	 (p	=	0.64)	 to	 baseline	 measurements	 in	 all	conditions	 (-6.1±22.4	 ms,	 -1.6±28.6	 ms	 and	 6.8±37.8	 ms	 for	 Indo,	 Hypo	 and	 Iso,	respectively).	Peak	to	peak	Mmax	amplitude	(Figure	5-2C)	was	unchanged	(p	=	0.82)	relative	to	baseline	measured	during	all	conditions	(0.2±2.3	mV,	-0.2±2.7	mV,	0.3±1.1	mV	for	Indo,	Hypo	 and	 Iso).	 pVA	 (Figure	 5-2F)	 decreased	 in	 response	 to	 all	 conditions	 (-7.4±16.5%,	p	=	0.03);	however,	there	was	no	interaction	between	Indo,	Hypo	or	Iso.	RRTw,pot	(Figure	5-2H;	-0.02±0.03	N⋅m-1,	0.02±0.04	N⋅m-1,	and	-0.01±0.02	N⋅m-1;	p	=	0.15)	 and	 RRTw,Pot	 (Figure	 5-2G;	 3.94±7.73	 N⋅m-1⋅s-1,	 -2.15±9.29	 N⋅m-1⋅s-1,	and	 -0.15±4.19N⋅m-1⋅s-1;	 p	=	 0.47)	 of	 the	 potentiated	 twitch	 remained	 similar	 to	baseline	values	in	all	conditions.	
5.1.3.3 Relationships	 Between	 Hypocapnia	 and	 Cerebral	 Blood	 Flow	 with	
Neuromuscular	Responses	Individual	correlations	between	changes	in	PETCO2	or	MCAv	with	cVA	or	MEP	amplitude	 are	 displayed	 in	 Figure	 5-3.	 MEP	 amplitude	 (%Mmax)	 was	 moderately	
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correlated	with	changes	 in	PETCO2	 for	data	pooled	across	condition	 (r2	=	0.50,	p	<	0.01,	 Figure	 4A);	 however,	 no	 apparent	 relationships	 were	 observed	 with	 MCAv.	Changes	in	cVA	was	weakly	correlated	with	both	MCAv	(r2	=	0.09,	p	=	0.09,	Figure	5-3D)	 for	 data	 pooled	 across	 conditions,	 whereas	 no	 correlations	 were	 observed	with	PETCO2	(p	=	0.29).	
	Figure	 5-3.	 Correlation	 analysis	 between	 changes	 from	 baseline	 in	 motor	 evoked	potential	 amplitude	 (∆MEP)	 and	 central	 voluntary	 activation	 (∆cVA)	 vs.	 end-tidal	partial	pressure	of	CO2	(∆PETCO2)	and	middle	cerebral	artery	velocity	(∆MCAv).		5.1.4 Discussion	The	 purpose	 of	 this	 study	 was	 to	 examine	 neuromuscular	 responses	 in	response	 to	 reductions	 in	CBF	with	 and	without	 consequent	 changes	 in	 PETCO2.	 It	
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was	hypothesized	that	hypocapnia,	 independent	of	changes	in	CBF,	would	mediate	changes	 in	 neuromuscular	 responses.	 The	 primary	 findings	 of	 this	 study	were	 1)	increased	corticospinal	excitability	was	associated	with	hypocapnia,	independent	of	changes	 in	 CBF	 and	 the	 mechanical	 changes	 associated	 with	 hyperpnea;	 and	 2)	reductions	in	cVA	were	associated	with	reduced	cerebral	blood	flow,	independent	of	hypocapnia.	
5.1.4.1 Peripheral	Neuromuscular	Responses	Reduced	 CBF	 and	 hypocapnia	 associated	 with	 controlled	 hyperventilation	were	 not	 associated	 with	 significant	 changes	 within	 the	 muscle	 fibre	 itself.	 The	amplitude	of	Mmax	elicited	by	stimulation	of	the	median	nerve	was	unaffected	across	all	 conditions	 (Figure	5-2C),	 suggesting	 that	neuromuscular	propagation	remained	intact.	 These	 findings	 are	 consistent	 with	 data	 obtained	 (i.e.,	 no	 change	 in	 Mmax	amplitude)	 following	 cyclooxygenase	 inhibition	 using	 acetaminophen	 (Mauger	 &	Hopker	2013);	however,	to	the	best	of	our	knowledge,	this	is	the	first	study	to	assess	changes	 in	 peripheral	 neuromuscular	 responses	 following	 indomethacin	 or	 any	other	NSAID	supplementation.	Also	consistent	with	our	findings,	previous	research	(Hilbert	et	al.	2012)	indicates	that	hyperventilation-induced	hypocapnia	(PETCO2	16	mmHg	 below	 baseline)	 had	 no	 effect	 on	 Mmax	 amplitude,	 despite	 significant	reductions	in	arterial	pH	obtained	via	direct	blood	sampling.	In	support	of	maintained	peripheral	neuromuscular	 responses,	RRTw,Pot	 and	RRTMS	 were	 unaffected	 across	 conditions	 (Figure	 5-2H,I).	 These	 findings	 are	supported	 by	 Morrow	 et	 al.	 (1988)	 who	 report	 no	 significant	 changes	 in	performance	outcome	measures	following	respiratory	alkalosis.	Similarly,	Spriet	et	
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al.	 (1986)	 found	 no	 significant	 changes	 in	 isometric	 force	 production	 following	sciatic	 nerve	 stimulation	 in	 mice	 and	 furthermore,	 no	 significant	 differences	 in	muscle	 oxygen	 uptake,	 glucose	 utilization	 and	 total	 lactate	 production	 following	induced	respiratory	alkalosis.	This	evidence	suggests	that	peripheral	neuromuscular	responses	 was	 maintained	 despite	 marked	 hypocapnia	 and	 related	 respiratory	alkalosis.	
5.1.4.2 Corticospinal	Excitability	and	Hypocapnia	A	central	finding	of	the	present	study	is	that	the	increased	MEP	amplitude	(%	Mmax)	was	enhanced	during	Hypo	(Figure	5-2B)	and	correlated	to	PETCO2	(r2	=	0.56,	p	 =	 0.02;	 Figure	 5-3A)	when	 data	were	 pooled	 across	 conditions.	 Our	 data	 are	 in	agreement	 with	 several	 previous	 reports	 (Seyal	 et	 al.	 1998;	 Sparing	 et	 al.	 2007)	using	controlled	hyperventilation	to	induce	hypocapnia;	however,	this	finding	is	not	universally	 accepted	 (Kong	 et	 al.	 1994;	 Priori	 et	 al.	 1995).	 Seyal	 el	 al.	 (1998)	reported	an	inverse	relationship	between	PETCO2	and	MEP	amplitude	during	graded	hyperventilation	 and	 noted	 significant	 enhancement	 of	 the	 MEP	 response	 when	reductions	in	PETCO2	were	greater	than	10	mmHg	below	eucapnia.	Similarly,	Sparing	et	 al.	 (2007)	 observed	 a	 significant	 decrease	 in	 the	 motor	 threshold	 and	 an	enhancement	 of	 the	 MEP	 stimulus-response	 curve	 to	 TMS	 after	 hyperventilation	resulting	in	a	15	mmHg	reduction	in	PETCO2.	In	contrast	to	these	findings,	Kong	et	al.	(1994)	and	Priori	et	al.	(1995)	did	not	report	significant	alterations	in	MEP	response	during	 hyperventilation-induced	 hypocapnia.	 A	 potential	 explanation	 for	 these	conflicting	results	may	be	related	to	methodological	issues.	For	example,	Kong	et	al.	(1994)	 suggest	 that	 their	 measure	 of	 motor	 cortex	 excitability	 (namely,	 post-
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stimulus	 time	 histograms)	 may	 be	 too	 insensitive	 to	 detect	 modest	 changes	associated	with	hypocapnia.	Similarly,	the	TMS	stimulus	intensity	utilized	by	Priori	et	al.	(1995)	may	have	been	too	high	to	discriminate	differences	in	MEP	amplitude,	despite	significant	reductions	in	PETCO2	(Seyal	et	al.	1998).	This	hypothesis	has	since	been	corroborated	by	Sparing	et	al.	(2007),	who	reported	significant	enhancement	in	the	TMS	stimulus-response	curve	only	at	intensities	lower	than	60%	of	stimulator	output.	The	 mechanistic	 influence	 of	 hypocapnia	 on	 motor	 cortex	 excitability	 has	been	 elucidated	 in	 rat	 hippocampal	 slice	 preparations	 (Dulla	 et	 al.	 2005).	 The	increase	 in	 extracellular	 pH	 associated	 with	 hypocapnia	 inhibits	 ecto-ATPase	activity	 (a	 trans-membrane	 enzyme	 that	 is	 involved	 in	 the	 hydrolysis	 of	extracellular	ATP),	causing	the	accumulation	of	extracellular	ATP	and	the	decrease	in	 extracellular	 adenosine.	 Increased	 extracellular	 ATP	 concentrations	 enhance	purinergic	 receptors,	 causing	 an	 increase	 in	 excitatory	 inputs	 on	 interneurons	(Khakh	et	al.	2003),	modulation	of	excitatory	post-synaptic	potentials	(Pankratov	et	
al.	 1998)	 and	 facilitation	 of	 long-term	 potentiation	 (Almeida	 et	 al.	 2003).	Conversely,	 decreased	 extracellular	 concentrations	 of	 adenosine	 decrease	 A1	receptor	activity,	reducing	the	tonic	inhibition	of	glutamate,	a	neurotransmitter	that	is	 responsible	 mediating	 excitatory	 signals	 (Johansson	 et	 al.	 2001).	 Collectively,	these	 changes	 are	 associated	 with	 increase	 neuronal	 excitability	 and	 therefore,	enhancement	of	the	MEP.	Similar	 research	 studies	 (Priori	 et	al.	 1995;	 Sparing	 et	al.	 2007)	 examining	supra-spinal	 responses	 to	 hypocapnia	 report	 a	 4-15%	 decrease	 in	 cortical	
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inhibition;	 however,	 the	 present	 data	 fail	 to	 support	 this	 observation	 as	 cSP	was	unaffected	by	the	experimental	manipulations	(Figure	5-2D).	It	is	plausible	that	the	duration	of	the	hyperventilation	protocol	utilized	in	the	present	study	was	too	short	to	induce	significant	changes	in	cortical	inhibition.	For	example,	Priori	et	al.	(1995)	reported	 that	 shortening	 of	 the	 cSP	 was	 significant	 only	 after	 10	 min	 of	hyperventilation	 and	 lagged	 significantly	 behind	 changes	 in	 PETCO2.	Hyperventilation	 is	associated	with	respiratory	alkalosis	and	a	reduction	 in	serum	ionized	calcium	concentration	(Davies	et	al.	1986).	The	 latter	 factor	may	modulate	the	primary	inhibitory	neurotransmitter	gamma-Aminobutyric	acid	(GABA)	and	N-methyl-D-asparate	 (NMDA)	 receptors	 (Chesler	 &	 Kaila	 1992;	 Lee	 et	 al.	 1996).	Specifically,	 shortening	 of	 the	 cSP	 is	 likely	mediated	 through	 the	 GABAB	 receptor	(Korchounov	 et	 al.	 2005);	 a	 metabotropic	 trans-membrane	 receptor	 that	 is	characterized	 by	 their	 coupling	 to	 G-proteins	 (Bowery	 et	 al.	 2002)	 and	consequently,	slow	time-course	response	in	motor	cortex	inhibition	(Kohl	&	Paulsen	2010).	Novel	 to	 the	 present	 study	 is	 the	 ability	 to	 delineate	 the	 influence	 of	hypocapnia	 versus	 the	 modulation	 of	 the	 sensory	 attention	 effects	 of	hyperventilation.	 Enhanced	 MEP	 amplitude	 during	 Hypo	 in	 comparison	 to	 Iso	suggests	 that	 hypocapnia,	 rather	 than	 confounds	 associated	 with	 hyperpnea	 and	potential	 activation	of	 the	CNS	 respiratory	 control	 centres	 (Neubauer	et	al.	 1983),	are	associated	with	the	increase	in	corticospinal	excitability.	For	example,	Ruge	et	al.	(2014)	 provide	 evidence	 that	 attention	 demands	 placed	 on	 internal	 or	 external	sources	(in	the	context	of	the	present	study,	focus	on	fbr	or	tidal	volume	represents	
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internal	 attention,	 whereas	 focusing	 on	 the	 sound	 of	 the	 metronome	 represents	external	 focus	 of	 attention)	 increases	 corticospinal	 excitability	 and	 reduces	 GABA	mediated	inhibition	in	humans.	This	finding	has	been	postulated	elsewhere	(Sparing	
et	al.	2007);	however,	to	the	best	of	our	knowledge,	the	present	study	is	the	first	to	investigate	systematically	this	question.	
5.1.4.3 Voluntary	Activation	and	Cerebral	Blood	Flow	Although	 there	 were	 no	 significant	 reductions	 in	 voluntary	 torque	production,	cVA	was	reduced	 in	comparison	to	baseline	during	the	Indo	and	Hypo	conditions	(Figure	5-2E).	Reduced	cVA	during	voluntary	contractions	occur	because	of	 sub-optimal	output	 from	 the	motor	 cortex,	 causing	a	decrease	 in	motor	neuron	firing	frequency	and/or	motor	neuron	recruitment	(Peters	&	Fuglevand	1999).	This	finding	suggests	that	reductions	in	cVA	are	associated	with	decreased	CBF;	however,	although	we	acknowledge	 the	 limitations	of	 correlations	 to	provide	 insight	 to	 into	physiological	causation,	we	failed	to	detect	a	significant	linear	relationship	between	the	two	variables	(Figure	5-3E).	Collectively,	since	cVA	was	selectively	lower	during	reductions	 in	 CBF	 independent	 of	 hypocapnia	 (Indo),	 these	 findings	 suggest	 that	although	 CBF	may	 be	 an	 important	mechanism	 regulating	 voluntary	 activation	 in	the	 present	 study	 –	 clearly,	 however,	 numerous	 additional	 factors	 contribute	 to	modulate	voluntary	descending	drive	from	the	motor	cortex	(Gandevia		2001).	Previous	research	 indicates	 that	reductions	 in	voluntary	activation	occur	 in	response	 to	 a	 variety	 of	 stressors,	 such	 as	 fatiguing	 exercise	 (Todd	 et	 al.	 2003),	hyperthermia	(Morrison	et	al.	2004;	Ross	et	al.	2012;	Thomas	et	al.	2006;	Todd	et	al.	2005)	and	hypoxia	(Goodall	et	al.	2010).	During	passive	heating,	Ross	et	al.	(2012)	
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observed	 a	 progressive	 decrease	 in	 voluntary	 activation	 that	was	 associated	with	thermal	hyperpnoea	and	concomitant	reductions	 in	PETCO2	and	CBF.	Furthermore,	breathing	a	hypercapnic	gas	mixture	 (5%	CO2)	at	 the	point	of	 thermal	 intolerance	caused	 the	 partial	 restoration	 of	 voluntary	 activation,	 suggesting	 that	cerebrovascular	 mechanisms,	 rather	 than	 the	 direct	 effects	 of	 hyperthermia,	mediate	 neuromuscular	 impairments.	 The	 present	 study	 supports	 these	 findings,	suggesting	 that	 cerebrovascular	 mechanisms	 mediate	 reductions	 in	 voluntary	activation	 and	 furthermore,	 delineate	 the	 primary	 role	 of	 CBF	 (rather	 than	hypocapnia	per	se)	as	a	modulator	of	descending	drive	from	the	motor	cortex.	In	addition	to	the	independent	influence	of	changes	in	CBF	on	neuromuscular	responses,	 increased	 perception	 of	 effort	 (Berchicci	 et	al.	 2013;	 Lampropoulou	 &	Nowicky	2014)	 or	 discomfort	 during	 Indo	 and	Hypo	may	have	 contributed	 to	 the	reductions	 in	 cVA.	 Both	 indomethacin	 and	 hyperventilation,	 via	 their	 impact	 on	causing	 cerebral	 vasoconstriction,	 are	 associated	 with	 similar	 neurological	 side	effects,	such	as	dizziness,	nervousness	and	headache	–	factors	that	contribute	to	an	overall	sensation	of	distress.	Recently,	Lampropoulou	and	Nowikcy	(2014)	indicate	that	 perception	of	 effort	 is	 a	 primary	 regulator	 of	 voluntary	motor	 control	 during	isometric	 contractions.	 Furthermore,	 Baweja	 et	 al.	 (2011)	 indicate	 that	 high-amplitude	respiration	contributes	to	a	lack	of	motor	control	during	MVC.	Although	the	 association	 between	 reductions	 in	 CBF	 and	 increased	 perception	 of	 effort	 or	distress	 remain	 speculative	 at	 best,	 the	 present	 study	 excludes	 the	 possible	psychosomatic	 modulating	 effect	 of	 elevations	 in	 ventilation,	 rather	 than	
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hypocapnia	 or	 reduced	 CBF	 per	 se,	 given	 that	 reductions	 in	 voluntary	 activation	were	not	observed	during	the	Iso	condition	(Figure	5-2E).	Quantification	 of	 voluntary	 activation	 was	 assessed	 using	 both	 electrical	stimulation	of	the	peripheral	motor	nerve	(pVA)	and	TMS	of	the	motor	cortex	(cVA).	Although	 both	 measures	 represent	 the	 magnitude	 of	 neural	 drive	 to	 the	 muscle,	comparing	the	stimulation	responses	obtained	at	different	locations	throughout	the	neuromuscular	system	may	help	localize	the	site	of	impairment	(Todd	et	al.	2004).	In	the	present	study,	voluntary	activation	assessed	as	either	pVA	or	cVA	decreased	in	 response	 to	 all	 conditions;	 however,	 a	 significant	 interaction	 effect	 with	 cVA	suggests	 that	a	more	pronounced	decrement	 in	neural	drive	occurred	during	 Indo	and	Hypo	(Figure	5-2E).	Collectively,	this	evidence	suggests	the	mechanism(s)	that	contribute	to	neuromuscular	impairments	in	response	to	decreased	CBF	reside	at	or	above	the	level	of	the	motor	cortex.		 	
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5.2 The	effects	of	 altered	 cerebral	blood	 flow	on	neuromuscular	 responses	
during	acute	hypoxia	5.2.1 Introduction	Recent	 evidence	 suggests	 that	 severe	 hypoxia	 [inspired	 oxygen	 fraction	(FiO2)	≤	0.1]	acts	directly	on	the	brain	to	impair	neuromuscular	responses	(Amann	
et	 al.	 2007);	 however,	 the	 mechanisms	 underlying	 these	 observations	 remain	contradictory,	 as	 hypoxia	 itself	 leads	 to	 a	 range	 of	 effects	 on	 the	 respiratory,	cerebrovascular,	 and	 central	 nervous	 systems	 (Goodall	 et	 al.	 2010;	 Miscio	 et	 al.	2009;	Szubski	et	al.	2006;	Szubski	et	al.	2007).	One	change	with	acute	hypoxia	 is	a	brisk	hypoxic	ventilatory	response	(HVR)	and	concomitant	decrease	in	arterial	PCO2	(PaCO2).	 If	 this	 hypocapnia	 is	 sufficiently	 large,	 the	 net	 response	 from	 PaCO2-mediated	 vasoconstriction	 versus	 arterial	 PO2	 (PaO2)	 vasodilation	 in	 the	 cerebral	vasculature	 is	 a	 decrease	 in	 cerebral	 blood	 flow	 (CBF).	 Therefore,	 resultant	hypocapnia	 is	 associated	 with	 not	 only	 increased	 cerebral	 pH,	 but	 also	 impaired	cerebral	 oxygen	 delivery	 (%c*+)	 via	 the	 reduced	 CBF.	 All	 of	 these	 factors	 can	separately	 or	 synergistically	 modulate	 the	 excitability	 of	 neurons	 in	 the	corticospinal	 tract,	 but	 existing	 research	 have	 not	 fully	 investigated	 the	 direct	contributions	of	reduced	CBF.	A	 possible	 mechanism	 regulating	 the	 central	 nervous	 system	 response	 to	hypoxia	is	inadequate	%c*+ 	and	subsequent	reductions	in	cerebral	capillary	oxygen	tension	(Nybo	&	Rasmussen	2007).	The	cerebral	 tissue	 is	protected	 from	hypoxia-induced	reductions	in	PaO2	by	an	associated	increase	in	CBF	(Ainslie	&	Ogoh	2010);	however,	%c*+ 	is	 impaired	 when	 the	 increase	 in	 CBF	 cannot	 compensate	 for	 the	
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reduction	in	arterial	O2	content	(CaO2)	or	when	a	large	HVR-mediated	reduction	in	PaCO2	 blunts	 hypoxia-induced	 increase	 in	 CBF	 (Ainslie	 &	 Subudhi	 2014).	 Several	studies	 have	provided	 evidence	 that	 decreased	 cerebral	 oxygenation	 is	 associated	with	 fatigue	 during	 isolated	 contractions	 (Goodall	 et	 al.	 2012)	 and	 whole	 body	exercise	 (Rasmussen	et	al.	2010);	however,	 improving	cerebral	oxygenation	above	baseline	 via	 CO2	 clamping	 during	 incremental	 exercise	 in	 hypobaric	 hypoxia	(barometric	pressure	=	452	mmHg;	1,650	m)	did	not	improve	whole-body	exercise	performance	(Subudhi	et	al.	2011).	Transcranial	 magnetic	 stimulation	 (TMS)	 has	 been	 used	 to	 examine	 the	corticospinal	responses	to	hypoxia	and	to	further	delineate	the	central	mechanisms	of	neuromuscular	 responses	associated	with	decreased	PaO2.	 Szubski	 et	 al.	 (2006)	reported	a	modest	increase	in	motor	cortex	excitability	and	deterioration	of	GABA-nergic	 mediated	 intracortical	 inhibition	 in	 response	 to	 ~45	 min	 hypoxia	 (FiO2	 =	0.12;	SaO2	=	75	±	2%)	exposure,	indicated	by	a	~2%	decrease	in	the	resting	motor	threshold	and	~7%	increase	in	cortical	silent	period,	respectively.	Rupp	et	al.	(2012)	reported	 a	 time-dependent	modulation	 of	 corticospinal	 excitability	 in	 response	 to	acute	hypoxia	(FiO2	=	0.12).	One	hour	of	hypoxia	exposure	(SaO2	=	83	±	5%)	had	no	discernible	 effect	 on	 motor	 evoked	 potential	 (MEP)	 amplitude	 or	 cortical	 silent	period	 (cSP),	whereas	 three	hours	of	hypoxia	exposure	 (SaO2	=	86±5%)	 increased	both	MEP	amplitude	(24-27%)	and	cSP	(14-20%)	at	various	contraction	strengths	(50-100%	MVC).	Increased	motor	cortex	excitability	in	response	to	hypoxia	is	not	a	universally	 accepted	 finding.	 For	 example,	 Goodall	 et	 al.	 (2010)	 did	 not	 observe	changes	in	supraspinal	contributions	to	hypoxia-induced	(FiO2	=	0.10;	SaO2	=	74.2	±	
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6.6%)	 fatigue,	 perhaps	 due	 in	 part	 to	 excitatory	 influence	 of	 HVR-induced	hypocapnia	on	cortical	neurons	(Dulla	et	al.	2005).	Furthermore,	chronic	(3-5	days)	high	 altitude	 exposure	 (4,554	 m;	 SaO2	 =	 84±4.9%)	 was	 associated	 with	 a	 ~13%	increase	in	resting	motor	threshold	and	a	51%	decrease	in	intra-cortical	inhibition,	suggesting	that	the	observed	modulation	of	cortical	excitability	is	mediated	by	GABA	and	 sodium	 channel	 dysfunction	 associated	 with	 decreased	 PaO2	 (Miscio	 et	 al.	2009).	A	novel	approach	to	examine	the	independent	influence	of	CBF	on	ventilation	control	in	humans	is	pharmaceutical	inhibition	of	cyclooxygenase	(Ainslie	&	Duffin	2009).	 Indomethacin	 is	 a	 reversible	 and	 safe	 cyclooxygenase	 inhibitor	 that	 blunts	the	 prostanoid-mediated	 responses	 of	 the	 cerebral	 vasculature,	 decreasing	 CBF	(Parfenova	 et	 al.	 1995)	 without	 concomitant	 changes	 in	 cerebral	 metabolic	 rate	(Hohimer	et	al.	1985;	Kraaier	et	al.	1992),	arterial	blood	gases	(Hoiland	et	al.	2014)	or	plasma	catecholamines	(Green	et	al.	1987;	Staessen	et	al.	1984;	Wennmalm	et	al.	1984).	 Additionally,	 evidence	 suggests	 that	 indomethacin	 reduces	 cerebrovscular	reactivity	 to	 CO2,	 causing	 enhanced	 central	 chemoreceptor	 activation	 (Fan	 et	 al.	2011;	 Xie	 et	al.	 2006)	 with	 little	 effect	 on	 the	 peripheral	 chemoreflex	 (Fan	 et	al.	2011;	 Hoiland	 et	 al.).	 Consequently,	 indomethacin	 has	 been	 used	 successfully	 to	investigate	 changes	 in	 CBF	 independent	 of	 changes	 in	 PaCO2.	 The	 purpose	 of	 this	study	was	 to	 examine	 the	 effects	 of	 altered	 CBF	 as	 a	 contributor	 to	 alterations	 in	neuromuscular	 responses	 during	 severe	 hypoxia.	 It	 was	 hypothesized	 that	reductions	 in	 CBF	 would	 have	 a	 primary	 role	 in	 mediating	 changes	 in	neuromuscular	responses	via	impaired	%c*+ .		
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5.2.2 Methods	
5.2.2.1 Participants	Seven	 healthy	 male	 volunteers,	 who	 were	 free	 from	 cardiovascular,	respiratory	and	neurological	disorders,	were	recruited	from	the	university	and	local	community.	The	mean	±	 S.D.	 age,	height,	mass	and	body	mass	 index	were	27±9	y,	1.78	±	0.06	m,	70.2	±	8.5	kg	and	22.1	±	1.6	kg⋅m-2,	respectively.	
5.2.2.2 Experimental	Design	In	 a	 placebo-controlled	 double-blinded	 design,	 baseline	 and	 experimental	measures	were	collected	in	the	following	conditions:		1) Poikilocapnic	hypoxia	(Poikilo);		2) Isocapnic	hypoxia	(Iso);	and,		3) Isocapnic	 hypoxia	 with	 cyclooxygenase	 inhibition	 via	 oral	 indomethacin	(Indo;	1.2	mg∙Kg-1)	supplementation	to	selectively	reduce	CBF.		Both	 indomethacin	 and	 placebo	 were	 administered	 in	 identical-looking	 gelatin	capsules	 along	 with	 150	 mg	 of	 ranitidine	 to	 reduce	 the	 possibility	 of	 gastro-intestinal	 irritation.	 Participants	 then	 rested	 for	 90	 minutes	 to	 allow	 for	 drug	concentrations	 to	peak	within	 the	bloodstream	 (Xie	et	al.	 2006).	During	 this	 time,	participants	rested	quietly	in	the	laboratory.	The	experimental	protocol	is	displayed	below	in	Figure	5-4.	
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	Figure	 5-4.	 Schematic	 outlining	 the	 protocol	 for	 experiment	 5.2.	 Transcranial	magnetic	 stimulation	 (TMS);	 Maximal	 M-wave	 (Mmax);	 Motor	 evoked	 potential	(MEP);	cortical	voluntary	activation	(cVA);	peripheral	voluntary	activation	(pVA).	
5.2.2.3 Calculations	The	 hypoxic	 ventilatory	 response	 (HVR;	 L∙min-1∙%)	 was	 calculated	 as	 the	change	 in	 Vm i	 (L∙min-1)	 from	 baseline	 normalized	 to	 the	 change	 in	 SaO2	 (%).	 To	account	 for	 the	 inherent	 time	 delay	 associated	with	 pulse	 oximetry	 (Trivedi	 et	al.	1997),	SaO2	was	estimated	using	PETO2	as	follows	(Severinghaus		1979):	
WE&' % = (d]&'e + 150 GH ∙ 23400 + 1 GH ∙ 100	%c*+ 	(arbitrary	 units;	 au.)	 was	 calculated	 as	 the	 product	 of	 MCAv	 and	 the	arterial	 content	 of	 oxygen	 (CaO2).	 Assuming	 a	 constant	 hemoglobin	 [Hb]	concentration	of	15	g∙dl-1,	CaO2	(ml∙dl-1)	was	calculated	as:	%E&' = j; ∙ 1.36 ∙ WE&' 100 + 0.003 ∙ (&'	
5.2.2.4 Statistical	Analysis	Normal	distribution	of	data	was	confirmed	with	the	Shapiro-Wilk	normality	test.	 Two-way	 repeated	measures	 ANOVA	 analyses	 were	 conducted	 to	 assess	 the	
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change	 in	 respiratory,	 cerebrovascular,	 cardiovascular	 and	 neuromuscular	responses	 between	 baseline	 versus	 experimental	 measurements	 and	 across	 the	three	 conditions	 (Poikilo,	 Iso	 and	 Indo).	 Sphericity	 for	 terms	 was	 assessed	 by	Mauchly's	test	of	sphericity;	 if	this	test	was	violated	(p	<	0.05),	data	were	assessed	using	a	Greenhouse-Geisser	adjustment.	Pair-wise	comparisons,	using	a	Bonferroni	correction,	were	used	to	identify	main	effects.	Significant	interactions	were	assessed	using	 separate	 repeated	 measures	 ANOVA.	 The	 relationship	 between	 MEP	amplitude	and	cVA	vs.	%c*+ 	and	HVR	was	assessed	using	a	Pearson	correlation.	All	statistical	analyses	were	conducted	using	SPSS	20	(SPSS	Inc.,	Chicago,	IL,	USA),	with	statistical	significance	set	a	p	<	0.05.	Data	are	presented	as	mean	±	S.D.	5.2.3 Results	
5.2.3.1 Respiratory,	Cerebrovascular	and	Cardiovascular	Responses	The	 experimental	 conditions	 were	 successful	 in	 eliciting	 the	 desired	physiological	 manipulations;	 baseline,	 post	 indomethacin/placebo	 wash-in,	 and	experimental	 respiratory,	 cerebrovascular	 and	 cardiovascular	 data	 during	 Poikilo,	Iso	 and	 Indo	 conditions	 are	displayed	 in	Table	5-2.	No	 significant	differences	 (p	>	0.05)	 in	baseline	measurements	between	conditions	were	observed	 for	any	of	 the	collected	respiratory,	cerebrovascular	or	cardiovascular	variables.		 Dynamic	end-tidal	 forcing	successfully	 controlled	end-tidal	PO2	 (PETO2)	and	end-tidal	PCO2	(PETCO2)	at	the	desired	levels	throughout	the	experimental	protocol.	During	the	experimental	phase,	PETO2	was	similar	across	all	experimental	conditions	(51.5	±	5.1	mmHg,	p	=	0.62)	and	significantly	lower	in	comparison	to	baseline	and	post	wash-in	measurements	across	all	 conditions	 (-53.8	±	6.6%,	p	<	0.01).	During	
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the	 Poikilo	 condition,	 PETCO2	 was	 reduced	 (-16.2	 ±	 6.5%,	 p	<	0.01)	 compared	 to	baseline	 and	 wash-in;	 however,	 PETCO2	 was	 effectively	 maintained	 at	 eucapnia	throughout	 the	entire	protocol	during	 Iso	 (-0.1	±	2.4%)	and	 Indo	 (-0.6	±	2.9%,	p	=	0.89).	 In	 comparison	 to	 baseline	 and	 post	 wash-in	 measurements,	 Vm i	 increased	during	 the	 experimental	 phase	 across	 all	 conditions	 (p	 =	 0.02);	 however,	 the	increase	in	Vm i	was	markedly	higher	(p	=	0.03)	during	Iso	(104.6	±	13.3%)	and	Indo	(124.7	±	92.3%)	compared	to	Poikilo	(25.7	±	13.3%).	
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Table	 5-2.	 Baseline,	 wash-in,	 and	 experimental	 cardio-respiratory	 data	 during	 Poikilocapnia,	 Isocapnia	 and	 Indomethacin	
conditions		 Poikilocapnia	 	 Isocapnia	 	 Indomethacin		 Baseline	 Wash-In	 Experimental	 	 Baseline	 Wash-In	 Experimental	 	 Baseline	 Wash-In	 Experimental	PETO2,	mmHg	 110.5	±	7.6	 110.0	±	8.7	 50.9	±	3.5†	 	 108.6	±	8.7	 108.3	±	9.4	 52.5	±	7.0†	 	 106.9	±	6.8	 108.2	±	5.5	 51.0	±	4.8†	PETCO2,	mmHg	 44.2	±	5.1	 43.7	±	5.2	 37.3	±	6.7†	 	 43.6	±	4.1	 43.4	±	4.3	 43.4	±	4.0	 	 43.8	±	2.8	 41.8	±	4.0	 41.6	±	3.8	MCAv,	cm·s-1	 68.5	±	11.7	 67.7	±	12.3	 70.1	±	9.1	 	 60.5	±	11.1	 65.8	±	13.4	 73.8	±	12.9*	 	 65.8	±	10.1	 46.2	±	11.6†	 54.3	±	13.6*	!"#$ ,	a.u.	 1221	±	551	 1205	±	537	 1076	±	454*	 	 1156	±	511	 1170	±	534	 1144	±	516	 	 1170	±	508	 823	±	398†	 837	±	399†	VN i,	L·min-1	 8.5	±	3.8	 11.3	±	3.4	 14.3	±	5.0*	 	 11.2	±	2.7	 11.0	±	3.4	 22.5	±	9.9†	 	 9.4	±	3.0	 10.3	±	1.9	 23.4	±	11.0†	HR,	beats·min-1	 56.4	±	7.7	 55.7	±	9.5	 67.6	±	5.7†	 	 57.3	±	7.8	 54.1	±	4.7	 68.9	±	8.5†	 	 59.5	±	5.2†	 52.2	±	4.5	 68.4	±	8.7†	SpO2,	%	 97.9	±	0.7	 98.5	±	1.0	 80.3	±	3.4†	 	 97.5	±	0.5	 98.2	±	0.5	 80.3	±	5.5†	 	 97.1	±	1.0	 98.3	±	0.7	 79.3	±	5.3†	MAP,	mmHg	 93	±	12	 94	±	16	 101	±	19†	 	 91	±	10	 92	±	9	 100	±	17†	 	 92	±	10	 96	±	9†	 103	±	11†	PETO2,	end-tidal	partial	pressure	of	oxygen;	PETCO2,	end-tidal	partial	pressure	of	carbon	dioxide;	MCAv,	middle	cerebral	artery	velocity;	!"#$ ,	cerebral	oxygen	delivery,	VN i,	 inspired	minute	ventilation;	HR,	heart	rate;	SpO2,	oxygen	saturation;	MAP,	mean	arterial	pressure;	Values	are	mean	±	SD;	n	=	7	recordings;	*	p	<	0.05;	†	p	<	0.01	vs.	Baseline	
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In	comparison	to	baseline,	MCAv	remained	unchanged	during	wash-in	during	Poikilo	and	Iso;	however,	it	was	markedly	decreased	during	Indo	(-30.1	±	11.1%,	p	<	0.01).	 Hypoxic	 exposure	 caused	 a	 significant	 increase	 in	 MCAv	during	 Iso	 (13.7	 ±	8.0%,	 p	 =	 0.01),	 decrease	 during	 Indo	 (-18.1	 ±	 12.6%,	 p	 =	 0.03);	 however,	 MCAv	remained	similar	to	baseline	values	during	Poikilo	(p	=	0.61).	Significant	reductions	in	!"#$from	 baseline	 were	 observed	 in	 response	 to	 Indo	 wash-in	 phase	 (-30.0	 ±	11.2	%,	p	<	0.01)	and	in	response	to	hypoxia	during	Poikilo	(-11.1	±	7.0%,	p	=	0.01)	and	Indo	(-29.0	±	9.5%,	p	<	0.01).	
5.2.3.2 Neuromuscular	Responses	Baseline	and	experimental	neuromuscular	data	during	Poikilo,	 Iso	and	Indo	are	 displayed	 in	 Figure	 5-5.	 No	 significant	 differences	 (p	>	 0.05)	 in	 baseline	measurements	 between	 conditions	 were	 observed	 for	 any	 of	 the	 neuromuscular	measurements.	 Voluntary	 torque	production	during	MVC	 (Figure	5-5A)	decreased	across	 all	 conditions	 (-9.4	 ±	 7.9%,	 p	 =	 0.01)	 during	 hypoxia	 in	 comparison	 to	baseline	measurements.	There	was	no	significant	difference	in	RMS	(p	=	0.62)	and	Fmedian	(p	=	0.71)	of	the	EMG	signal	during	MVC	in	all	conditions	when	examining	the	change	from	baseline	measurements.		Peak	to	peak	MEP	amplitude	(Figure	5-5B)	expressed	as	a	percentage	of	Mmax	decreased	in	response	to	hypoxia	during	Poikilo	(-51.0	±	17.7%,	p	<	0.01)	and	Indo	(-64.1	 ±	 12.8%,	 p	 <	 0.01)	 conditions;	 however,	 it	 was	 similar	 to	 baseline	 values	during	 Iso	 (-9.1	±	7.2%).	Decreased	cVA	(Figure	5-5E)	was	observed	during	 Iso	 (-15.9	±	10.9%,	p	=	0.01)	and	Indo	(-18.5	±	12.6%,	p	=	0.01)	and	remained	similar	to	
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baseline	 values	 during	 Poikilo	 (5.8	 ±	 16.2,	 p	 =	 0.49).	 cSP	 (Figure	 5-5D)	 remained	similar	to	baseline	measurements	across	all	conditions	(p	=	0.51).	
	Figure	5-5.	Neuromuscular	response	to	Poikilo,	 Iso	and	Indo.	(A)	Voluntary	torque	production;	 (B)	 motor	 evoked	 potential	 (MEP)	 amplitude;	 (C)	 maximal	 M-wave	(Mmax);	(D)	cortical	silent	period	(cSP);	(E)	central	voluntary	activation	(cVA);	(F)	peripheral	voluntary	activation	(pVA);	(G)	potentiated	twitch	amplitude	(QTw,Pot);	(H)	maximal	relaxation	rate	of	the	potentiated	twitch	(RRTw,Pot).	*	represents	p	<	0.05	from	baseline	measurements.	Peak	to	peak	Mmax	amplitude	(Figure	5-5C)	was	unaffected	by	hypoxia	across	all	conditions	(p	=	0.80);	therefore,	QTw,pot	(p	=	0.12;	Figure	5-5G)	and	RRTw,Pot	(p	=	
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0.26;	 Figure	 5-5H)	 of	 the	 potentiated	 twitch	 remained	 similar	 to	 baseline	 values	across	all	conditions.	
5.2.3.3 Relationship	 Between	 Cerebral	 Oxygen	 Delivery	 and	 Neuromuscular	
Responses	Individual	 correlations	 between	 changes	 in	!"#$ 	with	 MEP	 amplitude	 are	displayed	in	Figure	5-6).	MEP	amplitude	(%	Mmax)	was	moderately	correlated	with	changes	in	!"#$ 	for	data	pooled	across	condition	(r2	=	0.57,	p	<	0.01).	
	Figure	 5-6.	 Correlation	 analysis	 between	 changes	 from	 baseline	 in	 motor	 evoked	potential	 amplitude	 (∆MEP)	 to	 change	 in	 cerebral	 oxygen	 delivery	 (Δ!"#$)	 and	cortical	voluntary	activation	(cVA)	to	hypoxic	ventialtiory	response	(HVR).		5.2.4 Discussion	The	purpose	of	the	present	study	was	to	examine	neuromuscular	responses	during	acute	hypoxia	in	response	to	different	levels	of	CBF,	with	the	hypothesis	that	reductions	 in	 CBF	 would	 have	 a	 primary	 role	 in	 mediating	 changes	 in	neuromuscular	 responses	 via	 impaired	!"#$ .	 The	 primary	 findings	 of	 this	 study	
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were	 that	 reduced	 corticospinal	 excitability	 was	 mediated	 by	 reductions	 in	!"#$ ,	rather	than	hypoxia	per	se.	
5.2.4.1 Peripheral	Neuromuscular	Responses	Hypoxia,	 irrespective	of	changes	 in	CBF,	was	not	associated	with	significant	changes	 locally	 within	 the	 muscle	 fibre	 itself.	 The	 amplitude	 of	 Mmax	 elicited	 by	stimulation	of	 the	median	nerve	was	unaffected	across	all	 conditions	compared	 to	baseline	 (Figure	 3C),	 suggesting	 that	 neuromuscular	 propagation	 remained	 intact.	Consistent	with	our	findings,	previous	research	(Dousset	et	al.	2001)	indicates	that	acute	 hypoxemia	 (PaO2	 =	 56	 mmHg)	 had	 no	 effect	 on	 Mmax	 amplitude,	 despite	significant	 reductions	 in	 oxygen	 availability.	 Furthermore,	 these	 findings	 are	consistent	 with	 data	 obtained	 (i.e.,	 no	 change	 in	 Mmax	 amplitude)	 following	cyclooxygenase	inhibition	using	acetaminophen	(Mauger	&	Hopker	2013);	however,	to	the	best	of	our	knowledge,	this	is	the	first	study	to	assess	changes	in	peripheral	neuromuscular	 responses	 following	 indomethacin	 or	 any	 other	 NSAID	supplementation.	In	 support	 of	maintained	 peripheral	 neuromuscular	 responses,	 QTw,Pot	 (Figure	3G),	and	RRTw,Pot	(Figure	3H)	were	unaffected	across	conditions.	These	findings	are	supported	by	Amann	et	al.	(2007)	who	reported	no	significant	changes	in	QTw,Pot	in	response	 to	 severe	 hypoxia	 (FiO2	 =	 0.10;	 SpO2	 =	 66.6±1.2%)	 and	 suggested	 that	mechanisms	of	fatigue	switch	from	peripheral	to	central	origins	as	the	magnitude	of	the	hypoxic	stress	increases.	Although	our	findings	are	consistent	with	the	paradigm	of	 maintained	 peripheral	 neuromuscular	 responses	 during	 severe	 hypoxic	 stress	(i.e.,	FiO2	≤	0.10)	(Amann	et	al.	2007),	it	should	be	noted	that	we	did	not	investigate	
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a	 range	of	hypoxic	 stresses	 (FiO2	=	0.21	–	0.10)	and	 therefore,	 cannot	 confirm	 the	transition	 from	 peripheral	 to	 central	 neuromuscular	 fatigue	 as	 hypoxic	 stress	becomes	more	severe.		
5.2.4.2 Corticospinal	excitability	and	cerebral	oxygen	delivery	A	primary	finding	of	the	present	study	is	reduced	MEP	amplitude	(%	Mmax)	in	response	to	hypoxia	during	the	Poikilo	and	Indo	conditions	(Figure	3B),	suggesting	a	decrease	 in	 corticospinal	 excitability.	 A	 possible	 mechanism	 contributing	 to	corticospinal	 hypoexcitability	 is	 the	 combined	 reduction	 in	 CaO2	 and	 MCAv	contributing	to	impaired	!"#$ .	Pooling	data	across	all	three	experimental	conditions	indicates	 a	moderate	 correlation	 between	 reductions	 in	!"#$ 	and	 changes	 in	MEP	amplitude	 (r2	=	 0.57,	 p	 <	 0.01;	 Figure	 4A),	 suggesting	 that	 changes	 in	 CBF	 during	hypoxia	may	have	a	modulating	effect	on	neuromuscular	responses.	A	novel	aspect	of	 the	present	experimental	design	 is	 that	CBF	was	modulated	 independent	of	 the	prevailing	 PETO2,	 therefore	 allowing	 the	 investigation	 of	 changes	 in	 !"#$ 	independent	of	hypoxia	per	se.	Namely,	 isocapnic	hypoxia	during	 the	 Iso	condition	causes	a	marked	increase	in	CBF	and	maintains	!"#$ 	despite	reduced	CaO2,	whereas	cyclooxygenase	inhibition	causes	reductions	in	CBF	and	consequently,	!"#$ .	During	poikilocapnic	 hypoxia	 (i.e.,	 the	 Poikilo	 condition),	 the	magnitude	 of	 reductions	 in	CBF,	 and	 consequently	!"#$ ,	 are	 dependent	 on	 the	 composite	 response	 from	 the	peripheral	 and	 central	 chemoreflex	 arc.	 Activation	 of	 the	 peripheral	 chemoreflex	(PaO2	 ≤	 60	 mmHg)	 causes	 cerebral	 vasodilation	 and	 hyperventilation,	 thereby	decreasing	 PaCO2	 and	 subsequent	 cerebral	 vasoconstriction	 via	 the	 central	chemoreflex	 (Ainslie	 &	 Ogoh	 2010).	 Given	 the	 inherent	 inter-individual	 hypoxic	
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chemosensitivity	(Ainslie	&	Poulin	2004;	Kawakami	et	al.	1981),	it	is	plausible	that	poikilocapnic	 hypoxia	 may	 elicit	 disparate	 changes	 in	!"#$ 	within	 a	 given	 study	population.	Our	data	are	in	agreement	with	previous	work	by	Miscio	et	al.	(2009),	though	this	 finding	of	decreased	MEP	amplitude	 is	not	universally	accepted	(Goodall	et	al.	2012;	Szubski	et	al.	2006;	Szubski	et	al.	2007).	Chronic	high	altitude	exposure	(3	–	5	days;	 4,554	 m)	 was	 associated	 with	 an	 increase	 in	 resting	 motor	 threshold	 and	shortening	 of	 mean	 short-intracortical	 inhibition	 (Miscio	 et	 al.	 2009),	 suggesting	that	 hypoxia	 suppresses	 both	 excitatory	 and	 inhibitory	 cortical	 networks.	Conversely,	Szubski	et	al.	(2006)	reported	a	2%	decrease	in	resting	motor	threshold	following	 ~45	min	 of	 hypoxic	 exposure	 (FiO2	 =	 0.12).	 Hypoxia	 may	 have	 a	 time-dependent	 effect	 on	 corticospinal	 excitability.	 For	 example,	 Rupp	 et	 al.	 (2012)	reported	 no	 significant	 change	 in	 MEP	 amplitude	 or	 cSP	 following	 one	 hour	 of	hypoxic	exposure	(FiO2	=	0.12;	SpO2	=	83	±	5%),	but	MEP	was	enhanced	(24	–	27%)	and	cSP	lengthened	(14	–	20%)	following	three	hours	of	hypoxic	exposure	(SpO2	=	86	 ±	 5%).	 Possible	 mechanisms	 contributing	 to	 time-dependent	 changes	 in	corticospinal	 excitability	 are	 the	 ventilatory	 and	 associated	 acid-base	 adjustments	that	 accompany	 acute	 hypoxic	 exposure	 (Dempsey	 et	al.	 1975;	 Rupp	 et	al.	 2012).	During	 poikilocapnic	 hypoxia,	 the	 initial	 HVR	 causes	 a	 hypocapnic-mediated	reduction	 in	 CBF;	 however,	 peripheral	 chemoreceptor	 adaptations	 mediate	 the	subsequent	blunting	of	the	HVR	(Teppema	&	Dahan	2010)	and	restoration	of	CBF	to	levels	 equal	 to	 —	 or	 likely	 above	—	 baseline	 values	 (Steinback	 &	 Poulin	 2008).	Therefore,	 acute	 hypoxia	 is	 associated	 with	 bi-phasic	 changes	 in	 respiratory	
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alkalosis	and	!"#$ ,	which	likely	has	a	modulating	influence	on	neuronal	excitability	(Dulla	et	al.	2005;	Haddad	&	Jiang	1993).	The	underlying	mechanisms	contributing	to	depressed	neuronal	activity	with	impaired	!"#$ 	remain	 to	 be	 fully	 elucidated;	 however,	 cell	 hyperpolarization	 is	likely	mediated	by	ion	disturbances	(Hansen		1985)	and	the	release	of	extracellular	neurotransmitter	acting	post-synaptically	on	neurons	in	the	motor	cortex	(Haddad	&	 Jiang	 1993).	 Ion	 disturbances	 during	 hypoxia	 are	 mediated	 by	 changes	 in	intracellular	 activity	 of	 Ca2+	 associated	 with	 ATP	 regeneration	 (Hansen	 	 1985).	During	 hypoxia,	 cerebral	 metabolism	 is	 compromised	 via	 impairments	 in	 ATP	synthesis,	resulting	in	Ca2+	release	from	surrounding	organelles	and	activation	of	K+	channels	 in	 the	 cell	 membrane	 (Baker	 et	 al.	 1971).	 The	 net	 change	 in	 ion	distribution	results	in	cell	membrane	hyperpolarization	and	a	decrease	in	neuronal	excitability.	 Similarly,	 hypoxia	 is	 associated	 with	 the	 release	 of	 inhibitory	neurotransmitters,	such	as	GABA	and	glycine,	which	activate	K+	and	Cl-	channels	and	cause	cell	membrane	hyperpolarization	 (Haddad	&	 Jiang	1993).	Collectively,	 these	changes	 are	 associated	 with	 decreasing	 neuronal	 excitability	 and	 therefore	potentially	underpin	the	observed	decreases	in	MEP	amplitude.	The	 time-dependent	effect	of	hypoxia	on	corticospinal	 excitability	 (Rupp	et	al.	2012)	may	be	explained	by	cellular	mechanisms	within	the	cerebral	neurons.	During	prolonged	hypoxic	exposure	(≥30	min),	hypoxic	ventilatory	decline	(Robbins		1995)	is	associated	with	the	restoration	of	CBF	to	levels	equal	to	or	above	normoxic	levels.	The	 result	 is	 a	 relative	 increase	 in	!"#$ 	and	 re-oxygenation	 of	 the	 cerebral	 spinal	fluid	 and	 surrounding	 neurons.	 Post-hypoxia	 neuronal	 hyperexcitability	 has	 been	
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documented	using	 in	vitro	 hippocampal	 slice	preparations	 (Doolette	&	Kerr	1995;	Schiff	&	Somjen	1985)	and	rats	 in	vivo	 (Chang	et	al.	1989)	 following	periods	of	re-oxygenation	 caused	 by	 cerebral	 ischemia.	 For	 example,	 Schiff	 and	 Somjen	 (1985)	describe	 the	 enhancement	 of	 excitatory	 post-synaptic	 potentials	 following	 re-oxygenation	 to	 amplitudes	 greater	 than	 observed	 during	 normoxia.	 Although	 the	mechanisms	 underpinning	 post-hypoxia	 hyperexcitability	 remained	 to	 be	elucidated,	 it	has	been	suggested	that	 incomplete	re-acclimation	of	 intracellular	K+	(Schiff	 &	 Somjen	 1985),	 caused	 by	 Na+-K+	 pump	 damage	 (Syková	 	 1983),	 may	contribute	 to	atypical	 cell	membrane	depolarization.	Therefore,	 it	 is	plausible	 that	increased	corticospinal	excitability	observed	in	previous	studies	(Rupp	et	al.	2012;	Szubski	et	al.	2006)	may	be	caused	by	the	hypoxic	ventilatory	decline,	resulting	 in	cerebral	re-oxygenation	and	relative	depolarization	of	the	neuronal	membrane.	
5.2.4.3 Voluntary	Activation,	Work	of	Breathing	and	Dyspnea	Reduced	 cVA	during	 voluntary	 contractions	 can	 occur	 because	 of	 sub-optimal	output	from	the	motor	cortex,	causing	a	decrease	in	motor	neuron	firing	frequency	and/or	motor	neuron	recruitment	(Peters	&	Fuglevand	1999).	Although	there	were	significant	reductions	 in	voluntary	 torque	production	across	all	 conditions	 (Figure	5-5A),	hypoxia	induced	significant	reductions	in	cVA	during	the	Iso	(-15.9	±	10	%)	and	 Indo	 (-18.5	 ±	 12.6	 %)	 conditions,	 exclusively	 (Figure	 5-5E).	 This	 finding	suggests	 that	 reductions	 in	 cVA	 are	 associated	 with	 the	 magnitude	 of	 the	 HVR.	Previous	research	indicates	that	increased	inspiratory	muscle	work	during	exercise	(Harms	et	al.	2000)	and	hypoxia	(Amann	et	al.	2007;	Cibella	et	al.	1996;	Cibella	et	al.	1999)	 has	 been	 associated	 with	 locomotor	 muscle	 fatigue	 and	 impaired	
	 	 	
	
87	
performance.	 In	 response	 to	 hypoxia,	 Vp i	 increases	 in	 an	 attempt	 to	maintain	 SaO2	(Benoit	 et	 al.	 1995)	 and	 consequently,	 is	 associated	 with	 increased	 inspiratory	muscle	work	(Cibella	et	al.	1996).	Dempsey	et	al.	 (2006)	proposed	that	diaphragm	and	 accessory	 muscle	 fatigue	 associated	 with	 increased	 work	 of	 breathing	contributes	to	activation	of	the	respiratory	muscle	metaboreflex	and	consequently,	increased	 sympathetic	 outflow.	 In	 turn,	 sympathetic	 mediated	 vasoconstriction	contributes	 to	 skeletal	 muscle	 fatigue,	 which	 may	 be	 attributed	 in	 part	 by	 reflex	inhibition	of	central	motor	output	and	increased	perception	of	associated	effort	and	dyspnea.	 In	 addition	 to	 the	 independent	 influence	 of	 work	 of	 breathing	 and	respiratory	 muscle	 fatigue	 on	 neuromuscular	 responses,	 increased	 perception	 of	effort	 (Berchicci	et	al.	 2013;	Lampropoulou	&	Nowicky	2014)	during	 Iso	and	 Indo	may	 have	 contributed	 to	 the	 reductions	 in	 cVA.	 Recently,	 Lampropoulou	 and	Nowikcy	 (2014)	 indicated	 that	 perception	 of	 effort	 is	 a	 primary	 regulator	 of	voluntary	motor	 control	during	 isometric	 contractions.	Furthermore,	Baweja	et	al.	(2011)	 indicate	 that	 high-amplitude	 respiration	 contributes	 to	 a	 lack	 of	 motor	control	during	MVC.	It	would	therefore	be	reasonable	to	assume	that,	in	comparison	to	Poikilo	(0.26	±	0.15	l∙min-1∙%-1),	marked	increases	in	Vp i	associated	with	isocapnic	hypoxia	 during	 Iso	 (0.93	 ±	 .60	 l∙min-1∙%-1)	 and	 Indo	 (1.15	 ±	 0.72	 l∙min-1∙%-1)	conditions	 increases	 work	 of	 breathing	 and	 mediates	 the	 reduction	 in	 cVA	 via	perception	of	effort	and	dyspnea.	Quantification	 of	 voluntary	 activation	 was	 assessed	 using	 both	 electrical	stimulation	of	the	peripheral	motor	nerve	(pVA)	and	TMS	of	the	motor	cortex	(cVA).	Although	 both	 measures	 represent	 the	 magnitude	 of	 neural	 drive	 to	 the	 muscle,	
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comparing	the	stimulation	responses	obtained	at	different	locations	throughout	the	neuromuscular	system	may	help	localize	the	site	of	impairment	(Todd	et	al.	2004).	In	the	present	study,	voluntary	activation	assessed	as	cVA	(Figure	5-5E)	decreased	in	response	to	Iso	and	Indo	conditions;	however,	pVA	failed	to	detect	any	changes	in	voluntary	 activation	 in	 response	 to	 any	 condition	 (Figure	 5-5F).	 Collectively,	 this	evidence	 suggests	 that	 the	 mechanism(s)	 contributing	 to	 neuromuscular	impairments	 in	response	 to	 increased	work	of	breathing	and	dyspnea	reside	at	or	above	 the	 level	 of	 the	motor	 cortex.	 Although	we	 acknowledge	 the	 limitations	 of	correlations	 to	 provide	 insight	 into	 physiological	 causation,	 we	 failed	 to	 detect	 a	significant	 linear	relationship	between	HVR	and	cVA	(Figure	5-6B).	Since	cVA	was	selectively	 lower	 during	 conditions	 with	 a	 marked	 HVR	 response,	 these	 findings	suggest	 that	 although	HVR	may	 be	 an	 important	mechanism	 regulating	 voluntary	activation	 in	 the	 present	 study,	 it	 is	 clear	 that	 numerous	 additional	 factors	contribute	to	modulate	voluntary	descending	drive	from	the	motor	cortex	(Gandevia		2001).		 	
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5.3 Neuromuscular	fatigue	during	passive	heat	stress	5.3.1 Introduction	Increased	body	 temperature	 (i.e.,	 hyperthermia)	has	been	 shown	 to	 impair	performance	 during	 whole	 body	 exercise	 (Nybo	 et	 al.	 2001;	 Tucker	 et	 al.	 2006;	Tucker	 et	 al.	 2004;	 Watson	 et	 al.	 2005)	 and	 during	 isolated	 muscle	 contractions	(Morrison	 et	 al.	 2004;	 Thomas	 et	 al.	 2006).	 Data	 suggests	 that	 central	 nervous	system	(CNS)	activation	is	 impaired	in	direct	response	to	hyperthermia	(Gonzalez-Alonso	 et	al.	 1999;	 Morrison	 et	al.	 2004),	 and	 is	 independent	 of	 changes	 in	 skin	temperature,	 cardiovascular	 or	 psychophysical	 strain	 (Thomas	 et	 al.	 2006);	however,	 the	 mechanisms	 underpinning	 this	 observed	 central	 fatigue	 remain	elusive.	During	 both	 exercise	 induced	 (Nybo	 &	 Nielsen	 2001)	 and	 passive	hyperthermia	 (Thomas	 et	 al.	 2006;	 Todd	 et	 al.	 2005),	 superimposed	 twitch	amplitude	elicited	using	either	electrical	stimulation	of	the	peripheral	motor	nerve	or	 transcranial	magnetic	 stimulation	 (TMS)	 of	 the	motor	 cortex	 during	 voluntary	contraction	 was	 markedly	 larger,	 suggesting	 that	 maximal	 CNS	 drive	 to	 the	musculature	–	or	voluntary	activation	–	was	impaired.	Elevated	tissue	temperature	is	associated	with	a	~20%	increase	in	peak	muscle	relaxation	rate	(Todd	et	al.	2005)	and	 consequently,	 requires	 sufficiently	 higher	 motor	 unit	 firing	 frequencies	 to	achieve	fusion	of	force	(De	Ruiter	&	De	Haan	2000).	Therefore,	the	observed	central	fatigue	may	manifest	as	a	failure	of	the	CNS	to	compensate	for	temperature	induced	changes	in	muscle	properties.	
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A	possible	mechanism	regulating	the	CNS	response	during	heat	stress	is	the	reduction	 in	 cerebral	blood	 flow	 (CBF)	associated	with	elevated	core	 temperature	(Tc)	 (Nybo	&	Nielsen	2001).	During	passive	heat	 stress	 to	+1°C	above	baseline	Tc,	marked	hyperventilation	and	concomitant	hypocapnia	is	associated	with	a	10-15%	reduction	in	middle	cerebral	artery	velocity	(MCAv)	(Brothers	et	al.	2009;	Fan	et	al.	2008;	Nelson	et	al.	2011),	an	index	of	CBF.	The	combined	effect	of	increased	cerebral	metabolic	 rate	 [given	 the	 association	 between	 brain	 tissue	 temperature	 and	 the	Van’t	 Hoff	 Q10	 effect	 on	 tissue	 energy	 temperature	 (Busija	 et	 al.	 1988)]	 and	decreased	 CBF	 causes	 a	 reduction	 in	 cerebral	 oxygenation	 (Nybo	 	 2008)	 and	consequently,	 neuronal	 impairment	 (Haddad	 &	 Jiang	 1993;	 Hansen	 	 1985).	 In	response	to	passive	heating	to	thermal	tolerance	(≥2°C	above	baseline	Tc),	Ross	et	al.	 (2012)	 observed	 a	 22%	decrease	 in	 voluntary	 activation	 (assessed	using	TMS)	that	was	highly	correlated	to	changes	in	minute	ventilation	(r2	=	0.762),	PETCO2	(r2	=	0.628),	and	MCAv	(r2	=	0.608).	It	is	interesting	to	note	that,	at	the	point	of	thermal	intolerance,	 the	 restoration	 of	 PETCO2	 (via	 inhalation	 of	 5%	 CO2	 gas)	 towards	baseline	 values	 restored	 decrements	 in	 voluntary	 drive	 despite	 CBF	 remaining	below	 baseline	 levels.	 These	 findings	 suggest	 that	 changes	 in	 PaCO2,	 rather	 than	changes	 in	 CBF	per	se,	may	modulate	 neuromuscular	 impairments	 during	 passive	heat	stress.		A	novel	approach	to	examine	the	independent	influence	of	CBF	on	ventilation	control	in	humans	is	pharmaceutical	inhibition	of	cyclooxygenase	(Ainslie	&	Duffin	2009).	 Indomethacin	 is	 a	 reversible	 and	 safe	 cyclooxygenase	 inhibitor	 that	 blunts	the	 prostanoid-mediated	 responses	 of	 the	 cerebral	 vasculature,	 decreasing	 CBF	
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(Parfenova	 et	 al.	 1995)	 without	 concomitant	 changes	 in	 cerebral	 metabolic	 rate	(Hohimer	et	al.	1985;	Kraaier	et	al.	1992),	arterial	blood	gases	(Hoiland	et	al.	2014)	or	plasma	catecholamines	(Green	et	al.	1987;	Staessen	et	al.	1984;	Wennmalm	et	al.	1984).	Additionally,	 evidence	 suggests	 that	 indomethacin	 reduces	 cerebrovascular	reactivity	 to	 CO2,	 causing	 enhanced	 central	 chemoreceptor	 activation	 (Fan	 et	 al.	2011;	 Xie	 et	al.	 2006)	 with	 little	 effect	 on	 the	 peripheral	 chemoreflex	 (Fan	 et	al.	2011;	 Hoiland	 et	 al.).	 Consequently,	 indomethacin	 has	 been	 used	 successfully	 to	investigate	changes	in	CBF	independent	of	changes	in	PaCO2.	The	 purpose	 of	 this	 study	was	 to	 examine	 the	 effects	 of	 reductions	 in	 CBF	with	 and	 without	 hypocapnia	 on	 neuromuscular	 responses	 during	 passive	 heat	stress.	 It	 was	 hypothesized	 that	 hypocapnia,	 independent	 of	 changes	 in	 CBF	 and	elevated	core	temperature	(Tc),	would	have	a	primary	role	in	mediating	changes	in	neuromuscular	responses.	5.3.2 Methods	
5.3.2.1 Participants	Eight	 healthy	 male	 volunteers,	 who	 were	 free	 from	 cardiovascular,	respiratory	and	neurological	disorders,	were	recruited	from	the	university	and	local	community.	The	mean	±	 S.D.	 age,	height,	mass	and	body	mass	 index	were	26±8	y,	1.76	±	0.07	m,	78.6	±	8.2	kg	and	22.0	±	1.4	kg⋅m-2,	respectively.	
5.3.2.2 Experimental	Design	In	 a	 placebo-controlled	 single-blinded	 design,	 baseline	 and	 experimental	measures	were	collected	in	the	following	conditions:		1) Poikilocapnic	hyperthermia	(Poikilo);		
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2) Isocapnic	hyperthermia	(Iso);	and,		3) Isocapnic	 hyperthermia	 with	 cyclooxygenase	 inhibition	 via	 oral	indomethacin	(Indo;	1.2	mg∙Kg-1)	supplementation	to	selectively	reduce	CBF.		Both	 indomethacin	 and	 placebo	 were	 administered	 in	 identical-looking	 gelatin	capsules	 along	 with	 150	 mg	 of	 ranitidine	 to	 reduce	 the	 possibility	 of	 gastro-intestinal	 irritation.	 Participants	 then	 rested	 for	 90	 minutes	 to	 allow	 for	 drug	concentrations	 to	peak	within	 the	bloodstream	 (Xie	et	al.	 2006).	During	 this	 time,	participants	rested	quietly	in	the	laboratory.	The	experimental	protocol	is	displayed	below	in	Figure	5-7.	
	Figure	 5-7.	 Schematic	 outlining	 the	 experimental	 protocol.	 Transcranial	 magnetic	stimulation	(TMS);	Maximal	M-wave	(Mmax);	Motor	evoked	potential	(MEP);	cortical	voluntary	activation	(cVA);	peripheral	voluntary	activation	(pVA).	
5.3.2.3 Thermal	control	For	 the	 duration	 of	 the	 passive	 heating	 protocol,	 hot	 water	 (48°C)	 was	circulated	 through	 a	 two	 piece,	 tube-lined	 liquid	 conditioning	 garment	with	 long-sleeves	 and	 pants	 (Med-Eng,	 Ottawa,	 ON).	 To	 maximize	 heat	 exchange	 with	 the	body,	 participants	were	 instructed	 to	wear	 standard	workout	 shorts	 and	 no	 shirt	
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under	the	liquid	conditioning	garment.	Wrapping	participants’	torsos	and	legs	with	compression	 wrap	 bandages	 ensured	 maximal	 skin	 contact	 with	 the	 tubing.	Participants	also	wore	an	impermeable	rain	suit	(with	a	hood)	and	were	covered	in	a	foil	blanket	to	minimize	heat	loss	to	the	environment.		
5.3.2.4 Thermometry	Throughout	 the	 experimental	 protocol,	 rectal	 temperature	 (Tc)	 was	measured	 using	 a	 thin	 and	 flexible	 core	 temperature	 thermistor	 (Mon-A-Therm	Core,	Mallinkrodt	Medical,	St	Louis,	MO),	inserted	15	cm	beyond	the	anal	sphincter.	Skin	 temperature	 was	 measured	 by	 placement	 of	 a	 copper-constantan	thermocouple	(OMEGA	Engineering,	Stamford,	CT)	on	the	chest,	shoulder,	thigh,	and	calf.	 Mean	 skin	 temperature	 (Tz sk)	 was	 subsequently	 estimated	 as	 the	 weighted	distribution	 of	 0.3	 chest,	 0.3	 shoulder,	 0.2	 thigh,	 and	 0.2	 calf	 temperature	(Ramanathan		1964).	
5.3.2.5 Statistical	Analysis	Normal	distribution	of	data	was	confirmed	with	the	Shapiro-Wilk	normality	test.	 Two-way	 repeated	measures	 ANOVA	 analyses	 were	 conducted	 to	 assess	 the	change	 in	 respiratory,	 cerebrovascular,	 cardiovascular	 and	 neuromuscular	responses	 between	 baseline	 versus	 experimental	 measurements	 and	 across	 the	three	 conditions	 (Poikilo,	 Iso	 and	 Indo).	 Sphericity	 for	 terms	 was	 assessed	 by	Mauchly's	test	of	sphericity;	 if	this	test	was	violated	(p	<	0.05),	data	were	assessed	using	a	Greenhouse-Geisser	adjustment.	Pair-wise	comparisons,	using	a	Bonferroni	correction,	were	used	to	identify	main	effects.	Significant	interactions	were	assessed	using	separate	repeated	measures	ANOVA.	Multiple	regression	analysis	was	used	to	
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assess	the	relationship	within	participants	(Bland	&	Altman	1995)	between	changes	in	 MCAv	 (independent	 variable)	 vs.	 changes	 in	 cVA	 (dependent	 variable)	 with	participant	 as	 a	 categorical	 variable.	 All	 statistical	 analyses	were	 conducted	 using	SPSS	20	(SPSS	Inc.,	Chicago,	IL,	USA),	with	statistical	significance	set	a	p	<	0.05.	Data	are	presented	as	mean	±	S.D	change	from	baseline.	5.3.3 Results	All	participants	reported	to	the	laboratory	in	a	euhydrated	state,	as	indicated	by	a	urine	specific	gravity	of	≤	1.020.	Mean	heating	time	to	 thermal	 tolerance	was	122±21	min.	
5.3.3.1 Respiratory,	Cerebrovascular	and	Cardiovascular	Responses	Baseline	 and	 experimental	 respiratory,	 cerebrovascular	 and	 cardiovascular	data	 during	 Poikilo,	 Iso,	 and	 Indo	 conditions	 are	 displayed	 in	 Table	 5-3.	 No	significant	 differences	 (p	>	 0.05)	 in	 baseline	 measurements	 between	 conditions	were	 observed	 for	 any	 of	 the	 collected	 respiratory,	 cerebrovascular	 or	cardiovascular	variables.	In	 comparison	 to	 baseline	 and	 post	 wash-in,	 Vp i	 increased	 in	 response	 to	hyperthermia	 in	all	 conditions	 (p	<	0.01);	however,	 the	hyperventilation	 response	was	greater	during	Iso	(10.8	±	9.8	L∙min-1,	p	<	0.01)	and	Indo	(14.3	±	8.9	L∙min-1,	p	<	0.01)	 compared	 to	 Poikilo	 (4.1	 ±	 3.0	 L∙min-1,	 p	 <	 0.01).	 As	 expected,	 PETCO2	decreased	in	response	to	hyperthermia	during	Poikilo	(-10.5	±	4.8	mmHg,	p	<	0.01)	and	remained	at	baseline	values	throughout	Iso	(0.1	±	1.3	mmHg,	p	=	0.95)	and	Indo	(-1.9	±	1.6	mmHg,	p	=	0.97).	
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Table	 5-3	 Baseline,	 wash-in,	 and	 experimental	 cardio-respiratory	 and	 thermal	 data	 during	 Poikilocapnia,	 Isocapnia	 and	Indomethacin	conditions.		 Poikilocapnia	 	 Isocapnia	 	 Indomethacin		 Baseline	 Wash-In	 Experimental	 	 Baseline	 Wash-In	 Experimental	 	 Baseline	 Wash-In	 Experimental	PETCO2,	mmHg	 46.0	±	2.4	 46.0	±	1.9	 35.5	±	5.3†	 	 45.7	±	1.4	 46.2	±	1.2	 45.9	±	1.4	 	 45.4	±	2.1	 43.5	±	2.4	 43.5	±	2.4	MCAv,	cm·s-1	 74.2	±	6.1	 73.6	±	5.7	 47.3	±	6.1†	 	 68.3	±	3.4	 69.1	±	4.6	 56.8	±	5.1†	 	 69.9	±	8.0	 45.7	±	5.1†	 42.9	±	6.8†	VS i,	L·min-1	 14.3	±	4.0	 16.7	±	5.2	 18.4	±	6.7†*	 	 16.3	±	5.6	 17.3	±	5.8	 27.0	±	10.7†	 	 14.1	±	3.4	 16.0	±	2.4	 28.3	±	10.5†*	HR,	beats·min-1	 65.4	±	12.8	 61.2	±	8.9	 113.5	±	18.9	 	 64.5	±	8.8	 62.8	±	7.8	 120.7	±	19.5	 	 62.6	±	13.4	 51.8	±	5.7	 115.5	±	18.4	MAP,	mmHg	 90.3	±	9.8	 91.0	±	9.4	 81.2	±	12.6†	 	 91.2	±	10.2	 91.5	±	9.1	 80.2	±	11.5†	 	 90.6	±	9.4	 94.8	±	11.1	 81.3	±	10.9†	Tc,	°C	 36.8	±	0.5	 37.0	±	0.2	 38.5	±	0.4†	 	 36.9	±	0.2	 37.0	±	0.2	 38.4	±	0.3†	 	 36.9	±	0.2	 36.9	±	0.2	 38.5	±	0.6†	TX sk,	°C	 32.7	±	0.3	 33.2	±	0.6	 39.1	±	0.4†	 	 31.1	±	3.6	 33.4	±	39.3	 39.3	±	0.4†	 	 32.4	±	0.8	 32.9	±	0.6	 39.2	±	0.7†	PETCO2,	end-tidal	partial	pressure	of	carbon	dioxide;	MCAv,	middle	cerebral	artery	velocity;	VS i,	inspired	minute	ventilation;	HR,	heart	rate;	MAP,	mean	arterial	pressure;	Tc,	core	temperature;	TX sk,	mean	skin	temperature.	Values	are	mean	±	SD;	n	=	7	recordings;	*	p	<	0.01	vs.	Iso;	†	p	<	0.01	vs.	Baseline		
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MCAv	decreased	in	response	to	post	wash-in	during	Indo	(-24.3±4.4	cm⋅s-1	or	-34.6±3.9%,	p	<	0.01),	while	remaining	unchanged	during	Poikilo	(-0.6±2.9	cm⋅s-1	or	-0.7±3.7	%,	p	=	0.96)	and	Iso	(0.8±3.5	cm⋅s-1	or	1.3±5.3%,	p	=	0.92).	In	response	to	hyperthermia,	 MCAv	 decreased	 across	 all	 conditions	 (p<0.01);	 however,	 the	reductions	were	 larger	 in	 Poikilo	 (-26.9±9.5	 cm⋅s-1	 or	 -35.7±11.0%,	 p	<	0.01)	 and	Indo	(-26.9±9.5	cm⋅s-1	or	 -38.2±10.3%,	p	=	0.01)	compared	to	Iso	(-11.5±5.5	cm⋅s-1	or	-16.8±7.5%).			In	response	to	post	wash-in,	reductions	in	HR	were	observed	during	Indo	(-10.8	 ±	 11.2	 beats⋅min-1,	 p	<	0.01)	 in	 comparison	 to	 Poikilo	 and	 Iso.	 Subsequently,	hyperthermia	caused	significant	 increases	 in	HR	(52.4	±	18.3	beats∙min-1),	with	no	significant	differences	between	conditions	(p	>	0.18).	Significant	decreases	 in	MAP	were	observed	(-9.8±6.7	mmHg,	p	<	0.01)	across	all	conditions.	
5.3.3.2 Neuromuscular	Responses	Voluntary	 torque	 production	 (Figure	 5-8A)	 during	 MVC	 decreased	 in	response	to	hyperthermia	relative	to	baseline	(-1.27±1.19	Nm,	p	=	0.01)	during	all	conditions.	 Similarly,	 there	 was	 a	 significant	 reduction	 in	 RMS	 (Figure	 5-8H)	 in	response	to	hyperthermia	(-120.5±50.0	mV,	p	<	0.01)	relative	to	baseline	across	all	conditions;	however,	no	changes	in	Fmedian	(Figure	5-8G)	were	observed	in	response	to	hyperthermia.	Peak	 to	 peak	 MEP	 amplitude	 (Figure	 5-8B),	 expressed	 as	 a	 percentage	 of	Mmax,	decreased	significantly	in	response	to	hyperthermia	(-3.9±0.8%,	p	<	0.01)	and	reductions	 were	 similar	 across	 all	 conditions.	 Conversely,	 cVA	 (Figure	 5-8D)	was	significantly	lower	during	the	Poikilo	(-12.4±5.2	%,	p	<	0.01)	and	Indo	(-11.8±6.8%,	
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p	<	0.01)	conditions	in	comparison	to	baseline,	whereas	no	significant	changes	were	observed	during	Iso	(-5.40±6.2%,	p	=	21).		
	Figure	5-8.	Neuromuscular	response	to	Poikilocapnia,	 Isocapnia	and	Indomethacin	conditions.	Motor	evoked	potenitla	 (MEP);	Maximal	M-wave	(Mmax);	Motor	evoked	potential	(MEP);	cortical	voluntary	activation	(cVA);	peripheral	voluntary	activation	(pVA);	 Maximal	 relaxation	 rate	 of	 the	 potentiated	 twitch	 (RRTw,Pot);	 Median	Frequency	(FMedian);	Root	mean	square	(RMS). 	 Peak	 to	 peak	 Mmax	 amplitude	 (Figure	 5-8C)	 decreased	 significantly	 in	response	 to	 hyperthermia	 (-1.7±0.9	 mV,	 p	 <	 0.01)	 and	 reductions	 were	 similar	across	 all	 conditions.	 pVA	 (Figure	 5-8E)	 was	 significantly	 lower	 in	 response	 to	
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hyperthermia	 (-21.4±10.4%	p	<	0.01);	however,	 responses	were	 similar	 across	all	conditions.	 RRTw,Pot	 increased	 in	 response	 to	 hyperthermia	 (-12.2±6.5	 Nm∙s-1,	 p	 <	0.01)	and	changes	were	similar	across	all	conditions	(Figure	5-8F).	5.3.4 Discussion	The	purpose	of	the	present	study	was	to	examine	neuromuscular	responses	during	passive	heat	stress	in	response	to	changes	in	CBF	with	and	without	changes	in	 PaCO2.	 The	 primary	 findings	 were	 that	 passive	 heat	 stress	 resulted	 in	 1)	decrements	in	peripheral	neuromuscular	responses,	2)	decrements	in	corticospinal	excitability	were	 independent	of	 changes	 in	PETCO2	and	CBF;	 and	3)	 reductions	 in	cVA	that	were	associated	with	reduced	CBF.	
5.3.4.1 Peripheral	Neuromuscular	Responses	and	hyperthermia	Passive	heat	stress,	irrespective	of	changes	in	CBF	or	PETCO2,	was	associated	with	significant	 local	changes	within	the	muscle	 fibre	 itself.	The	amplitude	of	Mmax	elicited	 by	 stimulation	 of	 the	 median	 nerve	 was	 reduced	 across	 all	 conditions	compared	 to	 baseline	 (Figure	 5-8C)	 indicating	 a	 failure	 within	 the	 sarcolemmal	membrane	 to	 produce	 an	 action	 potential,	 despite	 similar	maximal	 stimulation	 of	the	median	nerve.	This	observation	is	supported	by	previous	research	during	whole	body	 passive	 heating	 (Racinais	 et	al.	 2008)	 and	 local	 heating	 of	 the	muscle	 tissue	itself	(Dewhurst	et	al.	2005).	The	mechanisms	underlying	the	reduction	in	Mmax	can	be	 attributed	 to	 impairments	 in	 motor	 nerve	 or	 synaptic	 transmission	 at	 the	neuromuscular	junction;	however,	it	is	likely	that	increased	tissue	temperature	has	the	greatest	influence	on	the	sarcolemmal	membrane	itself	(Racinais	&	Oksa	2010).	Dewhurst	 et	 al.	 (2005)	 suggest	 that	 a	 temperature	 induced	 increase	 in	 the	 rate	of	
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depolarization	is	associated	with	changes	in	ion	fluctuations	across	the	sarcolemmal	membrane.	 Specifically,	 high	 temperature	 is	 associated	 with	 a	 shortening	 of	membrane	 depolarization	 time,	 allowing	 less	 Na+	 to	 cross	 the	 membrane	 and	resulting	in	depression	of	the	action	potential.	It	is	interesting	to	note	that	local	head	cooling	 targeting	 the	 tissue	 of	 the	 CNS	 did	 not	 prevent	 Mmax	 decrements	 during	whole	body	hyperthermia	(Racinais	et	al.	2008),	suggesting	that	changes	 in	neural	drive	transmission	from	the	motor	neuron	to	the	sarcolemmal	membrane	is	not	the	result	of	a	central	adaptations,	but	likely	changes	within	the	muscle	itself.		Similarly,	passive	heat	stress	was	associated	with	an	increase	in	the	maximal	relaxation	 rate	 (Figure	5-8F)	of	 the	 flexor	 carpi	 radialis	muscle	 of	 the	potentiated	twitch	 elicited	 using	 motor	 nerve	 electrical	 stimulation.	 Functionally,	 increased	relaxation	rate	of	muscle	requires	a	higher	motor	neuron	discharge	rate	to	achieve	fusion	 force	and	 therefore,	maintain	 force	production	 (Todd	et	al.	 2005).	Previous	research	 (Morrison	 et	 al.	 2004)	 indicates	 that	 hyperthermia	 is	 associated	 with	suboptimal	 motor	 neuron	 firing	 frequency	 and	 therefore,	 it	 is	 possible	 that	voluntary	 torque	 decrements	 observed	 in	 the	 present	 study	 are	 a	 result	 of	 the	inability	 of	 the	 CNS	 to	 adapt	 to	 changes	 in	 peripheral	 neuromuscular	 responses,	namely	an	increase	in	the	maximal	relaxation	rate	of	the	muscle.	Consistent	with	 previous	 research	 (Ross	 et	al.	 2012),	 EMG	 amplitude	 during	MVC	(Figure	5-8H)	was	reduced	during	passive	heat	stress	and	was	independent	of	changes	in	CBF	and	PETCO2.	Such	observations	may	be	indicative	of	impairments	in	voluntary	 recruitment	 of	 motor	 neurons;	 however,	 changes	 in	 RMS	 of	 the	 EMG	signal	 reflect,	 in	 part,	 changes	 in	 sarcolemma	 excitability	 and	 therefore	 must	 be	
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interpreted	 in	 conjunction	 with	 changes	 in	 the	 muscle	 tissue	 itself.	 Given	 the	relationship	between	reductions	in	Mmax	and	passive	heat	stress	(Figure	5-8C),	 the	observed	changes	in	EMG	amplitude	cannot	be	attributed	exclusively	to	changes	in	motor	neuron	recruitment.	
5.3.4.2 Corticospinal	Excitability	and	Hyperthermia	Novel	 to	 the	 present	 study	 is	 a	 decrease	 in	MEP	 amplitude	 observed	 during	passive	 heat	 stress	 (Figure	 5-8B),	 suggesting	 impairments	 in	 corticopinal	excitability.	The	mechanism	underlying	the	supressed	MEP	amplitude	in	response	to	passive	 heat	 stress	 remains	 elusive.	 It	 has	 been	 suggested	 that	 temperature	sensitive	 (Bigland-Ritchie	 et	al.	 1986)	 group	 III	 and	 IV	 afferents	 act	 upstream	 to	impair	 the	 motor	 cortex	 (Taylor	 et	 al.	 2006),	 therefore	 it	 is	 possible	 that	 heat	induced	 increase	 in	muscle	 sympathetic	 nerve	 activity	 (Ray	 &	 Gracey	 1997)	may	account	 for	 the	 observed	 reductions	 in	MEP	 amplitude.	 This	 observation	 conflicts	with	 that	 of	 Ross	 et	 al.	 (2012)	 and	Todd	 et	 al.	 (2005)	who	 observe	 no	 significant	modulation	 of	 the	MEP	 in	 response	 to	 heat	 stress.	 It	 should	 be	 noted	 that,	 unlike	previous	 research	 (Ross	et	al.	 2012;	Todd	et	al.	 2005),	 the	present	 study	assessed	MEP	amplitude	at	rest	and	not	during	active	muscle	contraction.	MEP	amplitude	at	rest	 is	 indicative	 of	 both	 motor	 cortex	 and	 spinal	 excitability	 (i.e.,	 corticospinal	excitability),	therefore	it	is	possible	that	the	discrepancy	between	the	findings	of	the	present	study	and	that	of	Ross	et	al.	 (2012)	and	Todd	et	al.	 (2005)	may	be	due	to	heat	induced	changes	within	the	spinal	cord.	Passive	heat	stress	has	been	shown	to	attenuate	 the	 amplitude	 of	 the	 H-reflex	 (Racinais	 et	 al.	 2008),	 suggesting	modifications	 of	 the	 inhibition	 and/or	 control	 of	 the	 pre-synaptic	 element	 or	
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changes	 in	 excitability	 of	 the	 motor	 neuron.	 It	 should	 be	 noted	 that	 the	 present	study	 did	 not	 assess	 spinal	 cord	 excitability	 exclusively,	 therefore	 future	 studies	should	 incorporate	measures	of	H-reflex	or	V-wave	 to	 assess	 excitability	 of	 spinal	reflexes	and	central	drive	to	the	motor	neuron,	respectively.	
5.3.4.3 Voluntary	Activation	and	Cerebral	Blood	Flow	A	primary	 finding	of	 the	present	study	was	a	decrease	 in	cVA	 in	response	 to	passive	heat	stress	observed	during	the	Poikilo	and	Indo	conditions	(Figure	5-8D),	demonstrating	 supraspinal	 involvement	 in	 the	 inability	 of	 the	 CNS	 to	 voluntarily	activate	muscle	 fibres.	 Given	 that	 decrements	 in	 cVA	 occurred	 in	 response	 to	 the	Poikilo	 and	 Indo	 conditions	 and	 correlated	 to	 CBF,	 these	 data	 suggest	 that	reductions	 in	 CBF	 may	 be	 mechanistically	 linked	 to	 the	 regulation	 of	 voluntary	activation.	Similarly,	Ross	et	al.	(2012)	observed	impaired	voluntary	activation	that	was	 associated	with	 progressive	 thermal	 hyperpnoea-mediated	 reductions	 PETCO2	and	 consequently,	 CBF.	 It	 is	 important	 to	 note	 that	 at	 the	 point	 of	 thermal	intolerance,	 increased	 PETCO2	 while	 breathing	 +5%	 CO2	 restored	 cVA	 to	 near	baseline	 levels;	 however,	 this	 failed	 to	 affect	 CBF.	 Therefore,	 in	 conflict	 with	 the	present	findings,	it	was	concluded	that	impaired	voluntary	activation	was	associated	with	 thermal-hyperpnoea-mediated	 hypocapnia,	 rather	 than	 reductions	 in	 CBF	(Ross	et	al.	2012).		Impaired	voluntary	activation	 in	 response	 to	passive	hyperthermia	has	been	demonstrated	 previously	 (Morrison	 et	 al.	 2004;	 Ross	 et	 al.	 2012;	 Thomas	 et	 al.	2006);	 however,	 these	 findings	 are	 not	 universal	 when	 using	 TMS	 (Todd	 et	 al.	2005).	Todd	et	al.	(2005)	failed	to	demonstrate	reductions	in	cVA	during	brief	(2-3	
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s)	 MVC,	 while	 reductions	 in	 voluntary	 activation	 became	 apparent	 following	sustained	(2	min)	MVC.	The	additional	strain	imposed	by	sustained	MVC	(Todd	et	al.	2005)	 and	 exercise	 (Nybo	 &	 Nielsen	 2001)	 will	 undoubtedly	 potentiate	 the	reduction	 in	 voluntary	 activation;	 however,	 discrepancies	 between	 the	 present	findings	and	that	of	Todd	et	al.	(2005)	may	be	due	to	differences	in	heating	methods.		Quantification	 of	 voluntary	 activation	 was	 assessed	 using	 both	 electrical	stimulation	of	the	peripheral	motor	nerve	(pVA)	and	TMS	of	the	motor	cortex	(cVA).	Although	 both	 measures	 represent	 the	 magnitude	 of	 neural	 drive	 to	 the	 muscle,	comparing	the	stimulation	responses	obtained	at	different	locations	throughout	the	neuromuscular	system	may	help	localize	the	site	of	impairment	(Todd	et	al.	2004).	In	the	present	study,	voluntary	activation	assessed	as	either	pVA	or	cVA	decreased	in	 response	 to	 all	 conditions;	 however,	 a	 significant	 interaction	 effect	 with	 cVA	suggests	that	a	more	pronounced	decrement	in	neural	drive	occurred	during	Poikilo	and	Indo	(Figure	5-8D).	Collectively,	 this	evidence	suggests	 the	mechanism(s)	 that	contribute	to	neuromuscular	impairments	in	response	to	decreased	CBF	reside	at	or	above	the	level	of	the	motor	cortex.		 	
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6 GENERAL	DISCUSSION	AND	SUMMARY		 	
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6.1 General	Discussion	The	present	research	was	developed	to	investigate	neuromuscular	responses	in	response	to	changes	in	CBF	and	PaCO2	during	environmental	stress	(hypoxia	and	hyperthermia).	This	research	program	utilized	a	novel	methodological	approach	to	systematically	manipulate	CBF	with	and	without	consequent	changes	in	PETCO2.	We	were	 therefore	 able	 to	 isolate	 the	 effects	 of	 impaired	 cerebral	 oxygen	 delivery	associated	 with	 reduced	 CBF,	 from	 changes	 in	 neuronal	 pH	 associated	 with	hypocapnia.	 In	 addition	 to	 providing	 further	 insight	 to	mechanisms	 that	 regulate	neuromuscular	 responses	 during	 environmental	 stress,	 these	 findings	 have	relevance	 to	 several	 clinical	 populations,	 such	 as	 individuals	 who	 suffer	 from	chronic	 obstructive	 pulmonary	 disease	 and	 have	 impaired	 tissue	 oxygenation,	 or	individuals	who	suffer	from	multiple	sclerosis	and	have	experienced	neuromuscular	impairment	that	is	exacerbated	in	response	to	heat	stress.		 In	 response	 to	 environmental	 stress,	 such	 as	 passive	 heat	 stress	 or	 severe	hypoxia,	neuromuscular	 impairments	are	primarily	associated	with	central	 factors	(Amann	et	al.	2006;	Amann	et	al.	2007;	Millet	et	al.	2009;	Millet	et	al.	2012)	and	may	be	 attributed	 in	 part	 to	 a	 reduction	 in	 CBF	 (Nybo	 &	 Nielsen	 2001;	 Nybo	 &	Rasmussen	2007;	Secher	et	al.	2008).	The	present	research	program	supports	 this	hypothesis,	 namely	 that	 changes	 in	 CBF	 do	 indeed	 modulate	 neuromuscular	responses;	 however,	 our	 data	 emphasize	 the	 role	 of	 changes	 in	 PETCO2	 as	 an	independent	 and	 significant	modulator	 of	 neuromuscular	 responses.	 This	 primary	finding	emphasises	the	importance	of	investigating	changes	in	PETCO2	–	in	addition	to	 changes	 in	 CBF	 –	 as	 a	 modulator	 of	 neuromuscular	 responses	 during	
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environmental	 stress.	 Furthermore,	 these	 findings	 present	 the	 opportunity	 for	 a	viable	method	 of	 preserving	 neuromuscular	 responses	 in	 physiologically	 stressful	environments	(e.g.,	manipulating	inspired	gas	fractions	to	maintain	eucapnia).	A	primary	 finding	of	 the	present	 research	program	 is	 that	 the	 excitability	 of	the	 corticospinal	 tract	 is	 inherently	 sensitive	 to	 changes	 in	 PaCO2	 and	 PaO2.	 As	illustrated	 in	 project	 5.1,	moderate	 hypocapnia	 (-11.5±2.8	mmHg)	 causes	marked	increases	 in	corticospinal	excitability,	demonstrated	by	a	11.78±9.07%	 increase	 in	MEP	amplitude	 (Project	5.1;	Hypo	 condition).	The	 relationship	between	 increased	corticospinal	excitability	and	hypocapnia	has	been	reported	elsewhere	(Seyal	et	al.	1998;	 Sparing	 et	 al.	 2007);	 however,	 the	 present	 study	 is	 the	 first	 to	 separate	possible	 confounds	 associated	 with	 reduced	 CBF	 that	 accompany	 reductions	 in	PaCO2	(i.e.,	no	change	in	MEP	during	Project	5.1;	Indo	condition).	Conversely,	reductions	in	cerebral	O2	content	appear	to	decrease	corticospinal	excitability,	which	is	likely	a	result	of	CBF	mediated	reductions	in	CDO2.	For	example,	impaired	 CDO2	 during	 Project	 5.2	 resulted	 in	 a	 51.0	 ±	 17.7%	 and	 64.1	 ±	 12.8%	decrease	 in	 MEP	 amplitude	 in	 response	 to	 hypoxia	 during	 Poikilo	 and	 Indo,	respectively;	 however,	 MEP	 amplitude	 remained	 unchanged	 from	 baseline	 when	CBF	increased	due	to	PETCO2	clamping	at	eucapnia	(Project	5.2;	Iso).	In	response	to	passive	 heat	 stress,	 reductions	 in	 MEP	 amplitude	 were	 also	 observed	 (-3.91±0.80%).	Although	 it	 is	 plausible	 that	 the	 observed	 reduction	 in	 corticospinal	excitability	may	be	explained	by	reduced	CDO2	associated	with	the	combined	effects	of	thermal	hyperpnoea	and	reductions	in	mean	arterial	pressure,	it	is	acknowledged	that	 several	 other	 mechanisms	 (Bigland-Ritchie	 et	 al.	 1986;	 Ray	 &	 Gracey	 1997;	
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Taylor	et	al.	2006),	in	addition	to	changes	in	CDO2,	indeed	modulate	MEP	amplitude.	Therefore,	future	research	should	examine	the	corticospinal	response	to	changes	in	CDO2	in	isolation	of	other	cardio-respiratory	confounds.	The	collective	findings	from	the	research	program	indicate	that	the	 influence	of	 reduced	 cerebral	 O2	 content	 is	 far	 greater	 than	 hypocapnia	 on	 corticospinal	excitability.	 To	 highlight	 this,	 similar	 reductions	 in	 PETCO2	 were	 observed	 during	both	Project	5.1	Hypo	(-11.5±2.8	mmHg)	and	Project	5.2	Poikilo	(-15.6±6.5	mmHg)	conditions;	 however,	 reductions	 in	MEP	 amplitude	 associated	with	 impaired	 CDO2	during	 poikilocapnic	 hypoxia	 (Project	 5.2	 Poikilo)	 occurred	 despite	 marked	hypocapnia.	 The	mechanisms	 underlying	 this	 observation	 have	 yet	 to	 be	 directly	investigated,	although	the	independent	influence	of	PaCO2	and	PaO2	on	neuronal	cell	potentials	highlights	plausible	explanations.	In	response	to	reductions	in	PaCO2,	the	increase	in	local	pH	inhibits	Ecto-ATPase	activity	(Dulla	et	al.	2005)	and	results	in	an	accumulation	 of	 extracellular	 ATP,	 whereas	 reductions	 in	 PaO2	 result	 in	 ion	disturbances	 that	 compromise	 ATP	 synthesis	 altogether	 (Baker	 et	 al.	 1971).	Additionally,	previous	research	(Haddad	&	Jiang	1993)	indicates	that	reductions	in	PaO2	have	an	inhibitory	effect	on	neuronal	cells,	thereby	reducing	the	amplitude	of	MEPs.	The	 voluntary	 activation	 response	 to	 altered	 CBF	 and	 PETCO2	 during	environmental	 stress	 is	 complex	 and	 the	 mechanisms	 underlying	 the	 observed	reductions	 remain	 elusive.	 The	 collective	 evidence	 from	 this	 research	 program	suggests	 that	 impaired	 voluntary	 activation	 is	 associated	with	 reductions	 in	 CBF;	however,	 it	must	 be	 noted	 that	 changes	 in	 cVA	were	 not	 linearly	 correlated	with	
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changes	 in	 CBF	 (Figure	 5-3).	 In	 the	 absence	 of	 environmental	 stress	 (i.e.,	 Project	5.1),	 cVA	 was	 selectively	 lower	 during	 reductions	 in	 CBF	 and	 independent	 of	hypocapnia	 (Indo).	 Similarly,	 impairments	 in	 cVA	during	passive	heat	 stress	were	exacerbated	when	 CBF	was	 reduced	 during	 the	 Poikilo	 and	 Indo	 conditions.	 This	relationship	was	not	evident,	however,	when	CBF	was	reduced	during	Project	5.2	as	cVA	was	impaired	in	response	to	both	isocapnic	hypoxia	(i.e.,	 increase	in	CBF)	and	isocapnia	hypoxia	with	cyclooxygenase	inhibition	(i.e.,	decrease	in	CBF).		In	addition	to	the	independent	influence	of	changes	in	CBF	on	neuromuscular	responses,	 increased	 perception	 of	 effort	 (Berchicci	 et	al.	 2013;	 Lampropoulou	 &	Nowicky	 2014),	 distress	 or	 discomfort	may	 have	 contributed	 to	 the	 reductions	 in	cVA.	 Cerebral	 vasoconstriction	 is	 associated	with	 neurological	 side	 effects	 such	 as	dizziness,	 nervousness	 and	 headache	 –	 factors	 that	 contribute	 to	 an	 overall	sensation	 of	 distress.	 Recent	 evidence	 suggests	 that	 perception	 of	 effort	(Lampropoulou	 &	 Nowicky	 2014)	 and	 high-amplitude	 respiration	 (Baweja	 et	 al.	2011)	 are	 primary	 regulators	 of	 voluntary	 motor	 control	 during	 isometric	contractions.	Similarly,	 increased	 inspiratory	muscle	work	during	exercise	 (Harms	
et	al.	2000)	and	hypoxia	(Amann	et	al.	2007;	Cibella	et	al.	1996;	Cibella	et	al.	1999)	have	 been	 associated	 with	 locomotor	 muscle	 fatigue	 and	 impaired	 performance.	Specifically,	Dempsey	et	al.	(2006)	proposed	that	diaphragm	and	accessory	muscle	fatigue	associated	with	increased	work	of	breathing	contributes	to	activation	of	the	respiratory	 muscle	 metaboreflex	 and	 consequently,	 reflex	 inhibition	 of	 central	motor	output	and	increased	perception	of	associated	effort	and	dyspnea.	Although	the	 association	 between	 reductions	 in	 CBF	 and	 increased	 perception	 of	 effort	 or	
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distress	remain	speculative	at	best,	Project	5.1	excludes	the	possible	psychosomatic	modulating	 effect	 of	 elevations	 in	 ventilation,	 rather	 than	 hypocapnia	 or	 reduced	CBF	per	se,	given	that	reductions	in	voluntary	activation	were	not	observed	during	the	Project	5.1	Iso	condition	(Figure	5-2E).	In	 the	 present	 research	 program,	 voluntary	 activation	 was	 assessed	 using	both	electrical	stimulation	of	the	peripheral	motor	nerve	(pVA)	and	TMS	stimulation	of	 the	motor	 cortex	 (cVA).	 There	 was	 a	 systematic	 discrepancy	 between	 the	 two	measures	of	voluntary	activation	throughout	the	research	program	where	measures	of	 pVA	 failed	 to	 detect	 differences	 in	 voluntary	 activation	 across	 conditions	 that	were	identified	using	cVA.	This	evidence	suggests	the	mechanism(s)	that	contribute	to	neuromuscular	impairments	in	response	to	decreased	CBF	reside	at	or	above	the	level	 of	 the	motor	 cortex.	 Therefore,	 future	 research	 should	 use	 TMS	 to	 quantify	voluntary	 activation	when	 assessing	 neuromuscular	 fatigue	 during	 environmental	stress.	
6.2 Conclusions	In	response	to	the	collective	evidence	provided	by	the	three	projects	outlined	in	Chapter	3,	the	following	conclusions	may	be	drawn	from	this	research:	1. Despite	the	functional	association	between	reductions	in	CBF	and	hypocapnia,	both	variables	have	distinct	and	independent	influence	on	the	neuromuscular	system.	Therefore,	future	studies	should	control	or	acknowledge	the	separate	mechanistic	influence	of	these	two	factors.	2. Excitability	of	the	corticospinal	tract	is	inherently	sensitive	to	changes	in	PaCO2	and	 CDO2.	 Moderate	 hypocapnia	 (PETCO2	 approximately	 11	 mmHg	 below	
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eucapnia)	is	associated	with	a	~10%	increase	in	MEP	amplitude.	Reductions	in	CDO2	 (approximately	 12%	 below	 baseline	 values)	 during	 severe	 hypoxia	(PETO2	~	50	mmHg)	cause	>50%	reductions	in	MEP	amplitude.	3. Impaired	voluntary	activation	 is	associated	with	reductions	 in	CBF.	Although	there	was	 a	 systematic	 association	 between	 these	 two	 variables	 throughout	the	 entire	 research	 program,	 linear	 regression	 analysis	 failed	 to	 show	significant	correlations	between	the	change	in	CBF	and	cVA.	Therefore,	it	must	be	noted	that	impaired	cVA	during	environmental	stress	is	likely	mediated	by	other	factors	in	addition	to	reductions	in	CBF	(Gandevia		2001).	4. The	 mechanisms	 that	 contribute	 to	 impaired	 voluntary	 activation	 during	environmental	 stress	 reside	 at	 or	 above	 the	 level	 of	 the	 motor	 cortex.	 This	conclusion	 is	 supported	 by	 evidence	 that	 pVA	 failed	 to	 detect	 differences	 in	voluntary	activation	that	were	identified	using	cVA.	
6.3 Limitations	of	the	Research	In	the	present	research	program,	we	are	limited	to	measurements	of	PETCO2	for	 the	 estimation	 of	 arterial	 CO2	 content.	 Previous	 research	 (Willie	 et	 al.	 2012)	demonstrates	 that	 PETCO2	 accurately	 reflects	 measurements	 PaCO2	 throughout	progressive	 levels	 of	 hypocapnia	 (PETCO2	 ±25	mmHg	 baseline);	 therefore,	 we	 are	confident	 that	 measurements	 of	 PETCO2	 are	 representative	 of	 the	 degree	 of	hypocapnia	 in	 the	 present	 study.	 Measurements	 of	 MCAv	 using	 TCD	 provide	 an	index	representation	of	CBF;	however,	this	relationship	is	only	valid	assuming	that	the	diameter	of	the	middle	cerebral	artery	does	not	change	during	the	intervention.	The	stability	of	the	MCA	has	been	confirmed	via	MRI	during	prostaglandin	inhibition	
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using	 a	 100	mg	 oral	 dose	 of	 indomethacin.	 Changes	 in	 flow	 (Xie	 et	al.	 2006)	 are	adequately	reflected	by	changes	in	flow	velocity	only	when	conduit	artery	diameter	is	 unchanged	 (Valdueza	 et	 al.	 1997),	 which	 appears	 to	 be	 true	 during	 moderate	changes	in	MAP	(Giller	et	al.	1993).	Recent	evidence	indicates	that	middle	cerebral	artery	diameter	may	constrict	in	response	to	hypocapnia	(Ainslie	&	Hoiland	2014),	although	 small	 differences	 in	 MCAv	 and	 flow	 during	 hypocapnia	 are	 unlikely	 to	detract	 from	 our	 primary	 findings;	 if	 anything,	 MCA	 constriction	 would	underestimate	 our	 findings.	 Also,	 we	 only	 measured	 blood	 flow	 velocity	 in	 the	territory	of	 the	middle	cerebral	artery;	whether	the	observed	blood	flow	response	was	homogenous	across	all	vascular	territories	in	the	brain	is	unknown.	
6.4 Suggestions	for	Further	Research	The	 present	 research	 program	 has	 presented	 the	 following	 questions	 that	warrant	future	research:	1. What	 is	 the	 influence	of	PETCO2,	 ranging	 from	hypercapnia	 to	hypocapnia,	on	corticospinal	 excitability?	 Evidence	 from	 the	 present	 research	 program	suggests	 that	 mild	 hypocapnia	 causes	 marked	 corticospinal	 excitability;	however,	 confirmation	 of	 this	 association	 would	 be	 strengthen	 when	examining	a	range	of	PETCO2	–	specifically	including	hypercapnia	-	rather	than	hypocapnia	exclusively.	2. What	 are	 the	 time-dependent	 effects	 of	 changes	 in	 PETCO2	 and	 CBF	 on	corticospinal	 excitability	 during	 severe	 hypoxia?	 Findings	 from	 the	 present	research	 program,	 namely	 that	 hypoxia	 decreases	 corticospinal	 excitability,	conflict	 with	 previous	 findings	 (Rupp	 et	 al.	 2012;	 Szubski	 et	 al.	 2006);	
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however,	 it	 is	 noted	 that	 the	 short-term	 hypoxia	 in	 the	 present	 study	 may	contribute	 to	 the	 observed	differences.	Hypoxic	 ventilatory	 decline	 (Robbins		1995)	 is	 associated	 with	 the	 restoration	 of	 CBF	 and	 results	 in	 a	 relative	increase	in	!"#$ .	Re-oxygenation	of	neurons	may	cause	post-hypoxia	neuronal	hyperexcitability	(Doolette	&	Kerr	1995;	Schiff	&	Somjen	1985)	and	contribute	to	 increased	 corticospinal	 excitability	 during	 long	 term	 (>30	 min)	 hypoxia	exposure.	3. What	 is	the	 influence	of	changes	 in	CBF	and	PETCO2	on	spinal	reflexes	during	passive	heat	stress?	Novel	to	the	present	study	was	the	measurement	of	MEP	amplitude	at	rest;	a	measure	of	both	motor	cortex	and	spinal	excitability	(i.e.,	corticospinal	 excitability).	 It	 is	 possible	 that	 the	 discrepancy	 between	 the	findings	 of	 the	 present	 study	 and	 that	 of	 Ross	 et	 al.	 (2012)	 and	 Todd	 et	 al.	(2005)	–	which	measure	motor	cortex	excitability	exclusively	-	may	be	due	to	heat	 induced	changes	within	 the	spinal	 cord.	Future	studies	 that	 incorporate	measures	 of	 H-reflex	 or	 V-wave	 to	 assess	 excitability	 of	 spinal	 reflexes	 and	central	drive	to	 the	motor	neuron	may	help	 identify	 the	specific	mechanisms	that	modulate	neuromuscular	fatigue	during	passive	heat	stress.	
  
	 	 	
	
112	
REFERENCES	Abbiss	 CR	 &	 Laursen	 PB	 (2005).	 Models	 to	 explain	 fatigue	 during	 prolonged	endurance	cycling.	Sports	Medicine	35,	865-898.	Adams	RP	&	Welch	HG	(1980).	Oxygen-Uptake,	Acid-Base	Status,	and	Performance	with	Varied	 Inspired	Oxygen	Fractions.	 Journal	of	Applied	Physiology	49,	863-868.	Ainslie	 PN	 &	 Duffin	 J	 (2009).	 Integration	 of	 cerebrovascular	 CO2	 reactivity	 and	chemoreflex	 control	 of	 breathing:	 mechanisms	 of	 regulation,	 measurement,	and	interpretation.	American	Journal	of	Physiology	-	Regulatory	Integrative	and	
Comparative	Physiology	296,	R1473-95.	Ainslie	PN	&	Hoiland	RL	(2014).	Transcranial	Doppler	Ultrasound:	Valid,	Invalid,	or	Both?	J	Appl	Physiol	(1985)	117,	1081-1083.	Ainslie	PN	&	Ogoh	S	(2010).	Regulation	of	cerebral	blood	flow	in	mammals	during	chronic	hypoxia:	a	matter	of	balance.	Exp	Physiol	95,	251-62.	Ainslie	 PN	 &	 Poulin	 MJ	 (2004).	 Ventilatory,	 cerebrovascular,	 and	 cardiovascular	interactions	in	acute	hypoxia:	regulation	by	carbon	dioxide.	Journal	of	Applied	
Physiology	1,	149-159.	Ainslie	PN	&	Subudhi	AW	(2014).	Cerebral	blood	flow	at	high	altitude.	High	Alt	Med	
Biol	15,	133-40.	Ainslie	PN,	Barach	A,	Murrell	C,	Hamlin	M,	Hellemans	J	&	Ogoh	S	(2007).	Alterations	in	 cerebral	 autoregulation	 and	 cerebral	 blood	 flow	 velocity	 during	 acute	hypoxia:	 rest	 and	 exercise.	 American	 Journal	 of	 Physiology	 -	 Heart	 and	
Circulatory	Physiology	292,	H976-83.	Alexander	 JK,	 Hartley	 LH,	 Modelski	 M	 &	 Grover	 RF	 (1967).	 Reduction	 of	 stroke	volume	during	exercise	in	man	following	ascent	to	3,100	m	altitude.	Journal	of	
Applied	Physiology	23,	849-58.	
	 	 	
	
113	
Almeida	T,	Rodrigues	RJ,	de	Mendonça	A,	Ribeiro	JA	&	Cunha	RA	(2003).	Purinergic	P2	 receptors	 trigger	 adenosine	 release	 leading	 to	 adenosine	 A2A	 receptor	activation	and	facilitation	of	long-term	potentiation	in	rat	hippocampal	slices.	
Neuroscience	122,	111-21.	Amann	M	&	Calbet	 JA	 (2008).	 Convective	 oxygen	 transport	 and	 fatigue.	 Journal	of	
Applied	Physiology	104,	861-70.	Amann	 M,	 Eldridge	 MW,	 Lovering	 AT,	 Stickland	 MK,	 Pegelow	 DF	 &	 Dempsey	 JA	(2006).	 Arterial	 oxygenation	 influences	 central	 motor	 output	 and	 exercise	performance	via	effects	on	peripheral	 locomotor	muscle	 fatigue	 in	humans.	 J	
Physiol	575,	937-52.	Amann	M,	Pegelow	DF,	Jacques	AJ	&	Dempsey	JA	(2007).	Inspiratory	muscle	work	in	acute	hypoxia	 influences	 locomotor	muscle	 fatigue	and	exercise	performance	of	healthy	humans.	Am	J	Physiol	Regul	Integr	Comp	Physiol	293,	R2036-45.	Amann	M,	Romer	LM,	Pegelow	DF,	Jacques	AJ,	Hess	CJ	&	Dempsey	JA	(2006).	Effects	of	 arterial	 oxygen	 content	 on	 peripheral	 locomotor	 muscle	 fatigue.	 J	 Appl	
Physiol	101,	119-27.	Amann	M,	Romer	LM,	Subudhi	AW,	Pegelow	DF	&	Dempsey	 JA	 (2007).	Severity	of	arterial	 hypoxaemia	 affects	 the	 relative	 contributions	 of	 peripheral	 muscle	fatigue	to	exercise	performance	in	healthy	humans.	Journal	of	Physiology	581,	389-403.	Appell	HJ	 (1978).	Capillary	density	and	patterns	 in	skeletal	muscle.	 III.	Changes	of	the	capillary	pattern	after	hypoxia.	Pfluegers	Arch	377,	R53.	Archer	SL,	Tolins	JP,	Raij	L	&	Weir	EK	(1989).	Hypoxic	pulmonary	vasoconstriction	is	enhanced	by	inhibition	of	the	synthesis	of	an	endothelium	derived	relaxing	factor.	Biochem	Biophys	Res	Commun	164,	1198-205.	Baker	PF,	Hodgkin	AL	&	Ridgway	EB	 (1971).	Depolarization	 and	 calcium	entry	 in	squid	giant	axons.	J	Physiol	218,	709-55.	
	 	 	
	
114	
Banchero	N	(1982).	Long	term	adaptation	of	skeletal	muscle	capillarity.	Physiologist	
25,	385-9.	Barer	 GR,	 Howard	 P	 &	 Shaw	 JW	 (1970).	 Stimulus-response	 curves	 for	 the	pulmonary	 vascular	 bed	 to	 hypoxia	 and	 hypercapnia.	 Journal	 of	 Applied	
Physiology	211,	139-55.	Baweja	HS,	Patel	BK,	Neto	OP	&	Christou	EA	(2011).	The	interaction	of	respiration	and	visual	feedback	on	the	control	of	force	and	neural	activation	of	the	agonist	muscle.	Hum	Mov	Sci	30,	1022-38.	Benoit	 H,	 Busso	 T,	 Castells	 J,	 Denis	 C	 &	 Geyssant	 A	 (1995).	 Influence	 of	 hypoxic	ventilatory	 response	 on	 arterial	 O-2	 saturation	 during	 maximal	 exercise	 in	acute	 hypoxia.	 European	 Journal	 of	 Applied	 Physiology	 and	 Occupational	
Physiology	72,	101-105.	Berchicci	M,	Menotti	 F,	Macaluso	A	&	Di	 Russo	 F	 (2013).	 The	 neurophysiology	 of	central	 and	 peripheral	 fatigue	 during	 sub-maximal	 lower	 limb	 isometric	contractions.	Front	Hum	Neurosci	7,	135.	Bigland-Ritchie	B	&	Woods	JJ	(1984).	Changes	in	muscle	contractile	properties	and	neural	control	during	human	muscular	fatigue.	Muscle	Nerve	7,	691-9.	Bigland-Ritchie	BR,	Dawson	NJ,	Johansson	RS	&	Lippold	OC	(1986).	Reflex	origin	for	the	 slowing	 of	 motoneurone	 firing	 rates	 in	 fatigue	 of	 human	 voluntary	contractions.	J	Physiol	379,	451-9.	Bishop	 CC,	 Powell	 S,	 Rutt	 D	 &	 Browse	 NL	 (1986).	 Transcranial	 Doppler	measurement	of	middle	cerebral	artery	blood	flow	velocity:	a	validation	study.	
Stroke;	a	journal	of	cerebral	circulation	17,	913-5.	Bland	 JM	&	Altman	DG	(1995).	Statistics	notes:	Calculating	correlation	coefficients	with	 repeated	 observations:	 Part	 1—correlation	 within	 subjects.	 BMJ	 310,	446.	Boussuges	 A,	 Molenat	 F,	 Burnet	 H,	 Cauchy	 E,	 Gardette	 B,	 Sainty	 JM,	 Jammes	 Y	 &	Richalet	JP	(2000).	Operation	Everest	III	(Comex	'97):	modifications	of	cardiac	
	 	 	
	
115	
function	 secondary	 to	 altitude-induced	 hypoxia.	 An	 echocardiographic	 and	Doppler	study.	Am	J	Respir	Crit	Care	Med	161,	264-70.	Boutellier	 U,	 Howald	 H,	 di	 Prampero	 PE,	 Giezendanner	 D	 &	 Cerretelli	 P	 (1983).	Human	muscle	adaptations	to	chronic	hypoxia.	Prog	Clin	Biol	Res	136,	273-85.	Bowery	NG,	Bettler	B,	 Froestl	W,	Gallagher	 JP,	Marshall	 F,	 Raiteri	M,	Bonner	TI	&	Enna	 SJ	 (2002).	 International	 Union	 of	 Pharmacology.	 XXXIII.	 Mammalian	gamma-aminobutyric	acid(B)	receptors:	structure	and	function.	Pharmacol	Rev	
54,	247-64.	Brothers	 RM,	Wingo	 JE,	 Hubing	 KA	 &	 Crandall	 CG	 (2009).	 The	 effects	 of	 reduced	end-tidal	 carbon	dioxide	 tension	on	 cerebral	blood	 flow	during	heat	 stress.	 J	
Physiol	587,	3921-7.	Busija	 DW,	 Leffler	 CW	 &	 Pourcyrous	 M	 (1988).	 Hyperthermia	 increases	 cerebral	metabolic	rate	and	blood	flow	in	neonatal	pigs.	Am	J	Physiol	255,	H343-6.	Calbet	 JAL,	Robach	P	&	Lundby	C	(2009).	The	exercising	heart	at	altitude.	Cell	Mol	
Life	Sci	66,	3601-13.	Cassaglia	 PA,	 Griffiths	 RI	 &	Walker	 AM	 (2008).	 Sympathetic	 nerve	 activity	 in	 the	superior	cervical	ganglia	increases	in	response	to	imposed	increases	in	arterial	pressure.	Am	J	Physiol	Regul	Integr	Comp	Physiol	294,	R1255-61.	Cerretelli,	P.	(1987).	Extreme	hypoxia	in	air	breathers:	Some	problems.	In	P.	Dejours	(Ed.),	Adaptations	to	extreme	environments	(Vol.	Vol.	2).	Basel:	Karger.	Cerretelli	P,	Marconi	C,	Dériaz	O	&	Giezendanner	D	(1984).	After	effects	of	chronic	hypoxia	 on	 cardiac	 output	 and	 muscle	 blood	 flow	 at	 rest	 and	 exercise.	
European	Journal	of	Applied	Physiology	and	Occupational	Physiology	53,	92-6.	Chang	HS,	 Sasaki	T	&	Kassell	NF	 (1989).	Hippocampal	unit	 activity	after	 transient	cerebral	ischemia	in	rats.	Stroke	20,	1051-8.	Chesler	M	&	Kaila	K	(1992).	Modulation	of	pH	by	neuronal	activity.	Trends	Neurosci	
15,	396-402.	
	 	 	
	
116	
Cibella	F,	Cuttitta	G,	Kayser	B,	Narici	M,	Romano	S	&	Saibene	F	(1996).	Respiratory	mechanics	during	exhaustive	submaximal	exercise	at	high	altitude	 in	healthy	humans.	J	Physiol	494	(	Pt	3),	881-90.	Cibella	 F,	 Cuttitta	 G,	 Romano	 S,	 Grassi	 B,	 Bonsignore	 G	 &	 Milic-Emili	 J	 (1999).	Respiratory	 energetics	 during	 exercise	 at	 high	 altitude.	 J	Appl	Physiol	(1985)	
86,	1785-92.	Cohen	PJ,	Alexande.Sc,	Smith	TC,	Reivich	M	&	Wollman	H	(1967).	Effects	of	Hypoxia	and	Normocarbia	on	Cerebral	Blood	Flow	and	Metabolism	in	Conscious	Man.	
Journal	of	Applied	Physiology	23,	183-&.	Coppock	EA,	Martens	JR	&	Tamkun	MM	(2001).	Molecular	basis	of	hypoxia-induced	pulmonary	 vasoconstriction:	 role	 of	 voltage-gated	 K+	 channels.	 American	
Journal	of	Physiology	-	Lung	Cellular	and	Molecular	Pysiology	281,	L1-12.	Crandall	CG	(2008).	Heat	stress	and	baroreflex	regulation	of	blood	pressure.	Med	Sci	
Sports	Exerc	40,	2063-70.	Crandall	 CG	 &	 González-Alonso	 J	 (2010).	 Cardiovascular	 function	 in	 the	 heat-stressed	human.	Acta	Physiol	(Oxf)	199,	407-23.	D'Alecy	 LG,	 Rose	 CJ	 &	 Sellers	 SA	 (1979).	 Sympathetic	 modulation	 of	 hypercapnic	cerebral	vasodilation	in	dogs.	Circulation	Research	45,	771-85.	Daut	J,	Maier-Rudolph	W,	von	Beckerath	N,	Mehrke	G,	Günther	K	&	Goedel-Meinen	L	(1990).	 Hypoxic	 dilation	 of	 coronary	 arteries	 is	 mediated	 by	 ATP-sensitive	potassium	channels.	Science	247,	1341-4.	Davies	 HD,	 Carroll	 WM	 &	 Mastaglia	 FL	 (1986).	 Effects	 of	 hyperventilation	 on	pattern-reversal	 visual	 evoked	 potentials	 in	 patients	 with	 demyelination.	 J	
Neurol	Neurosurg	Psychiatry	49,	1392-6.	Davis	FA,	Becker	FO,	Michael	JA	&	Sorensen	E	(1970).	Effect	of	intravenous	sodium	bicarbonate,	disodium	edetate	(Na2EDTA),	and	hyperventilation	on	visual	and	oculomotor	signs	in	multiple	sclerosis.	 J	Neurol	Neurosurg	Psychiatry	33,	723-32.	
	 	 	
	
117	
Davis	JM	&	Bailey	SP	(1997).	Possible	mechanisms	of	central	nervous	system	fatigue	during	exercise.	Med	Sci	Sports	Exerc	29,	45-57.	Dempsey	 JA,	 Forster	 HV,	 Gledhill	 N	 &	 doPico	 GA	 (1975).	 Effects	 of	 moderate	hypoxemia	and	hypocapnia	on	CSF	[H+]	and	ventilation	in	man.	J	Appl	Physiol	
38,	665-74.	Dempsey	 JA,	 Romer	 L,	 Rodman	 J,	 Miller	 J	 &	 Smith	 C	 (2006).	 Consequences	 of	exercise-induced	respiratory	muscle	work.	Respir	Physiol	Neurobiol	151,	242-50.	Desplanches	D,	Hoppeler	H,	Linossier	MT,	Denis	C,	Claassen	H,	Dormois	D,	Lacour	JR	&	Geyssant	A	(1993).	Effects	of	training	in	normoxia	and	normobaric	hypoxia	on	human	muscle	ultrastructure.	Pflugers	Arch	425,	263-7.	Dewhurst	S,	Riches	PE,	Nimmo	MA	&	De	Vito	G	(2005).	Temperature	dependence	of	soleus	H-reflex	 and	M	wave	 in	 young	 and	 older	women.	European	journal	of	
applied	physiology	94,	491-9.	Doolette	DJ	&	Kerr	DI	(1995).	Hyperexcitability	in	CA1	of	the	rat	hippocampal	slice	following	hypoxia	or	adenosine.	Brain	Res	677,	127-37.	Dousset	E,	Steinberg	JG,	Balon	N	&	Jammes	Y	(2001).	Effects	of	acute	hypoxemia	on	force	and	surface	EMG	during	sustained	handgrip.	Muscle	Nerve	24,	364-71.	Dulla	 CG,	 Dobelis	 P,	 Pearson	 T,	 Frenguelli	 BG,	 Staley	 KJ	 &	 Masino	 SA	 (2005).	Adenosine	and	ATP	link	PCO2	to	cortical	excitability	via	pH.	Neuron	48,	1011-23.	Dutka	 TL,	 Cole	 L	 &	 Lamb	 GD	 (2005).	 Calcium	 phosphate	 precipitation	 in	 the	sarcoplasmic	 reticulum	 reduces	 action	 potential-mediated	 Ca2+	 release	 in	mammalian	skeletal	muscle.	Am	J	Physiol	Cell	Physiol	289,	C1502-12.	Enoka	 RM	&	 Stuart	 DG	 (1992).	 Neurobiology	 of	muscle	 fatigue.	 J	Appl	Physiol	72,	1631-48.	Fan	JL,	Burgess	KR,	Thomas	KN,	Peebles	KC,	Lucas	SJE,	Lucas	RAI,	Cotter	JD	&	Ainslie	PN	 (2010).	 Influence	 of	 indomethacin	 on	 ventilatory	 and	 cerebrovascular	
	 	 	
	
118	
responsiveness	to	CO2	and	breathing	stability:	the	influence	of	PCO2	gradients.	
AMERICAN	 JOURNAL	 OF	 PHYSIOLOGY-REGULATORY	 INTEGRATIVE	 AND	
COMPARATIVE	PHYSIOLOGY	6,	10.1152/ajpregu.00721.2009.	Fan	 J-L,	 Burgess	 KR,	 Thomas	 KN,	 Peebles	 KC,	 Lucas	 SJE,	 Lucas	 RAI,	 Cotter	 JD	 &	Ainslie	 PN	 (2011).	 Influence	 of	 indomethacin	 on	 the	 ventilatory	 and	cerebrovascular	responsiveness	to	hypoxia.	Eur	J	Appl	Physiol	111,	601-10.	Fan	 J-L,	 Cotter	 JD,	 Lucas	 RAI,	 Thomas	 K,	 Wilson	 L	 &	 Ainslie	 PN	 (2008).	 Human	cardiorespiratory	 and	 cerebrovascular	 function	 during	 severe	 passive	hyperthermia:	 effects	 of	 mild	 hypohydration.	 Journal	 of	 Applied	 Physiology	
105,	433-45.	Fishman,	 A.	 P.	 (1985).	 Pulmonary	 circulation.	 In	 A.	 B.	 Fisher	 (Ed.),	 Handbook	 of	
physiology	 (Vol.	Volume	1:	Circulation	and	nonrespiratory	 functions,	pp.	93	 -	165).	Bethesda,	MD:	American	Physiological	Society.	Fitts	 RH	 (1994).	 Cellular	mechanisms	 of	muscle	 fatigue.	Physiological	Reviews	74,	49-94.	Fuglevand	 AJ	 &	 Segal	 SS	 (1997).	 Simulation	 of	 motor	 unit	 recruitment	 and	microvascular	 unit	 perfusion:	 spatial	 considerations.	 Journal	 of	 Applied	
Physiology	83,	1223-34.	Galloway	SDR	&	Maughan	RJ	(1997).	Effects	of	ambient	temperature	on	the	capacity	to	 perform	 prolonged	 cycle	 exercise	 in	man.	Med	Sci	Sports	Exerc	29,	1240-1249.	Gandevia	SC	(2001).	Spinal	and	supraspinal	factors	in	human	muscle	fatigue.	Physiol	
Rev	81,	1725-89.	Gandevia	SC,	Petersen	N,	Butler	JE	&	Taylor	JL	(1999).	Impaired	response	of	human	motoneurones	 to	 corticospinal	 stimulation	 after	 voluntary	 exercise.	 J	Physiol	
521,	749-59.	
	 	 	
	
119	
Garner	 SH,	 Sutton	 JR,	 Burse	 RL,	McComas	AJ,	 Cymerman	A	&	Houston	 CS	 (1990).	Operation	 Everest	 II:	 neuromuscular	 performance	 under	 conditions	 of	extreme	simulated	altitude.	J	Appl	Physiol	68,	1167-72.	Gibson	GE,	 Pulsinelli	W,	 Blass	 JP	&	Duffy	 TE	 (1981).	 Brain	 dysfunction	 in	mild	 to	moderate	hypoxia.	Am	J	Med	70,	1247-54.	Giller	 CA,	 Bowman	 G,	 Dyer	 H,	 Mootz	 L	 &	 Krippner	 W	 (1993).	 Cerebral	 arterial	diameters	 during	 changes	 in	 blood	 pressure	 and	 carbon	 dioxide	 during	craniotomy.	Neurosurgery	32,	737-42.	Gonzalez-Alonso	J,	Crandall	CG	&	Johnson	JA	(2008).	The	cardiovascular	challenge	of	exercising	in	the	heat.	Journal	of	Physiology-London	586,	45-53.	Gonzalez-Alonso	 J,	 Teller	C,	Andersen	SL,	 Jensen	FB,	Hyldig	T	&	Nielsen	B	 (1999).	Influence	of	body	temperature	on	the	development	of	fatigue	during	prolonged	exercise	in	the	heat.	Journal	of	Applied	Physiology	86,	1032-1039.	Goodall	S,	González-Alonso	J,	Ali	L,	Ross	EZ	&	Romer	LM	(2012).	Supraspinal	fatigue	after	normoxic	and	hypoxic	exercise	in	humans.	J	Physiol	590,	2767-82.	Goodall	 S,	 Ross	 EZ	 &	 Romer	 LM	 (2010).	 Effect	 of	 graded	 hypoxia	 on	 supraspinal	contributions	to	fatigue	with	unilateral	knee-extensor	contractions.	Journal	of	
Applied	Physiology	109,	1842-51.	Green	 HJ,	 Sutton	 JR,	 Cymerman	 A,	 Young	 PM	 &	 Houston	 CS	 (1989).	 Operation	Everest	II:	adaptations	in	human	skeletal	muscle.	Journal	of	Applied	Physiology	
66,	2454-61.	Green	RS,	Leffler	CW,	Busija	DW,	Fletcher	AM	&	Beasley	DG	(1987).	 Indomethacin	does	 not	 alter	 the	 circulating	 catecholamine	 response	 to	 asphyxia	 in	 the	neonatal	piglet.	Pediatric	research	21,	534-7.	Haddad	 GG	 &	 Jiang	 C	 (1993).	 O2	 deprivation	 in	 the	 central	 nervous	 system:	 on	mechanisms	 of	 neuronal	 response,	 differential	 sensitivity	 and	 injury.	 Prog	
Neurobiol	40,	277-318.	
	 	 	
	
120	
Hansen	AJ	 (1985).	Effect	of	anoxia	on	 ion	distribution	 in	 the	brain.	Physiol	Rev	65,	101-48.	Harms	 CA,	 Wetter	 TJ,	 St	 Croix	 CM,	 Pegelow	 DF	 &	 Dempsey	 JA	 (2000).	 Effects	 of	respiratory	 muscle	 work	 on	 exercise	 performance.	 J	Appl	Physiol	 (1985)	89,	131-8.	Heyes	MP,	Garnett	ES	&	Coates	G	 (1985).	Central	dopaminergic	activity	 influences	rats	ability	to	exercise.	Life	Sci	36,	671-7.	Hilbert	M,	Shushakov	V	&	Maassen	N	(2012).	The	influence	of	respiratory	acid-base	changes	 on	 muscle	 performance	 and	 excitability	 of	 the	 sarcolemma	 during	strenuous	intermittent	hand	grip	exercise.	J	Appl	Physiol	(1985)	112,	571-9.	Hogan	MC,	Richardson	RS	&	Kurdak	SS	(1994).	Initial	Fall	 in	Skeletal-Muscle	Force	Development	 during	 Ischemia	 Is	 Related	 to	 Oxygen	 Availability.	 Journal	 of	
Applied	Physiology	77,	2380-2384.	Hohimer	 AR,	 Richardson	 BS,	 Bissonnette	 JM	 &	Machida	 CM	 (1985).	 The	 effect	 of	indomethacin	 on	 breathing	 movements	 and	 cerebral	 blood	 flow	 and	metabolism	in	the	fetal	sheep.	Journal	of	developmental	physiology	7,	217-28.	Hoiland	 RL,	 Ainslie	 PN,	 Wildfong	 KW,	 Smith	 KJ,	 Bain	 AR,	 Willie	 CK,	 Foster	 G,	Monteleone	B	&	Day	TA	(2014).	Indomethacin-induced	impairment	of	regional	cerebrovascular	 reactivity:	 implications	 for	 respiratory	 control.	 J	 Physiol	10.1113/jphysiol.2014.284521	Hoppeler	 H,	 Howald	 H	 &	 Cerretelli	 P	 (1990).	 Human	 muscle	 structure	 after	exposure	to	extreme	altitude.	Experientia	46,	1185-7.	Howald	H,	Pette	D,	Simoneau	JA,	Uber	A,	Hoppeler	H	&	Cerretelli	P	(1990).	Effect	of	chronic	 hypoxia	 on	 muscle	 enzyme	 activities.	 International	 Journal	of	 Sports	
Medicine	11	Suppl	1,	S10-4.	Huang	 SY,	 Tawney	 KW,	 Bender	 PR,	 Groves	 BM,	 McCullough	 RE,	 McCullough	 RG,	Micco	AJ,	Manco-Johnson	M,	Cymerman	A	&	Greene	ER	(1991).	Internal	carotid	
	 	 	
	
121	
flow	velocity	with	exercise	before	and	after	acclimatization	to	4,300	m.	Journal	
of	Applied	Physiology	71,	1469-76.	Hughson	 RL,	 Yamamoto	 Y,	 McCullough	 RE,	 Sutton	 JR	 &	 Reeves	 JT	 (1994).	Sympathetic	 and	parasympathetic	 indicators	 of	 heart	 rate	 control	 at	 altitude	studied	by	spectral	analysis.	Journal	of	Applied	Physiology	77,	2537-42.	Ide	 K	 &	 Secher	 NH	 (2000).	 Cerebral	 blood	 flow	 and	metabolism	 during	 exercise.	
Prog	Neurobiol	61,	397-414.	Ide	K,	Eliasziw	M	&	Poulin	MJ	(2003).	Relationship	between	middle	cerebral	artery	blood	 velocity	 and	 end-tidal	 PCO2	 in	 the	 hypocapnic-hypercapnic	 range	 in	humans.	Journal	of	Applied	Physiology	95,	129-37.	Ignarro	 LJ,	 Buga	 GM,	 Wood	 KS,	 Byrns	 RE	 &	 Chaudhuri	 G	 (1987).	 Endothelium-derived	 relaxing	 factor	 produced	 and	 released	 from	artery	 and	 vein	 is	 nitric	oxide.	Proc	Natl	Acad	Sci	U	S	A	84,	9265-9.	Imray	CHE,	Myers	SD,	Pattinson	KTS,	Bradwell	AR,	Chan	CW,	Harris	S,	Collins	P	&	Wright	AD	(2005).	Effect	of	exercise	on	cerebral	perfusion	in	humans	at	high	altitude.	Journal	of	Applied	Physiology	99,	699-706.	Iwasaki	K-I,	Ogawa	Y,	Shibata	S	&	Aoki	K	(2007).	Acute	exposure	to	normobaric	mild	hypoxia	 alters	 dynamic	 relationships	 between	 blood	 pressure	 and	 cerebral	blood	flow	at	very	low	frequency.	J	Cereb	Blood	Flow	Metab	27,	776-84.	Jakovcevic	 D	 &	 Harder	 DR	 (2007).	 Role	 of	 astrocytes	 in	 matching	 blood	 flow	 to	neuronal	activity.	Current	topics	in	developmental	biology	79,	75-97.	Johansson	B,	Halldner	 L,	Dunwiddie	TV,	Masino	 SA,	 Poelchen	W,	Giménez-Llort	 L,	Escorihuela	RM,	Fernández-Teruel	A,	Wiesenfeld-Hallin	Z,	Xu	XJ,	Hårdemark	A,	Betsholtz	 C,	 Herlenius	 E	 &	 Fredholm	 BB	 (2001).	 Hyperalgesia,	 anxiety,	 and	decreased	hypoxic	neuroprotection	in	mice	lacking	the	adenosine	A1	receptor.	
Proc	Natl	Acad	Sci	U	S	A	98,	9407-12.	
	 	 	
	
122	
Jordan	J,	Shannon	JR,	Diedrich	A,	Black	B,	Costa	F,	Robertson	D	&	Biaggioni	I	(2000).	Interaction	of	carbon	dioxide	and	sympathetic	nervous	system	activity	 in	 the	regulation	of	cerebral	perfusion	in	humans.	Hypertension	36,	383-8.	Kamat	SR	&	Banerji	BC	(1972).	Study	of	cardiopulmonary	 function	on	exposure	to	high	altitude.	I.	Acute	acclimatization	to	an	altitude	of	3,5000	to	4,000	meters	in	 relation	 to	 altitude	 sickness	 and	 cardiopulmonary	 function.	Am	Rev	Respir	
Dis	106,	404-13.	Katayama	 K,	 Amann	 M,	 Pegelow	 DF,	 Jacques	 AJ	 &	 Dempsey	 JA	 (2007).	 Effect	 of	arterial	oxygenation	on	quadriceps	fatigability	during	isolated	muscle	exercise.	
American	 Journal	 of	 Physiology	 -	 Regulatory	 Integrative	 and	 Comparative	
Physiology	292,	R1279-R1286.	Katayama	K,	Sato	Y,	Morotome	Y,	Shima	N,	Ishida	K,	Mori	S	&	Miyamura	M	(2001).	Intermittent	hypoxia	increases	ventilation	and	Sa(O2)	during	hypoxic	exercise	and	hypoxic	chemosensitivity.	Journal	of	Applied	Physiology	90,	1431-40.	Katayama	K,	Shima	N,	Sato	Y,	Qiu	JC,	Ishida	K,	Mori	S	&	Miyamura	M	(2001).	Effect	of	intermittent	 hypoxia	 on	 cardiovascular	 adaptations	 and	 response	 to	progressive	hypoxia	 in	humans.	High	Altitude	Medicine	&amp;	Biology	2,	501-508.	Kawakami	 Y,	 Yoshikawa	 T,	 Shida	 A	 &	 Asanuma	 Y	 (1981).	 Relationship	 between	hypoxic	and	hypercapnic	ventilatory	responses	in	man.	The	Japanese	journal	of	
physiology	31,	357-68.	Kenney	WL	&	Johnson	JM	(1992).	Control	of	Skin	Blood-Flow	during	Exercise.	Med	
Sci	Sports	Exerc	24,	303-312.	Kety	 SS	 &	 Schmidt	 CF	 (1948).	 The	 nitrous	 oxide	 method	 for	 the	 quantitative	determination	 of	 cerebral	 blood	 flow	 in	man;	 theory,	 procedure	 and	 normal	values.	J	Clin	Invest	27,	476-83.	Khakh	 BS,	 Gittermann	 D,	 Cockayne	 DA	 &	 Jones	 A	 (2003).	 ATP	 modulation	 of	excitatory	synapses	onto	interneurons.	J	Neurosci	23,	7426-37.	
	 	 	
	
123	
Koehle	MS,	 Giles	 LV,	 Curtis	 AN,	Walsh	ML	&	White	MD	 (2009).	 Performance	 of	 a	compact	 end-tidal	 forcing	 system.	Respiratory	physiology	&amp;	neurobiology	
167,	155-61.	Kohl	 MM	&	 Paulsen	 O	 (2010).	 The	 roles	 of	 GABAB	 receptors	 in	 cortical	 network	activity.	Adv	Pharmacol	58,	205-29.	Kong	K,	Ukachoke	C,	Ashby	P	&	Chapman	KR	(1994).	Excitability	of	human	motor	cortex	 during	 hyperventilation	 and	 hypercapnia.	Can	J	Physiol	Pharmacol	72,	909-13.	Kontos	 HA,	 Levasseur	 JE,	 Richardson	 DW,	Mauck	 Jr	 HP	 &	 Patterson	 Jr	 JL	 (1967).	Comparative	 circulatory	 responses	 to	 systemic	 hypoxia	 in	 man	 and	 in	unanesthetized	dog.	Journal	of	Applied	Physiology	23,	381-386.	Korchounov	 A,	 Ilic	 TV,	 Schwinge	 T	 &	 Ziemann	 U	 (2005).	 Modification	 of	 motor	cortical	 excitability	 by	 an	 acetylcholinesterase	 inhibitor.	 Exp	Brain	Res	164,	399-405.	Kraaier	 V,	 Van	 Huffelen	 AC,	 Wieneke	 GH,	 Van	 der	 Worp	 HB	 &	 Bar	 PR	 (1992).	Quantitative	 EEG	 changes	 due	 to	 cerebral	 vasoconstriction.	 Indomethacin	versus	 hyperventilation-induced	 reduction	 in	 cerebral	 blood	 flow	 in	 normal	subjects.	Electroencephalography	and	clinical	neurophysiology	82,	208-12.	Kukumberg	 P,	 Benetin	 J	 &	 Kuchar	 M	 (1996).	 Changes	 of	 motor	 evoked	 potential	amplitudes	 following	 magnetic	 stimulation	 after	 hyperventilation.	
Electromyogr	Clin	Neurophysiol	36,	271-3.	Lampropoulou	SI	&	Nowicky	AV	(2014).	Perception	of	effort	changes	 following	an	isometric	fatiguing	exercise	of	elbow	flexors.	Motor	Control	18,	146-64.	Lee	J,	Taira	T,	Pihlaja	P,	Ransom	BR	&	Kaila	K	(1996).	Effects	of	CO2	on	excitatory	transmission	 apparently	 caused	 by	 changes	 in	 intracellular	 pH	 in	 the	 rat	hippocampal	slice.	Brain	Res	706,	210-6.	Liu	 JQ,	 Sham	 JSK,	 Shimoda	 LA,	 Kuppusamy	 P	 &	 Sylvester	 JT	 (2003).	 Hypoxic	constriction	and	reactive	oxygen	species	in	porcine	distal	pulmonary	arteries.	
	 	 	
	
124	
American	 Journal	 of	 Physiology	 -	 Lung	 Cellular	 and	Molecular	 Pysiology	285,	L322-33.	Lloyd	TC	 (1965).	Pulmonary	vasoconstriction	during	histotoxic	hypoxia.	 Journal	of	
Applied	Physiology	20,	488-90.	Lo	A,	Fuglevand	AJ	&	Secomb	TW	(2003).	Oxygen	delivery	to	skeletal	muscle	fibers:	effects	 of	 microvascular	 unit	 structure	 and	 control	 mechanisms.	 American	
Journal	of	Physiology	-	Heart	and	Circulatory	Physiology	285,	H955-63.	Lucas	SJE,	Tzeng	YC,	Galvin	SD,	Thomas	KN,	Ogoh	S	&	Ainslie	PN	(2010).	Influence	of	changes	 in	 blood	 pressure	 on	 cerebral	 perfusion	 and	 oxygenation.	
Hypertension	55,	698-705.	Lundby	C,	 Calbet	 JAL	&	Robach	P	 (2009).	 The	 response	of	 human	 skeletal	muscle	tissue	to	hypoxia.	Cell	Mol	Life	Sci	66,	3615-23.	Macefield	 G	 &	 Burke	 D	 (1991).	 Paraesthesiae	 and	 tetany	 induced	 by	 voluntary	hyperventilation.	Increased	excitability	of	human	cutaneous	and	motor	axons.	
Brain	114,	527-40.	Marticorena	 E,	 Ruiz	 L,	 Severino	 J,	 Galvez	 J	 &	 Peñaloza	 D	 (1969).	 Systemic	 blood	pressure	in	white	men	born	at	sea	level:	changes	after	long	residence	at	high	altitudes.	Am	J	Cardiol	23,	364-8.	Mathieu-Costello	O	(1989).	Muscle	capillary	tortuosity	in	high	altitude	mice	depends	on	sarcomere	length.	Respir	Physiol	76,	289-302.	Mauger	AR	&	Hopker	JG	(2013).	The	effect	of	acetaminophen	ingestion	on	cortico-spinal	excitability.	Can	J	Physiol	Pharmacol	91,	187-9.	Meeusen	 R	 &	 Roelands	 B	 (2010).	 Central	 fatigue	 and	 neurotransmitters,	 can	thermoregulation	be	manipulated?	Scand	J	Med	Sci	Sports	20	Suppl	3,	19-28.	Meeusen	 R,	 Watson	 P,	 Hasegawa	 H,	 Roelands	 B	 &	 Piacentini	 MF	 (2006).	 Central	fatigue	-	The	serotonin	hypothesis	and	beyond.	Sports	Medicine	36,	881-909.	
	 	 	
	
125	
Mercker	 H	 &	 Schneider	 M	 (1949).	 Über	 Capillarveränderungen	 des	 Gehirns	 bei	Höhenanpassung.	Pflügers	Archiv	European	Journal	of	Physiology	251,	49-55.	Merletti	R,	Knaflitz	M	&	De	Luca	CJ	(1990).	Myoelectric	manifestations	of	fatigue	in	voluntary	and	electrically	elicited	contractions.	J	Appl	Physiol	69,	1810-20.	Merton	PA	(1954).	Voluntary	strength	and	fatigue.	J	Physiol	123,	553-64.	Millet	GY,	Aubert	D,	Favier	FB,	Busso	T	&	Benoit	H	(2009).	Effect	of	acute	hypoxia	on	central	 fatigue	 during	 repeated	 isometric	 leg	 contractions.	 Scandinavian	
Journal	of	Medicine	&amp;	Science	in	Sports	19,	695-702.	Millet	 GY,	Muthalib	M,	 Jubeau	M,	 Laursen	 PB	&	Nosaka	 K	 (2012).	 Severe	 hypoxia	affects	 exercise	 performance	 independently	 of	 afferent	 feedback	 and	peripheral	fatigue.	Journal	of	Applied	Physiology	112,	1335-44.	Miscio	 G,	 Milano	 E,	 Aguilar	 J,	 Savia	 G,	 Foffani	 G,	 Mauro	 A,	 Mordillo-Mateos	 L,	Romero-Ganuza	 J	 &	 Oliviero	 A	 (2009).	 Functional	 involvement	 of	 central	nervous	system	at	high	altitude.	Exp	Brain	Res	194,	157-62.	Mogyoros	I,	Kiernan	MC,	Burke	D	&	Bostock	H	(1997).	Excitability	changes	in	human	sensory	 and	motor	 axons	 during	 hyperventilation	 and	 ischaemia.	Brain	120,	317-25.	Morrison	 S,	 Sleivert	 GG	 &	 Cheung	 SS	 (2004).	 Passive	 hyperthermia	 reduces	voluntary	 activation	 and	 isometric	 force	 production.	 European	 Journal	 of	
Applied	Physiology	91,	729-736.	Morrison	 SA,	 Sleivert	 GG,	 Neary	 JP	 &	 Cheung	 SS	 (2009).	 Prefrontal	 cortex	oxygenation	is	preserved	and	does	not	contribute	to	impaired	neuromuscular	activation	during	passive	hyperthermia.	Appl	Physiol	Nutr	Metab	34,	66-74.	Morrow	JA,	Fell	RD	&	Gladden	LB	(1988).	Respiratory	alkalosis:	no	effect	on	blood	lactate	 decline	 or	 exercise	 performance.	 Eur	 J	Appl	Physiol	Occup	Physiol	58,	175-81.	Moss,	R.	F.,	Raven,	P.	B.,	Knochel,	 J.	P.,	Peckham,	 J.	R.,	&	Blachley,	 J.	D.	 (1983).	The	effect	of	training	on	resting	muscle	membrane	potentials.	In	K.	HG,	V.	JA,	&	P.	J	
	 	 	
	
126	
(Eds.),	 Biochemistry	 of	 exercise	 (pp.	 806-11).	 Champaign,	 Illinois:	 Human	Kinetics.	Motley	 HL,	 Werko	 L	 &	 Cournard	 A	 (1947).	 Influence	 of	 intermittent	 positive	pressure	breathing	on	cardiac	output.	Federation	Proceedings	6,	167.	Naeije	 R	 (2010).	 Physiological	 adaptation	 of	 the	 cardiovascular	 system	 to	 high	altitude.	Prog	Cardiovasc	Dis	52,	456-66.	Nelson	MD,	Haykowsky	MJ,	Stickland	MK,	Altamirano-Diaz	LA,	Willie	CK,	Smith	KJ,	Petersen	 SR	 &	 Ainslie	 PN	 (2011).	 Reductions	 in	 cerebral	 blood	 flow	 during	passive	 heat	 stress	 in	 humans:	 partitioning	 the	 mechanisms.	 Journal	 of	
Physiology	16,	10.1113/jphysiol.2011.212118.	Neubauer	 JA,	 Strumpf	 DA	 &	 Edelman	 NH	 (1983).	 Regional	 medullary	 blood	 flow	during	 isocapnic	hyperpnea	 in	anesthetized	cats.	 J	Appl	Physiol	Respir	Environ	
Exerc	Physiol	55,	447-52.	Nielsen	B,	Hales	JRS,	Strange	S,	Christensen	NJ,	Warberg	J	&	Saltin	B	(1993).	Human	Circulatory	 and	 Thermoregulatory	 Adaptations	 with	 Heat	 Acclimation	 and	Exercise	 in	 a	 Hot,	 Dry	 Environment.	 Journal	of	Physiology-London	460,	467-485.	Nishimura	N,	Iwasaki	K-I,	Ogawa	Y	&	Aoki	K	(2010).	Decreased	steady-state	cerebral	blood	 flow	 velocity	 and	 altered	 dynamic	 cerebral	 autoregulation	 during	 5-h	sustained	15%	O2	hypoxia.	J	Appl	Physiol	(1985)	108,	1154-61.	Nordander	C,	Willner	 J,	Hansson	G-A,	Larsson	B,	Unge	 J,	Granquist	L	&	Skerfving	S	(2003).	 Influence	 of	 the	 subcutaneous	 fat	 layer,	 as	measured	 by	 ultrasound,	skinfold	calipers	and	BMI,	on	the	EMG	amplitude.	European	journal	of	applied	
physiology	89,	514-9.	Nuttall	GA,	Cook	DJ,	 Fulgham	 JR,	Oliver	WCJ	&	Proper	 JA	 (1996).	The	 relationship	between	 cerebral	 blood	 flow	 and	 transcranial	 Doppler	 blood	 flow	 velocity	during	hypothermic	cardiopulmonary	bypass	in	adults.	Anesth	Analg	82,	1146-51.	
	 	 	
	
127	
Nybo	L	(2008).	Hyperthermia	and	fatigue.	Journal	of	Applied	Physiology	104,	871-8.	Nybo	 L	 &	 Nielsen	 B	 (2001).	 Hyperthermia	 and	 central	 fatigue	 during	 prolonged	exercise	in	humans.	Journal	of	Applied	Physiology	91,	1055-60.	Nybo	L	&	Nielsen	B	 (2001).	Middle	 cerebral	 artery	blood	velocity	 is	 reduced	with	hyperthermia	during	prolonged	exercise	in	humans.	Journal	of	Physiology	534,	279-286.	Nybo	 L	 &	 Rasmussen	 P	 (2007).	 Inadequate	 cerebral	 oxygen	 delivery	 and	 central	fatigue	during	strenuous	exercise.	Exercise	and	Sport	Sciences	Reviews	35,	110-118.	Nybo	 L,	 Jensen	 T,	 Nielsen	 B	 &	 Gonzalez-Alonso	 J	 (2001).	 Effects	 of	 marked	hyperthermia	with	and	without	dehydration	on	Vo(2)	kinetics	during	intense	exercise.	Journal	of	Applied	Physiology	90,	1057-1064.	Ogoh	 S	 &	 Ainslie	 PN	 (2009).	 Cerebral	 blood	 flow	 during	 exercise:	mechanisms	 of	regulation.	Journal	of	Applied	Physiology	107,	1370-80.	Ogoh	S	&	Ainslie	PN	(2009).	Regulatory	mechanisms	of	cerebral	blood	flow	during	exercise:	new	concepts.	Exercise	and	Sport	Sciences	Reviews	37,	123-9.	Ogoh	S,	Brothers	RM,	Barnes	Q,	 Eubank	WL,	Hawkins	MN,	Purkayastha	 S,	A	OY	&	Raven	PB	(2005).	The	effect	of	changes	 in	cardiac	output	on	middle	cerebral	artery	mean	blood	velocity	at	rest	and	during	exercise.	J	Physiol	569,	697-704.	Östrand	PO	(2003).	Textbook	of	Work	Physiology:	Physiological	Bases	of	Exercise.	Human	Kinetics,		Pankratov	 Y,	 Castro	 E,	 Miras-Portugal	 MT	 &	 Krishtal	 O	 (1998).	 A	 purinergic	component	of	the	excitatory	postsynaptic	current	mediated	by	P2X	receptors	in	the	CA1	neurons	of	the	rat	hippocampus.	Eur	J	Neurosci	10,	3898-902.	Parfenova	H,	Zuckerman	S	&	Leffler	CW	(1995).	Inhibitory	effect	of	indomethacin	on	prostacyclin	receptor-mediated	cerebral	vascular	responses.	American	Journal	
of	Physiology	268,	H1884-90.	
	 	 	
	
128	
Peebles	 KC,	 Richards	 AM,	 Celi	 L,	 McGrattan	 K,	 Murrell	 CJ	 &	 Ainslie	 PN	 (2008).	Human	 cerebral	 arteriovenous	 vasoactive	 exchange	 during	 alterations	 in	arterial	blood	gases.	Journal	of	Applied	Physiology	105,	1060-8.	Peltonen	 JE,	Kowalchuk	 JM,	Paterson	DH,	DeLorey	DS,	Dumanoir	GR,	Petrella	RJ	&	Shoemaker	 JK	 (2007).	 Cerebral	 and	 muscle	 tissue	 oxygenation	 in	 acute	hypoxic	ventilatory	 response	 test.	Respiratory	Physiology	&amp;	Neurobiology	
155,	71-81.	Peltonen	JE,	Rantamaki	J,	Niittymaki	SPT,	Sweins	K,	Viitasalo	JT	&	Rusko	HK	(1995).	Effects	 of	 Oxygen	 Fraction	 in	 Inspired	 Air	 on	 Rowing	 Performance.	Med	Sci	
Sports	Exerc	27,	573-579.	Peltonen	 JE,	Rusko	HK,	Rantamaki	 J,	 Sweins	K,	Niittymaki	 S	&	Viitasalo	 JT	 (1997).	Effects	 of	 oxygen	 fraction	 in	 inspired	 air	 on	 force	 production	 and	electromyogram	 activity	 during	 ergometer	 rowing.	 European	 Journal	 of	
Applied	Physiology	and	Occupational	Physiology	76,	495-503.	Peñaloza	 D	 &	 Sime	 F	 (1971).	 Chronic	 cor	 pulmonale	 due	 to	 loss	 of	 altitude	acclimatization	(chronic	mountain	sickness).	Am	J	Med	50,	728-43.	Peters	EJ	&	Fuglevand	AJ	(1999).	Cessation	of	human	motor	unit	discharge	during	sustained	maximal	voluntary	contraction.	Neurosci	Lett	274,	66-70.	Powell	 FL,	 Milsom	 WK	 &	 Mitchell	 GS	 (1998).	 Time	 domains	 of	 the	 hypoxic	ventilatory	response.	Respiration	Physiology	112,	123-34.	Priori	 A,	 Berardelli	 A,	Mercuri	 B,	 Inghilleri	M	&	Manfredi	M	 (1995).	 The	 effect	 of	hyperventilation	 on	 motor	 cortical	 inhibition	 in	 humans:	 a	 study	 of	 the	electromyographic	 silent	 period	 evoked	 by	 transcranial	 brain	 stimulation.	
Electroencephalogr	Clin	Neurophysiol	97,	69-72.	Pugh	LG,	Gill	MB,	Lahiri	S,	Milledge	JS,	Ward	MP	&	West	JB	(1964).	Muscular	exercise	at	great	altitudes.	Journal	of	Applied	Physiology	19,	431-40.	Racinais	S	&	Oksa	J	(2010).	Temperature	and	neuromuscular	function.	Scand	J	Med	
Sci	Sports	20	Suppl	3,	1-18.	
	 	 	
	
129	
Racinais	 S,	 Gaoua	 N	 &	 Grantham	 J	 (2008).	 Hyperthermia	 impairs	 short-term	memory	and	peripheral	motor	drive	transmission.	J	Physiol	586,	4751-62.	Ramanathan	NL	(1964).	A	new	weighting	system	for	mean	surface	temperature	of	the	human	body.	Journal	of	Applied	Physiology	19,	531-3.	Rasmussen	P,	Dawson	EA,	Nybo	L,	 van	Lieshout	 JJ,	 Secher	NH	&	Gjedde	A	 (2007).	Capillary-oxygenation-level-dependent	 near-infrared	 spectrometry	 in	 frontal	lobe	of	humans.	J	Cereb	Blood	Flow	Metab	27,	1082-93.	Rasmussen	 P,	 Nielsen	 J,	 Overgaard	 M,	 Krogh-Madsen	 R,	 Gjedde	 A,	 Secher	 NH	 &	Petersen	 NC	 (2010).	 Reduced	 muscle	 activation	 during	 exercise	 related	 to	brain	oxygenation	and	metabolism	in	humans.	J	Physiol	588,	1985-95.	Rasmussen	P,	Nybo	L,	Volianitis	S,	Møller	K,	Secher	NH	&	Gjedde	A	(2010).	Cerebral	oxygenation	is	reduced	during	hyperthermic	exercise	in	humans.	Acta	Physiol	
(Oxf)	199,	63-70.	Ray	CA	&	Gracey	KH	(1997).	Augmentation	of	exercise-induced	muscle	sympathetic	nerve	activity	during	muscle	heating.	J	Appl	Physiol	(1985)	82,	1719-25.	Reeves	JT,	Groves	BM,	Sutton	JR,	Wagner	PD,	Cymerman	A,	Malconian	MK,	Rock	PB,	Young	PM	&	Houston	CS	(1987).	Operation	Everest	II:	preservation	of	cardiac	function	at	extreme	altitude.	Journal	of	Applied	Physiology	63,	531-9.	Reynafarje	B	 (1962).	Myoglobin	 content	 and	 enzymatic	 activity	 of	 human	 skeletal	muscle--their	 relation	 with	 the	 process	 of	 adaptation	 to	 high	 altitude.	
Technical	 documentary	 report.	 SAM-TDR.	 USAF	 School	 of	 Aerospace	 Medicine	
SAM-TDR-62-89,	8p.	Richalet	JP	(1990).	Hypoxia:	The	Adaptations.	B.C.	Decker,		Robbins	PA	(1995).	Hypoxic	ventilatory	decline:	site	of	action.	J	Appl	Physiol	(1985)	
79,	373-4.	Romanowski	 W	 &	 Grabiec	 S	 (1974).	 The	 role	 of	 serotonin	 in	 the	 mechanism	 of	central	fatigue.	Acta	Physiol	Pol	25,	127-34.	
	 	 	
	
130	
Romer	 LM,	 Haverkamp	 HC,	 Amann	 M,	 Lovering	 AT,	 Pegelow	 DF	 &	 Dempsey	 JA	(2007).	 Effect	 of	 acute	 severe	 hypoxia	 on	 peripheral	 fatigue	 and	 endurance	capacity	 in	 healthy	 humans.	 American	 Journal	 of	 Physiology	 -	 Regulatory	
Integrative	and	Comparative	Physiology	292,	R598-606.	Ross	EZ,	Cotter	JD,	Wilson	L,	Fan	J-L,	Lucas	SJE	&	Ainslie	PN	(2012).	Cerebrovascular	and	 corticomotor	 function	 during	 progressive	 passive	 hyperthermia	 in	humans.	J	Appl	Physiol	(1985)	112,	748-58.	Rowell	LB,	Brengelm,	GL	&	Murray	JA	(1969).	Cardiovascular	response	to	sustained	high	skin	temperature	in	resting	man.	Journal	of	Applied	Physiology	5,	1969.	Rowell	 LB,	 Detry	 JR,	 Profant	 GR	&	Wyss	 C	 (1971).	 Splanchnic	 vasoconstriction	 in	hyperthermic	man--role	of	falling	blood	pressure.	Journal	of	Applied	Physiology	
31,	864-9.	Rubanyi	 GM,	 Romero	 JC	 &	 Vanhoutte	 PM	 (1986).	 Flow-induced	 release	 of	endothelium-derived	relaxing	factor.	Am	J	Physiol	250,	H1145-9.	De	 Ruiter	 CJ	 &	 De	 Haan	 A	 (2000).	 Temperature	 effect	 on	 the	 force/velocity	relationship	of	the	fresh	and	fatigued	human	adductor	pollicis	muscle.	Pflugers	
Arch	440,	163-70.	Rupp	T,	 Jubeau	M,	Wuyam	B,	Perrey	S,	Levy	P,	Millet	GY	&	Verges	S	(2012).	Time-dependent	 effect	 of	 acute	 hypoxia	 on	 corticospinal	 excitability	 in	 healthy	humans.	Journal	of	Neurophysiology	108,	1270-7.	Saito	M,	Mano	T,	Iwase	S,	Koga	K,	Abe	H	&	Yamazaki	Y	(1988).	Responses	in	muscle	sympathetic	activity	to	acute	hypoxia	in	humans.	Journal	of	Applied	Physiology	
65,	1548-52.	Schiff	 SJ	 &	 Somjen	 GG	 (1985).	 Hyperexcitability	 following	 moderate	 hypoxia	 in	hippocampal	tissue	slices.	Brain	Res	337,	337-40.	Schoene	RB	(1982).	Control	of	ventilation	in	climbers	to	extreme	altitude.	Journal	of	
applied	physiology:	respiratory,	environmental	and	exercise	physiology	53,	886-90.	
	 	 	
	
131	
Secher	NH,	Seifert	T	&	Van	Lieshout	JJ	(2008).	Cerebral	blood	flow	and	metabolism	during	 exercise:	 implications	 for	 fatigue.	 Journal	 of	 Applied	 Physiology	104,	306-314.	Semenza	JC,	Rubin	CH,	Falter	KH,	Selanikio	JD,	Flanders	WD,	Howe	HL	&	Wilhelm	JL	(1996).	 Heat-related	 deaths	 during	 the	 July	 1995	 heat	wave	 in	 Chicago.	The	
New	England	journal	of	medicine	335,	84-90.	Serrador	JM,	Picot	PA,	Rutt	BK,	Shoemaker	JK	&	Bondar	RL	(2000).	MRI	measures	of	middle	 cerebral	 artery	 diameter	 in	 conscious	 humans	 during	 simulated	orthostasis.	Stroke;	a	journal	of	cerebral	circulation	31,	1672-8.	Severinghaus	 JW	 (1979).	 Simple,	 accurate	 equations	 for	 human	 blood	 O2	dissociation	computations.	 J	Appl	Physiol	Respir	Environ	Exerc	Physiol	46,	599-602.	Seyal	M,	Mull	B	&	Gage	B	(1998).	Increased	excitability	of	the	human	corticospinal	system	with	hyperventilation.	Electroencephalogr	Clin	Neurophysiol	109,	263-7.	Somjen	GG,	Allen	BW,	Balestrino	M	&	Aitken	PG	(1987).	Pathophysiology	of	pH	and	Ca2+	in	bloodstream	and	brain.	Can	J	Physiol	Pharmacol	65,	1078-85.	Sparing	R,	Dafotakis	M,	Buelte	D,	Meister	IG	&	Noth	J	(2007).	Excitability	of	human	motor	 and	 visual	 cortex	 before,	 during,	 and	 after	 hyperventilation.	 J	 Appl	
Physiol	102,	406-11.	Spriet	LL,	Lindinger	MI,	Heigenhauser	GJ	&	Jones	NL	(1986).	Effects	of	alkalosis	on	skeletal	 muscle	 metabolism	 and	 performance	 during	 exercise.	 Am	 J	 Physiol	
251,	R833-9.	Staessen	J,	Cattaert	A,	Fagard	R,	Lijnen	P,	Moerman	E,	De	Schaepdryver	A	&	Amery	A	(1984).	 Hemodynamic	 and	 humoral	 effects	 of	 prostaglandin	 inhibition	 in	exercising	humans.	Journal	of	Applied	Physiology	56,	39-45.	
	 	 	
	
132	
Steinback	CD	&	Poulin	MJ	(2008).	Cardiovascular	and	cerebrovascular	responses	to	acute	 isocapnic	 and	 poikilocapnic	 hypoxia	 in	 humans.	 Journal	 of	 Applied	
Physiology	104,	482-9.	Strandgaard	 S	 &	 Sigurdsson	 ST	 (2008).	 Point:Counterpoint:	 Sympathetic	 activity	does/does	not	influence	cerebral	blood	flow.	Counterpoint:	Sympathetic	nerve	activity	 does	 not	 influence	 cerebral	 blood	 flow.	 Journal	of	Applied	Physiology	
105,	1366-7;	discussion	1367-8.	Subudhi	AW,	Lorenz	MC,	Fulco	CS	&	Roach	RC	(2008).	Cerebrovascular	responses	to	incremental	 exercise	 during	 hypobaric	 hypoxia:	 effect	 of	 oxygenation	 on	maximal	 performance.	American	Journal	of	Physiology	-	Heart	and	Circulatory	
Physiology	294,	H164-71.	Subudhi	AW,	Olin	 JT,	Dimmen	AC,	Polaner	DM,	Kayser	B	&	Roach	RC	(2011).	Does	cerebral	 oxygen	 delivery	 limit	 incremental	 exercise	 performance?	 J	 Appl	
Physiol	(1985)	111,	1727-34.	Syková	E	(1983).	Extracellular	K+	accumulation	in	the	central	nervous	system.	Prog	
Biophys	Mol	Biol	42,	135-89.	Szubski	C,	Burtscher	M	&	Löscher	WN	(2006).	The	effects	of	short-term	hypoxia	on	motor	 cortex	 excitability	 and	 neuromuscular	 activation.	 Journal	 of	 Applied	
Physiology	101,	1673-7.	Szubski	 C,	 Burtscher	 M	 &	 Löscher	 WN	 (2007).	 Neuromuscular	 fatigue	 during	sustained	contractions	performed	in	short-term	hypoxia.	Med	Sci	Sports	Exerc	
39,	948-54.	Taylor	 JL	 &	 Gandevia	 SC	 (2001).	 Transcranial	 magnetic	 stimulation	 and	 human	muscle	fatigue.	Muscle	Nerve	24,	18-29.	Taylor	JL,	Todd	G	&	Gandevia	SC	(2006).	Evidence	for	a	supraspinal	contribution	to	human	muscle	fatigue.	Clinical	and	Experimental	Pharmacology	and	Physiology	
33,	400-405.	
	 	 	
	
133	
Tenney	SM	&	Ou	LC	(1970).	Physiological	evidence	for	increased	tissue	capillarity	in	rats	acclimatized	to	high	altitude.	Respiration	physiology	8,	137-50.	Teppema	LJ	&	Dahan	A	 (2010).	The	ventilatory	 response	 to	hypoxia	 in	mammals:	mechanisms,	measurement,	and	analysis.	Physiological	Reviews	90,	675-754.	ter	 Minassian	 A,	 Melon	 E,	 Leguerinel	 C,	 Lodi	 CA,	 Bonnet	 F	 &	 Beydon	 L	 (1998).	Changes	 in	 cerebral	 blood	 flow	 during	 PaCO2	 variations	 in	 patients	 with	severe	 closed	 head	 injury:	 comparison	 between	 the	 Fick	 and	 transcranial	Doppler	methods.	Journal	of	neurosurgery	88,	996-1001.	Thomas	MM,	Cheung	SS,	Elder	GC	&	Sleivert	GG	(2006).	Voluntary	muscle	activation	is	impaired	by	core	temperature	rather	than	local	muscle	temperature.	Journal	
of	Applied	Physiology	100,	1361-1369.	Thomson	AJ,	Drummond	GB,	Waring	WS,	Webb	DJ	&	Maxwell	SRJ	(2006).	Effects	of	short-term	 isocapnic	 hyperoxia	 and	 hypoxia	 on	 cardiovascular	 function.	
Journal	of	Applied	Physiology	101,	809-16.	Todd	G,	Butler	 JE,	Taylor	 JL	&	Gandevia	 SC	 (2005).	Hyperthermia:	 a	 failure	of	 the	motor	cortex	and	the	muscle.	J	Physiol	563,	621-31.	Todd	 G,	 Taylor	 JL	 &	 Gandevia	 SC	 (2003).	Measurement	 of	 voluntary	 activation	 of	fresh	 and	 fatigued	human	muscles	using	 transcranial	magnetic	 stimulation.	 J	
Physiol	551,	661-71.	Todd	G,	Taylor	 JL	&	Gandevia	 SC	 (2004).	Reproducible	measurement	of	 voluntary	activation	 of	 human	 elbow	 flexors	 with	 motor	 cortical	 stimulation.	 J	 Appl	
Physiol	(1985)	97,	236-42.	Todnem	 K,	 Knudsen	 G,	 Riise	 T,	 Nyland	 H	 &	 Aarli	 JA	 (1989).	 The	 non-linear	relationship	between	nerve	conduction	velocity	and	skin	temperature.	Journal	
of	neurology,	neurosurgery,	and	psychiatry	52,	497-501.	Trivedi	 NS,	 Ghouri	 AF,	 Lai	 E,	 Shah	 NK	 &	 Barker	 SJ	 (1997).	 Pulse	 oximeter	performance	 during	 desaturation	 and	 resaturation:	 a	 comparison	 of	 seven	models.	J	Clin	Anesth	9,	184-8.	
	 	 	
	
134	
Tucker	R,	Kayser	B,	Rae	E,	Rauch	L,	Bosch	A	&	Noakes	T	(2007).	Hyperoxia	improves	20	 km	 cycling	 time	 trial	 performance	 by	 increasing	muscle	 activation	 levels	while	 perceived	 exertion	 stays	 the	 same.	 European	 Journal	 of	 Applied	
Physiology	101,	771-781.	Tucker	R,	Marle	T,	Lambert	EV	&	Noakes	T	(2006).	The	rate	of	heat	storage	mediates	an	anticipatory	reduction	in	exercise	intensity	during	cycling	at	a	fixed	rating	of	perceived	exertion.	Journal	of	Physiology	574,	905-915.	Tucker	R,	Rauch	L,	Harley	YXR	&	Noakes	TD	(2004).	Impaired	exercise	performance	in	 the	 heat	 is	 associated	 with	 an	 anticipatory	 reduction	 in	 skeletal	 muscle	recruitment.	Pflugers	Archiv-European	Journal	of	Physiology	448,	422-430.	Valdueza	 JM,	 Balzer	 JO,	 Villringer	 A,	 Vogl	 TJ,	 Kutter	 R	 &	 Einhäupl	 KM	 (1997).	Changes	 in	 blood	 flow	 velocity	 and	 diameter	 of	 the	 middle	 cerebral	 artery	during	 hyperventilation:	 assessment	 with	 MR	 and	 transcranial	 Doppler	sonography.	AJNR	Am	J	Neuroradiol	18,	1929-34.	Valdueza	JM,	Schmierer	K,	Mehraein	S	&	Einhaupl	KM	(1996).	Assessment	of	normal	flow	velocity	in	basal	cerebral	veins.	A	transcranial	doppler	ultrasound	study.	
Stroke;	a	journal	of	cerebral	circulation	27,	1221-5.	Verges	S,	Rupp	T,	Jubeau	M,	Wuyam	B,	Esteve	F,	Levy	P,	Perrey	S	&	Millet	GY	(2012).	Invited	Review:	Cerebral	Perturbations	During	Exercise	in	Hypoxia.	American	
Journal	 of	 Physiology	 -	 Regulatory	 Integrative	 and	 Comparative	 Physiology	10.1152/ajpregu.00555.2011	Vogel	 JA	 &	 Harris	 CW	 (1967).	 Cardiopulmonary	 responses	 of	 resting	man	 during	early	exposure	to	high	altitude.	Journal	of	Applied	Physiology	22,	1124-8.	Vogel	 JA,	 Hartley	 LH	&	 Cruz	 JC	 (1974).	 Cardiac	 output	 during	 exercise	 in	 altitude	natives	at	sea	level	and	high	altitude.	Journal	of	Applied	Physiology	36,	173-6.	Wagner	PD	(2010).	The	physiological	basis	of	reduced	VO2max	in	Operation	Everest	II.	High	Alt	Med	Biol	11,	209-15.	
	 	 	
	
135	
Watson	P,	Hasegawa	H,	Roelands	B,	Piacentini	MF,	Looverie	R	&	Meeusen	R	(2005).	Acute	dopamine/noradrenaline	reuptake	inhibition	enhances	human	exercise	performance	 in	 warm,	 but	 not	 temperate	 conditions.	 Journal	 of	 Applied	
Physiology	565,	873-83.	Wehrlin	 JP	 &	 Hallen	 J	 (2006).	 Linear	 decrease	 in	 VO2max	 and	 performance	with	increasing	 altitude	 in	 endurance	 athletes.	 European	 journal	 of	 applied	
physiology	96,	404-412.	Weibel	 ER	 (1984).	 The	 Pathway	 for	 Oxygen:	 Structure	 and	 Function	 in	 the	Mammalian	Respiratory	System.	Harvard	University	Press,		Welsh	 DG,	 Jackson	 WF	 &	 Segal	 SS	 (1998).	 Oxygen	 induces	 electromechanical	coupling	 in	 arteriolar	 smooth	muscle	 cells:	 a	 role	 for	 L-type	 Ca2+	 channels.	
American	Journal	of	Physiology	274,	H2018-24.	Wennmalm	A,	Carlsson	I,	Edlund	A,	Eriksson	S,	Kaijser	L	&	Nowak	J	(1984).	Central	and	 peripheral	 haemodynamic	 effects	 of	 non-steroidal	 anti-inflammatory	drugs	 in	 man.	 Archives	 of	 toxicology.	 Supplement.	 =	 Archiv	 fur	 Toxikologie.	
Supplement	7,	350-9.	Westerblad	 H,	 Allen	 DG	 &	 Lännergren	 J	 (2002).	 Muscle	 fatigue:	 lactic	 acid	 or	inorganic	phosphate	the	major	cause?	News	Physiol	Sci	17,	17-21.	WEST	 JB	 (1962).	 Regional	 differences	 in	 gas	 exchange	 in	 the	 lung	 of	 erect	 man.	
Journal	of	Applied	Physiology	17,	893-8.	White	 RP,	 Vallance	 P	 &	 Markus	 HS	 (2000).	 Effect	 of	 inhibition	 of	 nitric	 oxide	synthase	 on	 dynamic	 cerebral	 autoregulation	 in	 humans.	 Clin	Sci	 (Lond)	99,	555-60.	Wilkinson	KA,	Huey	K,	Dinger	B,	He	L,	Fidone	S	&	Powell	FL	(2010).	Chronic	hypoxia	increases	the	gain	of	the	hypoxic	ventilatory	response	by	a	mechanism	in	the	central	nervous	system.	J	Appl	Physiol	(1985)	109,	424-30.	Willie	 CK,	 Colino	 FL,	 Bailey	 DM,	 Tzeng	 YC,	 Binsted	 G,	 Jones	 LW,	 Haykowsky	 MJ,	Bellapart	J,	Ogoh	S,	Smith	KJ,	Smirl	JD,	Day	TA,	Lucas	SJ,	Eller	LK	&	Ainslie	PN	
	 	 	
	
136	
(2011).	 Utility	 of	 transcranial	 Doppler	 ultrasound	 for	 the	 integrative	assessment	of	cerebrovascular	 function.	 Journal	of	Neuroscience	Methods	196,	221-37.	Willie	CK,	Cowan	EC,	Ainslie	PN,	Taylor	CE,	Smith	KJ,	Sin	PYW	&	Tzeng	YC	(2011).	Neurovascular	 coupling	 and	 distribution	 of	 cerebral	 blood	 flow	 during	exercise.	Journal	of	Neuroscience	Methods	198,	270-3.	Willie	CK,	Macleod	DB,	Shaw	AD,	Smith	KJ,	Tzeng	YC,	Eves	ND,	 Ikeda	K,	Graham	 J,	Lewis	 NC,	 Day	 TA	 &	 Ainslie	 PN	 (2012).	 Regional	 Brain	 Blood	 Flow	 in	 Man	during	 Acute	 Changes	 in	 Arterial	 Blood	 Gases.	 J	 Physiol	10.1113/jphysiol.2012.228551	Wilson	MH,	Newman	 S	&	 Imray	 CH	 (2009).	 The	 cerebral	 effects	 of	 ascent	 to	 high	altitudes.	Lancet	Neurol	8,	175-91.	Wolfel	 EE,	 Selland	MA,	Mazzeo	 RS	 &	 Reeves	 JT	 (1994).	 Systemic	 hypertension	 at	4,300	m	 is	 related	 to	 sympathoadrenal	 activity.	 Journal	of	Applied	Physiology	
76,	1643-50.	Wollman	H,	Smith	TC,	Stephen	GW,	Colton	ET,	Gleaton	HE	&	Alexander	SC	(1968).	Effects	 of	 extremes	 of	 respiratory	 and	metabolic	 alkalosis	 on	 cerebral	 blood	flow	in	man.	J	Appl	Physiol	24,	60-5.	Wyndham	CH,	Rogers	GG,	Benade	AJ	&	Strydom	NB	(1971).	Physiological	effects	of	the	 amphetamines	 during	 exercise.	 South	 African	 medical	 journal	 =	 Suid-
Afrikaanse	tydskrif	vir	geneeskunde	45,	247-52.	Xie	A,	Skatrud	JB,	Puleo	DS	&	Morgan	BJ	(2001).	Exposure	to	hypoxia	produces	long-lasting	 sympathetic	 activation	 in	 humans.	 Journal	 of	 Applied	 Physiology	 91,	1555-62.	Xie	AL,	Skatrud	JB,	Morgan	B,	Chenuel	B,	Khayat	R,	Reichmuth	K,	Lin	J	&	Dempsey	JA	(2006).	 Influence	of	 cerebrovascular	 function	on	 the	hypercapnic	ventilatory	response	 in	 healthy	 humans.	 Journal	 of	 Physiology	 -	 London	 1,	10.1113/jphysiol.2006.110627.	
	 	 	
	
137	
Yoshimoto	S,	Ishizaki	Y,	Kurihara	H,	Sasaki	T,	Yoshizumi	M,	Yanagisawa	M,	Yazaki	Y,	Masaki	T,	Takakura	K	&	Murota	S	(1990).	Cerebral	microvessel	endothelium	is	producing	endothelin.	Brain	Res	508,	283-5.		 	
	 	 	
	
138	
7 APPENDIX	A:	ELECTROMYOGRAPHY		
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Although	 the	 implementation	 of	 electromyography	 (EMG)	 is	 fairly	straightforward	and	provides	easy	access	to	physiological	data,	the	interpretation	of	EMG	 is	very	 complex	and	 is	 influenced	by	many	physiological	 and	methodological	factors.	 In	 addition	 to	 the	 basic	 understanding	 of	 the	 physiological	 origin	 of	myoelectric	 signals	 and	 related	 signal	 processing	 techniques,	 practitioners	 must	understand	 the	 influence	 of	 extrinsic	 (such	 as	 electrode	 configuration	 and	placement)	and	intrinsic	factors	(namely	the	physiological	consequences	of	different	testing	protocols)	on	the	resultant	EMG	signal.	
7.1 	Physiological	origin	of	the	EMG	signal	The	functional	unit	of	the	neuromuscular	system	is	the	motor	unit,	consisting	of	 the	 cell	 body	 and	 dendrites	 of	 the	 neuron,	 the	 axon	 and	 the	 muscle	 fibres	 it	innervates.	When	the	∝-motor	neuron	is	fired,	an	action	potential	propagates	along	the	sarcolemma	membrane	of	the	muscle	tissue,	resulting	in	muscular	contraction.	The	 ability	 of	 the	 sarcolemma	 to	 propagate	 action	 potentials	 is	 achieved	 by	 the	semipermeable	 nature	 of	 the	 membrane	 and	 the	 maintenance	 of	 a	 resting	membrane	 potential.	 Sodium	 (Na+)	 and	 chloride	 (Cl-)	 ions	 remain	 in	 high	concentrations	 in	 the	 extracellular	matrix,	whereas	 potassium	 ions	 (K+)	 is	 in	 high	concentration	 in	 the	 intracellular	 environment,	 resulting	 in	 a	 net	 membrane	potential	of	-80	to	-90	mV.	The	resting	membrane	potential	is	influenced	by	several	factors	such	as	exercise	 (Moss	et	al.	1983),	and	muscle	 fibre	 type	and	size	 (Ruff	&	Whittlesey	1993).	When	an	action	potential	is	generated	by	activation	of	the	motor	unit	(either	by	the	CNS	or	a	reflex	from	the	spinal	cord),	acetylcholine	release	from	the	synapse	
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causes	an	end-plate	potential	that	originates	from	the	neuromuscular	junction.	The	resultant	 voltage	 change	 causes	 a	 modification	 in	 the	 permeability	 of	 the	sarcolemma	 membrane,	 causing	 a	 large	 influx	 of	 Na+	 and	 small	 efflux	 of	 K+	 and	therefore,	net	decrease	in	membrane	potential	(i.e.,	closer	to	zero).	If	the	change	in	membrane	potential	surpasses	the	activation	threshold,	an	action	potential	will	be	initiated,	resulting	in	the	rapid	depolarization	of	the	membrane	from	approximately	-80	mV	 to	 +30	mV.	 Following	 the	 depolarization	 phase,	membrane	 repolarization	occurs,	 followed	 by	 a	 hyperpolarization	 phase.	 Action	 potentials	 propagate	 bi-directionally	from	the	motor	end	plate	origin.	The	 EMG	 apparatus	 records	 the	 electrical	 potential	 created	 by	 the	depolarization	and	repolarization	of	the	muscle	membrane,	resulting	from	a	single	muscle	 fibre	 action	 potential	 (MFAP).	 Since	 one	 motor	 neuron	 innervates	 many	muscle	 fibres,	 multiple	 MFAPs	 propagate	 near	 simultaneously	 within	 the	 muscle	tissue;	 the	 EMG	 apparatus	 records	 the	 summation	 of	 these	 individual	 MFAPs,	collectively	know	as	a	motor	unit	action	potential.	Since	the	conduction	velocity	of	each	MFAP	is	dependent	on	the	characteristics	of	each	individual	muscle	fibre,	 the	variability	 in	 shape	 and	 temporal	 position	 of	 each	 individual	 MFAP	 at	 the	 active	recording	site	results	 in	a	complex	motor	unit	action	potential	(MUAP)	shape	with	numerous	spikes.	
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	Figure	 7-1.	 The	 sEMG	 signal	 is	 composed	 of	 the	 algebraic	 sum	 of	 all	 MUAPs	(placeholder)	
7.2 EMG	Signal	Processing	The	 EMG	 signal	 can	 be	 represented	 using	 numerous	 signal-processing	techniques,	 often	 classified	 as	 either	 amplitude	 or	 frequency	 analyses.	 The	amplitude	of	the	EMG	signal	represents	the	magnitude	of	neural	drive	to	the	muscle	and	 can	 be	 measured	 using	 several	 different	 techniques.	 Primitive	 amplitude	measures	 involved	 measuring	 peak-to-peak	 amplitude	 of	 a	 single	 MUAP,	 or	manually	 counting	 the	 number	 of	 times	 a	 signal	 surpasses	 a	 given	 threshold;	however,	 the	 development	 of	more	 sophisticated	 computer	 techniques	 allows	 for	more	 in-depth	 measurements.	 Typically,	 raw	 EMG	 signals	 are	 full-wave	 rectified	such	 that	all	values	represent	positive	signal.	Common	methods	of	quantifying	 the	average	 amplitude	 of	 an	 EMG	 signal	 is	 to	 use	 the	 average	 rectified	 value	 (ARV),	where	 the	 absolute	 value	 of	 each	 EMG	 signal	 data	 point	 is	 taken	 over	 a	 specified	time	interval:	
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%&' = 	 1+ ,-. /01234 	where	T	 represents	 time	and	EMG	 represents	 the	EMG	signal.	Alternatively,	a	root	mean	square	(RMS)	calculation	can	be	employed	to	represent	the	amplitude	content	of	the	EMG	signal.	This	method	is	preferred,	as	wave	cancellation	does	not	influence	this	metric	(De	Luca		1979).	The	RMS	calculation	of	the	EMG	signal	is	represented	by	the	following	formula:	
&-5 = 	 1+ ,-.6 /01234 	where	 T	 represents	 time	 and	 EMG	 represents	 the	 EMG	 signal.	 There	 are	 many	physiological	and	methodological	 factors	 that	will	 influence	 the	amplitude	content	of	 the	 EMG	 signal.	 These	 considerations	 will	 be	 discussed	 in	 detail	 later	 in	 this	document.		 Frequency	 analysis	 involves	 the	 transformation	 of	 the	 EMG	 time-domain	signal	 into	 a	 frequency	 spectrum,	 providing	 both	 physiological	 and	 non-physiological	 data.	 Modern	 computing	 technology	 provides	 easy	 access	 to	decomposition	 techniques,	 such	 as	 the	 Fast	 Fournier	 Transform,	 separating	 the	time-domain	EMG	signal	into	separate	sine	and	cosine	waves	of	varying	frequencies.	The	resultant	Fourier	series	can	be	expressed	using	the	following	formula:	
7 / = 892 + 8< cos @A/ + B< sin @A/E<34 	where	 f	 represents	 the	 periodic	 EMG	waveform,	a0/2	represents	 the	 amplitude	 of	any	 DC	 component	 that	 may	 be	 present	 in	 the	 sinusoid	 and	 nωt	 represents	 the	
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angular	 frequency	of	 the	waveform.	The	coefficients	an	and	bn	are	selected	using	a	least	 squares	 method	 so	 that	 the	 summation	 of	 the	 decomposed	 Fourier	 series	provides	the	least	error	when	reconstructing	the	original	waveform.	The	frequency	distribution	 of	 the	 EMG	 data	 can	 be	 obtained	 by	 plotting	 the	 magnitude	 of	 the	Fourier	series	by	each	harmonic	of	ω,	 thereby	creating	the	basis	of	EMG	frequency	analyses.		 Typical	 metrics	 that	 are	 used	 in	 frequency	 analysis	 are	 derived	 from	 the	frequency	 distribution	 of	 the	 EMG	 signal.	 The	 most	 common	 metric	 reported	 in	scientific	 literature	 is	 the	 median	 frequency;	 the	 parameter	 that	 divides	 the	frequency	spectrum	in	 two	equal	halves.	Alternatively,	 the	mean	 frequency	can	he	calculated;	 however,	 this	 metric	 is	 often	 confounded	 by	 outlier	 data	 that	 may	 be	present	 in	 the	 EMG	 signal.	 Peak	 power	 represents	 the	 maximum	 value	 of	 the	frequency	 distribution	 whereas	 the	 total	 power	 represents	 the	 integral	 of	 the	frequency	distribution	curve.	Physiologically,	metrics	from	EMG	frequency	analysis	represent	 changes	 in	 the	 motor	 unit	 action	 potential	 waveform	 and,	 to	 a	 lesser	extent,	 motor	 unit	 firing	 rates.	 Additionally,	 frequency	 analysis	 provides	 non-physiological	 information,	 such	 as	 the	 source	 of	 noise	 contamination	 that	may	 be	present	in	the	recording	environment.		
7.3 Factors	influencing	EMG	signal	A	 recent	 review	 (De	 Luca	 	 1997)	 has	 summarized	 numerous	 physiological	factors	 that	will	 influence	 the	EMG	signal,	 classifying	 factors	 as	 either	 extrinsic	 or	intrinsic.	 Although	 separate	 classifications	 have	 been	 created,	 there	 are	 many	complex	 interactions	 that	 will	 ultimately	 influence	 the	 resultant	 EMG	 signal.	
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Extrinsic	 causative	 factors	 are	 related	 to	 the	 choice	 of	 electrode	 and	 its	configuration	 relative	 to	 the	muscle	 belly,	 whereas	 intrinsic	 factors	 are	 primarily	influenced	 by	 physiological,	 anatomical	 and	 biochemical	 factors.	 Therefore,	 it	 is	important	 that	 proper	 experimental	 set-up	 and	 protocols	 are	 selected	 to	 address	extrinsic	factors,	while	proper	interpretation	of	EMG	data	is	required	to	address	the	intrinsic	factors.	7.3.1 Extrinsic	factors	influencing	the	EMG	signal	One	 of	 the	 most	 important	 considerations	 in	 EMG	 set-up	 is	 the	 choice	 of	electrode	 and	 its	 placement	 on	 the	 muscle	 of	 interest.	 EMG	 electrodes	 can	 be	classified	as	either	surface	electrodes,	those	that	are	attached	using	adhesive	to	the	skin	surface,	or	indwelling	electrodes,	those	that	are	inserted	into	the	muscle	belly,	penetrating	 the	 skin,	 fascia	 and	 other	 subcutaneous	 tissues.	 Regardless	 of	 the	electrode	type,	the	electrode	configuration	must	be	selected	properly	based	on	the	requirements	 of	 the	 experimental	 protocol.	 EMG	 electrode	 configurations	 can	 be	considered	 as	 mono-polar	 or	 bi-polar	 with	 regards	 to	 the	 number	 of	 recoding	surfaces,	and	relative	position	to	the	muscle,	tendon	and	bony	surfaces.		A	 mono-polar	 configuration	 utilizes	 three	 electrodes:	 the	 active	 recording	electrode	 (G1),	 the	 reference	 electrode	 (G2)	 and	 the	 ground.	 The	 G1	 electrode	 is	placed	 on	 the	muscle	 belly,	 whereas	 the	 G2	 electrode	 is	 placed	 on	 an	 electrically	neutral	landmark,	such	as	a	tendon.	The	potential	difference	between	the	G1	and	G2	electrodes	produces	the	resultant	EMG	signal.	The	ground	electrode	utilized	in	the	mono-polar	configuration	is	placed	on	a	bony	surface	that	is	located	far	from	the	G1	and	 G2	 electrodes.	 When	 using	 a	 mono-polar	 configuration	 to	 record	 evoked	
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potentials,	placement	of	the	G1	electrode	should	be	in	close	proximity	to	the	motor	point	 to	maximize	the	quality	of	 the	evoked	potential	and	minimize	the	amount	of	distortion.	Alternatively,	a	bi-polar	EMG	configuration	utilizes	three	electrodes	where	G1	and	G2	are	both	active	recording	electrodes	that	are	placed	on	the	muscle	belly	and	the	ground	electrode	is	placed	on	an	electrically	neutral	landmark,	such	as	a	bone	or	tendon.	The	advantage	to	the	bi-polar	configuration	is	that	it	utilizes	the	differential	characteristics	 of	 the	 amplifier.	 Differential	 amplification	 is	 the	 process	 where	unwanted	“noise”	signals	that	are	common	to	both	G1	and	G2	(termed	the	common	mode	 signal)	 are	 removed	 by	 mathematical	 subtraction.	 Therefore,	 the	 resultant	EMG	signal	can	be	expressed	as:	'9 = % .4 + @FGHI − .6 + @FGHI 	or,	 '9 = % .4 − .6 	where,	 V0	 represents	 the	 EMG	 voltage	 obtained	 from	 differential	 amplification,	 A	represents	the	gain	of	the	amplifier,	G1	and	G2	represents	the	EMG	signal	from	each	active	recording	electrode	and	noise,	represents	unwanted	signal	that	is	common	to	both	G1	and	G2	electrodes.	
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	Figure	7-2.	Differential	amplification	When	 using	 a	 bi-polar	 configuration,	 an	 important	 consideration	 is	 the	interelectrode	distance,	 that	 is,	 the	 separation	between	G1	 and	G2	 electrodes,	 as	 it	affects	 the	 amplitude	 and	 frequency	 content	 of	 the	 resultant	 EMG	 signal.	 As	 the	distance	between	active	 recording	electrodes	 increases,	 the	 time	 in	which	 is	 takes	for	the	propagating	diploe	to	reach	the	G2	electrode	relative	to	G1	will	increase.	This	results	in	a	summated	potential	that	is	larger	in	amplitude,	and	lower	in	frequency	content.	 If	 the	wavelength	 of	 the	 propagating	 dipole	 is	 equal	 to	 that	 of	 the	 inter-electrode	 separation,	 summation	 of	 G1	 and	 G2	 will	 result	 in	 wave	 cancellation.	Conversely,	 if	 the	 inter-electrode	separation	 is	equal	do	 the	dipole	 spacing	 (i.e.,	½	wavelength),	 differential	 amplification	 results	 in	 perfect	 addition	 of	 the	 signal.	Therefore,	 bi-polar	 configurations	 should	 be	 considered	 as	 a	 comb	 filter	 as	 only	specific	frequencies	are	allowed	to	pass.	
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	Figure	7-3.	Interelectrode	separation	and	wave	cancellation	(placeholder)		Form	a	methodological	standpoint,	 interelectrode	spacing	will	 influence	the	pickup	 volume	 of	 the	 EMG	 apparatus.	 Electrodes	 can	 detect	 a	 volume	 of	 active	musculature	that	is	equal	to	½	the	volume	of	a	sphere	with	a	radius	that	is	equal	to	the	 inter-electrode	 spacing.	 Therefore,	 as	 inter-electrode	 spacing	 increases,	 the	magnitude	 of	 the	 detected	 EMG	 signal	 increases	 as	 a	 function	 of	 greater	 detected	active	 musculature.	 Caution	 must	 be	 taken	 when	 selecting	 the	 correct	 inter-electrode	spacing,	as	large	inter-electrode	distances	and	therefore,	pickup	volumes	
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are	associated	with	muscle	cross	talk,	whereas	small	inter-electrode	distances	may	cause	the	formation	of	a	salt	bridge	between	recording	electrodes.	Placement	of	 the	electrode	configuration	 relative	 to	 the	muscle	and	 related	structures	will	 influence	the	EMG	signal	as	well.	Unlike	mono-polar	configurations,	bi-polar	electrodes	should	not	be	placed	in	close	proximity	to	a	motor	point.	Action	potentials	propagate	bi-directionally,	originating	at	the	motor	point;	therefore,	if	G1	and	G2	were	to	straddle	the	motor	point,	wave	cancellation	would	occur,	resulting	in	decreased	 amplitude	 and	 higher-frequency	 content.	 To	 accurately	 quantify	 the	conduction	 velocity	 characteristics	 of	 the	 muscle	 tissue,	 bi-polar	 electrode	configurations	should	be	arranged	such	that	G1	and	G2	electrodes	are	placed	parallel	with	the	muscle	fibre	orientation.	Changes	in	conduction	velocity	will	influence	both	the	amplitude	and	frequency	content	of	the	EMG	signal,	therefore	emphasizing	the	importance	 of	 proper	 and	 consistent	 electrode	 configuration	 set-up	 between	experimental	trials.	An	alternative	to	surface	EMG	electrodes	configurations	is	the	use	of	needle	electrodes.	 Needle	 electrodes	 are	 advantageous	 because	 they	 penetrate	 the	 skin,	subcutaneous	 adiposity	 tissue	 and	 fascia,	 thereby	 decreasing	 the	 effect	 of	 tissue	filtering	and	placing	the	active	recording	surface	closer	to	the	source	of	the	signal.	If	the	needle	electrode	is	used	in	a	mono-polar	configuration,	a	single	wire	is	treaded	through	a	23	–	28	gauge	needle	serves	as	the	G1	electrode,	the	cannula	acts	at	the	G2	electrode	 and	 a	 separate	 ground	 electrode	 is	 placed	 on	 the	 skin	 surface.	 Needle	electrodes	can	be	configured	in	a	bi-polar	arrangement	by	placing	two	wires	within	the	 cannula	 (G1	 and	 G2)	 and	 the	 outer	 surface	 of	 the	 cannula	 acts	 as	 the	 ground.	
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Methodological	 considerations,	 such	 as	 inter-electrode	 separation	 and	 pick-up	volume,	 are	 similar	 between	 surface	 EMG	 measurements	 and	 needle	 EMG	measurement.	Digital	and/or	analogue	 filters	alter	 the	 frequency	content	of	 the	signal	and	therefore,	 can	 be	 used	 to	 suppress	 unwanted	 noise	 contamination	 from	 the	 EMG	signal.	High-pass	filters	are	designed	to	attenuate	the	frequency	component	of	that	signal	 that	 is	 below	 the	 cut-off	 frequency,	 whereas	 low-pass	 filters	 attenuate	frequencies	 that	 fall	above	 the	cut	off	 frequency.	High-	and	 low-pass	 filters	can	be	used	 concurrently,	 creating	 a	 band-pass	 filter	 that	 attenuates	 the	 frequency	component	 of	 the	 signal	 that	 falls	 above	 and	 below	 the	 respective	 cut-off	frequencies.	Typically,	EMG	signals	are	band-pass	 filtered	between	20	Hz	and	500	Hz	 to	 remove	 low-frequency	 movement	 artefacts	 and	 high-frequency	 noise	contamination;	however,	these	parameters	may	change	depending	on	the	research	objectives.	 All	 filters	 will	 cause	 a	 slight	 phase	 delay	 of	 the	 EMG	 signal	 and	furthermore,	changes	 in	cut-off	 frequency	parameters	will	 influence	the	amplitude	and	 latency	 of	 the	 resultant	 signal.	 For	 example,	 decreasing	 the	 high-pass	 cut-off	frequency	will	cause	a	decrease	 in	amplitude	and	 increase	 in	 latency	of	 the	signal.	Conversely,	 increasing	 the	 low-pass	 cut-off	 frequency	will	decrease	 the	amplitude,	latency	and	duration	of	the	resultant	signal.	The	digitization	(analogue-to-digital	conversion;	A/D)	of	the	biological	signal	is	 a	 necessity	 for	 sophisticated	EMG	analyses	 and	 requires	proper	 specification	of	the	 sampling	 rate	 and	 amplitude	 resolution.	 Aliasing	 is	methodological	 error	 that	occurs	 when	 the	 A/D	 sampling	 rate	 is	 too	 low	 to	 capture	 the	 frequency	 content	
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contained	in	the	waveform	of	interest.	For	example,	a	sinusoid	with	a	period	of	10	Hz	that	is	sampled	at	a	frequency	of	1	Hz	will	be	aliased;	the	digitized	signal	would	fail	 to	 capture	 9	 full	 cycles	 of	 the	 original	 waveform,	 effectively	 decreasing	 the	frequency	 of	 the	 digitized	 waveform.	 To	 avoid	 aliasing,	 the	 Nyquist	 sampling	theorem	suggests	 that	sampling	 frequency	should	occur	at	a	rate	 twice	 that	of	 the	highest	frequency	in	the	original	waveform.	This	is	known	as	the	Nyquist	frequency.	Therefore,	if	the	highest	expected	physiologically	valid	frequency	in	the	EMG	signal	is	500	Hz,	 the	Nyquist	 theorem	suggest	 that	 the	sampling	rate	should	be	1000	Hz.	Although	the	Nyquist	 frequency	 is	adequate	 in	representing	the	 frequency	content	of	the	analogue	signal,	even	higher	sampling	frequencies	are	required	to	accurately	digitize	 the	 amplitude	 of	 the	 original	 waveform.	 Given	 that	 computer	 processing	power	 does	 not	 limit	 current	 A/D	 systems,	 sampling	 rates	 of	 at	 least	 4	 times	maximum	expected	biological	frequency	are	suggested.	The	process	of	converting	the	amplitude	value	of	an	EMG	signal	 to	a	digital	value	 is	 known	 as	 quantization.	 Proper	 quantization	 is	 dependent	 on	 the	 input	voltage	range	and	the	resolution	of	 the	A/D	system.	The	 input	voltage	range	of	an	A/D	system	refers	to	the	measurable	voltage-range	of	the	system	and	is	typically	-5	to	5	V	for	an	EMG	set-up.	Computers	represent	the	amplitude	of	the	EMG	signal	 in	binary	 form	 (i.e.,	 0	 s	 and	 1	 s)	 and	 the	 bit	 count	 represent	 the	 number	 of	 binary	combinations	and	consequently,	unique	digital	amplitude	values.	The	resolution	of	the	 A/D	 system	 is	 represented	 by	 2n,	 where	 n	 represents	 the	 number	 of	 bits.	Therefore,	a	4-bit	A/D	system	has	24	=	16	unique	amplitude	values,	whereas	a	12-bit	A/D	 system	 (common	 specification	 for	 current	 systems)	 has	 212	 =	 4096	 unique	
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amplitude	values.	The	gain	of	 the	amplifier	must	be	set	 to	optimize	 the	amplitude	resolution	of	 the	 system.	For	 example,	 consider	 an	 amplified	EMG	waveform	with	peak-to-peak	amplitude	of	5	mV.	If	the	input	range	of	a	12-bit	A/D	system	were	set	to	 -5	 to	 5	 V,	 the	 digital	 signal	 would	 span	 only	 2	 quantization	 levels,	 effectively	creating	a	binary	signal.	Alternatively,	the	same	A/D	system	could	be	used	to	digitize	an	 amplified	waveform	with	 peak-to-peak	 amplitude	 of	 15	 V.	 Since	 the	 amplified	signal	is	larger	than	the	10	V	input	range	of	the	A/D	signal,	the	extremes	(±5	to	±7.5	V)	of	the	signal	would	not	be	acquired,	resulting	in	a	“clipped”	digital	waveform.	The	consensus	 approach	 is	 to	 amplify	 the	 EMG	 signal	 such	 that	 the	 peak-to-peak	amplitude	of	the	waveform	spans	two	thirds	of	the	input	voltage	range.	7.3.2 Intrinsic	factors	influencing	the	EMG	signal	Intrinsic	 factors	 are	 physiological,	 anatomic	 or	 biochemical	 factors	 that	influence	 the	EMG	signal	 and	cannot	be	 controlled	by	experimental	 set-up.	One	of	the	most	prominent	intrinsic	factors	that	must	be	considered	is	the	number	of	active	motor	units	during	a	contraction	at	any	given	time.	During	a	muscular	contraction,	motor	units	are	recruited	in	an	organized	manner	from	smaller	to	larger	motor	units	as	 force	 requirements	 increase.	 This	 phenomenon	 is	 known	 as	 Henneman's	 size	principle	 (Henneman	 et	al.	 1965).	 As	 the	 number	 of	 active	 motor	 units	 increase,	higher	 threshold	 (larger)	 motor	 units	 are	 recruited	 resulting	 in	 inherently	 larger	MUAPs.	Furthermore,	higher	threshold	motor	units	often	fire	at	higher	frequencies,	resulting	 in	 increase	 temporal	 summation	 and	 consequently,	 higher	 amplitude	values.	The	mechanism	in	which	the	neuromuscular	system	modulates	force	output	during	a	contraction	is	rate	coding,	that	 is,	changing	the	frequency	at	which	motor	
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units	 generate	 action	 potentials	 to	 either	 increase	 or	 decrease	 force	 production.	Collectively,	 these	 intrinsic	 physiological	 factors	 will	 modify	 the	 amplitude	 and	frequency	 content	 of	 the	 EMG	 signal	 either	 independently	 or	 through	 combined	mechanisms.	Another	intrinsic	factor	that	will	influence	the	EMG	signal	is	the	fibre	type	of	the	active	muscle	(Kupa	et	al.	1995).	Using	isolated	whole-muscle	preparations	from	rat,	significant	relationships	between	muscle	fibre	type	and	spectral	EMG	measures	were	 observed.	 Muscles	 were	 classified	 using	 histochemical	 techniques	 as	 either	slow	 oxidative,	 fast	 oxidative	 glycolytic	 or	 fast	 glycolytic	 and	 EMG	 signals	 were	obtained	 from	 each	 subset	 during	 electrically	 evoked	 contraction.	 Regression	analysis	 suggests	 that	muscle	 fibre	 type	composition	 is	 related	 to	mean	 frequency	content	and	conduction	velocity;	 therefore,	 the	authors	suggest	 that	EMG	analyses	may	be	utilized	as	a	non-invasive	method	of	fibre	typing.	Given	that	motor	unit	firing	characteristics	were	constant	between	muscle	fibre	types	(because	of	experimenter	controlled	 electrical	 stimulation),	 the	 different	 EMG	 values	 obtained	 during	contractions	 are	 attributed	 to	 differences	 in	 muscle	 metabolic	 activity	 and	membrane	properties	(Kupa	et	al.	1995).	For	example,	the	greater	concentration	of	extracellular	potassium	reported	in	fast	glycolytic	fibres	are	attributed	to	a	slowing	of	 action	potential	 propagation	 and	 a	 decrease	 in	 action	potential	 amplitude	 (Juel		1986).	In	accordance	with	fibre	type,	differences	in	muscle	blood	flow	and	therefore,	metabolite	 accumulation	 has	 been	 shown	 to	 shift	 the	 EMG	 spectrum	 to	 lower	frequencies	 (Mortimer	 et	 al.	 1970).	 Lactic	 acid,	 a	 by-product	 of	 anaerobic	
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metabolism,	causes	a	decrease	in	sarcolemma	pH,	resulting	in	the	decrease	in	mean	fibre	 conduction	 velocity	 and	 subsequent	 shift	 in	 EMG	 frequency	 content.	 Muscle	capillary	perfusion	is	regulated	in	response	to	motor	unit	activation	such	that	blood	flow	meets	the	metabolic	demand	of	the	muscle	(Fuglevand	&	Segal	1997;	Lo	et	al.	2003).	 The	 functional	 unit	 of	 blood	 flow	 control	 within	 a	 muscle	 is	 known	 as	 a	microvascular	 unit,	 consisting	 of	 20	 –	 25	 capillaries	 that	 supply	 50	 –	 100	mm3	 of	muscle	 tissue.	 The	 spatial	 organization	 of	 microvascular	 units	 within	 a	 muscle	 is	widespread,	 such	 that	 muscles	 are	 completely	 perfused	 at	 low	 levels	 of	 muscle	activation.	Therefore,	when	a	motor	unit	 activates	an	adjacent	microvascular	unit,	perfusion	 of	 the	 local	 capillary	 network	 supplies	 blood	 to	 numerous	 non-active	adjoining	motor	units.	Modeling	(Fuglevand	&	Segal	1997)	suggests	that	widespread	arrangements	 constitute	 a	 feed-forward	 mechanism	 whereby	 muscle	 perfusion	occurs	 in	 advance	 of	 motor	 unit	 activation.	 In	 theory,	 this	 facilitates	 oxidative	metabolism	in	the	local	muscle	tissue.	The	 amount	 and	 type	 of	 tissue	 that	 is	 located	 between	 the	 source	 of	 the	myoelectric	 signal	 and	 the	 active	 recording	 electrode	 is	 another	 intrinsic	physiological	factor	that	will	influence	the	resultant	EMG	signal.	Analogous	to	a	low-pass	 filter,	biological	 tissue	absorbs	high-frequency	components	of	 the	EMG	signal	while	low-frequency	components	to	propagate	unimpeded,	therefore	causing	a	left-shift	 in	 the	 overall	 frequency	 distribution.	 Therefore,	 myoelectric	 signals	 that	originate	 deep	 relative	 to	 the	 active	 electrode	 (located	 on	 the	 skin,	 usually)	 are	subject	to	greater	tissue	filtering	in	comparison	to	more	superficial	signals.	The	type	of	 tissue	through	which	the	myoelectric	signal	propagates	will	 influence	the	signal	
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obtained	by	the	active	recording	electrode.	For	example,	adipose	tissue	has	a	lower	density	in	comparison	to	muscle	tissue	and	therefore,	will	cause	a	greater	change	in	the	 frequency	 content	 of	 the	 signal.	 Attempts	 have	 been	made	 to	 normalize	 EMG	signals	 to	 variables,	 such	 as	 sub-cutaneous	 adiposity	 (Nordander	 et	 al.	 2003);	however,	 tissue	 filtering	 remains	 an	 intrinsic	 factor	 that	 will	 confound	 the	 EMG	signal.		 	
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8 APPENDIX	B:	CONSENT	DOCUMENTS			 	
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8.1 Informed	Consent:	Projects	5.1	and	5.2	
Date:	December	7th,	2012	
Project	Title:	The	effects	of	changes	in	cerebral	blood	flow	and	cerebral	alkalosis	on	neuromuscular	function	(EEL	073-1)	
Principal	Investigator:	Dr.	Stephen	Cheung,	Ph.D.	(Professor)	Department	 of	 Kinesiology,	 Brock	 University,	 (905)	 688-5550	 x	 5662,	scheung@brocku.ca		
Principal	Student	Investigator:	Mr.	Geoff	Hartley	(Ph.D.	Candidate)	Faculty	 of	 Applied	 Health	 Sciences,	 Brock	 University,	 (905)	 688-5550	 x	 4901,	geoff.hartley@brocku.ca		
Co-Investigator:	Dr.	Matt	Greenway,	MD,	Ph.D.	(Adjunct	Professor)	Department	of	Kinesiology,	Brock	University,	greenwam@mcmaster.ca		
INVITATION	You	are	invited	to	participate	in	a	study	that	involves	research.	The	purpose	of	 this	 study	 is	 to	 examine	 the	 separate	 and	 combined	 changes	 in	 cerebral	 blood	flow	(CBF)	and	cerebral	alkalosis	 (increased	pH)	on	 the	ability	of	your	muscles	 to	produce	force	(neuromuscular	function).	You	may	participate	in	this	study	if	you	are	a	male,	18-45	years	of	age,	with	no	 history	 of	 fainting,	 seizures	 or	 convulsions,	 and	 respiratory,	 cardiovascular,	neuromuscular	or	kidney	disease.	You	should	not	participate	in	this	research	if	you	are	 a	 smoker	or	have	 allergies	 to	non-steroidal	 anti-inflammatory	drugs	 (NSAIDS;	such	as	advil/naproxen/celecoxib).	You	should	also	not	participate	if	you	have	been	to	an	altitude	of	2500m	(∼8200	ft),	including	flying,	within	the	last	month.	
WHAT’S	INVOLVED	There	 will	 be	 a	 total	 of	 four	 sessions.	 During	 the	 first	 session	 you	 will	 be	screened	 for	 participation	 and	 given	 the	 opportunity	 to	 practice	 the	 experimental	protocols.	During	the	second,	and	fourth	sessions,	blood	flow	to	your	brain	will	be	reduced	 by	 either	 (a)	 drug	 manipulation	 or	 (b)	 and	 (c)	 altering	 your	 breathing	pattern.	 Prior	 to	 each	 session,	 you	 will	 be	 asked	 to	 refrain	 from	 alcohol	 and/or	heavy	exercise	for	24	hours	prior	to	the	trial	and	caffeine	on	the	day	of	the	trial.	
Health	Screening	Before	being	allowed	 to	participate,	you	will	be	asked	 to	 fill	out	a	standard	screening	questionnaire	detailing	your	current	health	status,	use	of	medications	and	history	 of	 lung,	 heart,	 muscle	 and/or	 kidney	 disease.	 This	 will	 be	 done	 with	 Dr.	Matthew	Greenway,	MD,	Ph.D.			
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Screening	Session	In	the	first	session	the	protocols	for	the	study	will	be	explained	in	detail	and	any	questions	regarding	the	study	will	be	answered.	You	will	be	introduced	to	all	of	the	equipment	being	used	during	the	experimental	sessions.	After	this,	you	will	have	your	height,	weight,	 and	 the	 amount	of	 body	 fat	 in	 your	body	measured.	Body	 fat	testing	 will	 be	 performed	 using	 skinfold	 calipers,	 which	 might	 cause	 a	 slight	pinching	sensation,	and	will	be	taken	by	someone	of	the	same	sex	in	a	private	room.	During	 this	 session	you	will	be	asked	 to	 lay	down	quietly	while	blood	 flow	through	your	internal	carotid	artery	(artery	located	in	your	neck)	is	measured	using	Doppler	 ultrasound.	 Similarly,	 blood	 flow	 velocity	 through	 your	 middle	 cerebral	artery	 (artery	 located	within	 your	 skull)	will	 be	measured.	 Previous	 research	 has	found	that	only	70%	of	 individuals	have	blood	vessels	that	can	be	measured	using	Doppler	 ultrasound	 and	 therefore,	 you	 may	 be	 excluded	 from	 the	 study	 if	 good	measurements	are	not	obtainable.	You	may	find	that	the	Doppler	ultrasound	causes	slight	warming	of	the	skin	and/or	a	faint	high-frequency	noise.	Following	 blood	 vessel	 localization,	 you	 will	 preform	 a	 cerebrovascular	reactivity	 test	 to	 carbon	 dioxide.	 During	 this	 test,	 you	will	 breath	 normally	while	carbon	dioxide	levels	are	controlled	at	baseline	(stage	1),	high	carbon	dioxide	(stage	2)	 and	 low	 carbon	 dioxide	 (stage	 3).	 Each	 stage	will	 last	 4	minutes	 and	 cerebral	blood	flow	will	be	measured	throughout	the	duration	of	the	test.	The	 time	commitment	 for	 the	 familiarization	 session	will	 be	approximately	105	min.	
Experimental	Sessions	There	will	be	a	 total	of	 three	experimental	conditions,	given	 in	order	(a)	 to	(c)	and	separated	by	a	minimum	of	three	days,	with	the	following	protocol:		
  
(a) Indomethacin (drug), 
(b) Hyperventilation (low CO2), or 
(c) Hyperventilation (controlled CO2)   
Instrumentation Baseline  Wash-in Experimental  Recovery 
20 min 30 min (a) 90 min or (b) and (c) 15 min 30 min 30 min 	 During	 all	 sessions	 you	will	 be	 required	 to	 dress	 into	 comfortable	 clothing	(loose	fitting	t-shirt,	pants/shorts).	Appropriate	change	rooms	will	be	provided	for	you	 to	 change	 into	 the	 required	 clothing.	 Before	 and	 after	 each	 session,	 you	 will	have	your	body	weight	measured	and	provide	a	small	urine	sample,	which	we	will	use	 to	measure	 your	 hydration	 status.	 A	well-hydrated	 threshold	 of	 ≤1.02	will	 be	used	as	a	cut	off	value.	If	you	are	above	this	threshold,	we	will	ask	you	to	consume	0.5L	 of	water	 and	we	will	 reassess	 your	 hydration	 status	 30	min	 later.	 If	 you	 are	below	the	defined	threshold	at	this	point	we	will	continue	with	the	study.	If	not,	we	
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will	ask	you	to	reschedule	the	session	for	a	later	date	to	ensure	your	safety	during	the	experiments.	
Instrumentation	A	3-lead	electrocardiogram	will	monitor	your	heart	rate.	A	total	of	three	skin	sites	 on	 your	 chest	 and	 abdomen	 will	 be	 shaved	 and	 swabbed	 with	 alcohol	 to	remove	 any	 oils	 or	 dead	 skin	 cells,	 which	 may	 interfere	 with	 recordings.	Subsequently,	electrodes	will	be	attached	to	these	sites	with	adhesive	disks.	Surface	electromyography	(EMG)	will	be	used	to	measure	muscle	activity	in	the	flexor	carpi	radialis	 (FCR)	muscle	(located	 in	your	 forearm).	 Initially,	your	skin	surface	will	be	shaved,	 lightly	 scrubbed	 and	 cleaned	 with	 alcohol.	 The	 motor	 point	 (the	 most	electrically	sensitive	region)	of	the	FCR	will	be	identified	by	placing	an	electrode	to	the	backside	of	 the	 forearm	and	using	a	metal	probe	 to	gently	 stimulate	 the	 front	side	of	the	forearm	(overtop	the	muscle	belly	of	the	FCR)	until	the	point	at	which	the	largest	response	with	the	least	amount	of	voltage	is	identified	(i.e.,	the	motor	point).	During	this	process,	you	will	feel	a	slight	muscle	twitch	sensation.	Two	surface	EMG	electrodes	will	be	placed	on	the	surface	of	 the	skin,	one	over	 the	 top	of	 the	motor	point	and	the	other	on	the	tendon	located	in	the	palm	of	the	hand.	A	similar	ground	electrode	 will	 be	 placed	 on	 the	 back	 of	 the	 hand.	 Application	 of	 the	electrocardiogram	or	EMG	electrodes	may	cause	redness	or	dryness	of	the	skin.	This	can	be	remedied	with	skin	moisturizer.		Your	 blood	 pressure	will	 be	measured	 throughout	 each	 experiment	with	 a	finger	blood	pressure	cuff	placed	on	your	left	hand.	Similarly,	the	oxygen	saturation	of	your	blood	will	be	measured	with	a	pulse	oximeter	placed	over	an	adjacent	finger.	You	will	wear	a	soft	silicone	facemask	to	collect	expired	gases	 for	determining	the	concentration	 of	 oxygen	 and	 carbon	 dioxide.	 A	 computer-controlled	 system	 will	then	adjust	the	gas	levels	appropriately	for	your	next	breath	(during	conditions	“b”	and	“c”,	only).	This	system	allows	the	investigators	to	keep	oxygen	delivery	constant	while	either	“clamping”	carbon	dioxide	levels	at	your	resting	values	(controlled	CO2;	condition	 “c”)	 or	 allowing	 them	 to	 decrease	 naturally	 (low	 CO2;	 condition	 “b”)	throughout	 the	experiment.	You	will	be	permitted	 to	briefly	remove	the	mask	and	drink	 if	you	require	 fluid	during	the	experimental	protocol.	Middle	cerebral	artery	blood	 flow	will	 be	measured	 non-invasively	 by	 a	 transcranial	 Doppler	 ultrasound	probe	placed	next	 to	 your	 ear	 (temporal	window)	on	either	 side	of	 the	head.	You	may	find	that	the	transcranial	Doppler	ultrasound	probe	will	produce	a	faint	high-frequency	noise.	
Baseline	Measures	In	 addition	 to	 above	 measures,	 your	 internal	 carotid	 artery	 and	 brachial	artery	 blood	 flow	 will	 be	 measured	 during	 the	 baseline	 measurement	 period.	Internal	 carotid	 artery	 blood	 flow	 will	 be	 measured	 non-invasively	 using	 a	 high-resolution	ultrasound	machine.	You	will	lie	on	your	back	with	a	slight	side	tilt	of	the	neck	 away	 from	 the	 side	 being	 scanned.	Measurements	will	 be	 taken	 on	 the	 neck	below	 the	 jaw	 line	 over	 the	 duration	 of	 10	 cardiac	 cycles	 (approximately	 60	seconds).	 Similarly,	 brachial	 artery	 blood	 flow	will	 be	measured	while	 you	 lie	 on	
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your	 back	 with	 your	 forearm	 extend	 in	 a	 comfortable	 position.	 Blood	 flow	measurements	will	be	taken	in	the	top	1/3	of	the	upper	arm	over	the	duration	of	10	cardiac	 cycles	 (approximately	 60	 seconds).	 You	 may	 find	 that	 the	 Doppler	ultrasound	causes	slight	warming	of	the	skin	and/or	a	faint	high-frequency	noise.	Following	 blood	 flow	 measures,	 you	 will	 perform	 the	 neuromuscular	 test	battery.	The	neuromuscular	test	battery	is	comprised	of	the	following	four	tests:	
Motor	 Evoked	 Potential	 Recruitment	 Curve.	 The	 motor	 evoked	 potential	(MEP)	 recruitment	 curve	 represents	 the	ability	of	 the	brain	 to	activate	muscles	at	different	 force	 levels.	MEPs	will	be	evoked	using	a	magnetic	coil	placed	overtop	of	your	scalp.	When	activated,	the	magnetic	coil	will	cause	a	very	brief	muscle	twitch	in	your	forearm.	To	identify	the	area	of	stimulation,	a	tight	lycra	cap	will	be	positioned	over	your	head.	Using	high-stimulus	intensity,	the	coil	will	be	systematically	moved	over	your	scalp	to	determine	the	optimal	location	for	eliciting	a	maximal	amplitude	MEP.	Once	the	optimal	position	of	the	coil	is	established,	it	will	be	marked	on	the	cap	to	 ensure	a	 constant	 coil	placement	 throughout	 the	experiment.	To	determine	 the	MEP	 recruitment	 curve,	 stimulator	 intensity	will	 be	 increased	 incrementally	 from	the	smallest	observable	muscle	 twitch	by	10%	increments	until	a	maximal	muscle	twitch	is	observed.	During	this	test,	you	will	feel	an	involuntary	muscle	contraction	in	your	forearm	and	possible	local	heating	at	the	site	of	stimulation.	
H-Reflex.	 The	 H-Reflex	 is	 a	 measure	 of	 the	 sensitivity	 of	 your	 nerves	 that	attach	 the	 spinal	 column	 to	 the	muscle.	 Initially,	 a	maximal	muscle	 twitch	will	 be	elicited	 by	 electrically	 stimulating	 the	 nerve	 in	 your	 forearm.	 Once	 the	 maximal	twitch	is	established,	the	EMG	activity	following	a	5%	maximal	muscle	twitch	will	be	measured.	During	this	test,	you	will	 feel	an	involuntary	muscle	contraction	in	your	forearm.	
Maximal	 Voluntary	 Contraction.	 A	 maximal	 voluntary	 contraction	 (MVC)	represents	 the	 highest	 amount	 of	 force	 that	 you	 can	 produce	 during	 a	 muscular	contraction.	 During	 MVC	 testing,	 the	 your	 right	 arm	 will	 be	 secured	 in	 a	 custom	made	 device	 used	 to	 isolate	 force	 production	 in	 the	 wrist.	 You	 will	 be	 asked	 to	produce	a	5-second	MVC	and	will	be	verbally	encouraged	to	maintain	maximal	force	production	 throughout	 the	 duration	 of	 the	 contraction.	 EMG	 activity	 and	 force	production	 will	 be	 recorded	 throughout	 the	 duration	 of	 your	 MVC.	 During	 the	contraction,	a	maximal	muscle	twitch	will	be	elicited	-	using	identical	techniques	as	mentioned	above	(see	H-Reflex)	-	to	assess	the	capacity	of	your	muscle	to	produce	force,	independent	of	your	brain.	Following	MVC	testing,	you	will	feel	minor	muscle	fatigue.		
Sustained	Maximal	 Voluntary	 Contraction:	 Using	 similar	 procedures	 as	 the	MVC	(see	Maximal	Voluntary	Contraction),	you	will	be	asked	to	perform	a	sustained,	120-second	 MVC.	 You	 will	 be	 verbally	 encouraged	 to	 maintain	 maximal	 force	production	 throughout	 the	 duration	 of	 the	 contraction.	 EMG	 activity	 and	 force	production	will	be	recorded	throughout	the	duration	of	the	sustained	MVC.	During	the	contraction,	a	maximal	muscle	twitch	will	be	elicited	using	identical	techniques	as	mentioned	above	(see	H-Reflex)	to	assess	the	capacity	of	your	muscle	to	produce	
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force,	 independent	 of	 your	 brain.	 Following	 sustained	MVC	 testing,	 you	will	 likely	feel	muscle	fatigue.	
Wash-in	Period		 You	will	 then	perform	the	wash-in	phase	of	either	(a)	 indomethacin	(drug),	(b)	 hyperventilation	 (low	 CO2)	 or	 (c)	 hyperventilation	 (controlled	 CO2)	intervention.	 The	 amount	 of	 oxygen	 in	 your	 bloodstream	 will	 be	 held	 constant	during	 the	 hyperventilation	 protocols	 (conditions	 “b”	 and	 “c”)	 by	 controlling	 the	concentration	 of	 oxygen	 that	 you	 inhale.	 During	 the	 indomethacin	 trials,	 you	will	ingest	 the	 supplement	 and	 wait	 for	 90-minutes	 in	 the	 lab	 before	 further	 testing	(indomethacin	 concentrations	 peak	 in	 the	 bloodstream	 90-minutes	 following	ingestion).	During	this	time	you	may	de-instrument	and	rest	or	work	quietly	in	the	lab.		 During	 the	 hyperventilation	 trials,	 you	 will	 perform	 the	 hyperventilation	protocol	 for	 15-minutes	 before	 further	 testing.	 The	 hyperventilation	 protocol	will	require	you	to	breathe	in	a	controlled	manner	to	reduce	the	concentration	of	carbon	dioxide	 in	 the	 bloodstream.	 During	 condition	 “b”	 (low	 CO2),	 you	will	 see	 a	 graph	that	 continuously	 displays	 your	 carbon	 dioxide	 levels	 in	 reference	 to	 the	 desired	“hypocapnia”	 (or	 low	 carbon	 dioxide)	 level.	 Based	 on	 this	 feedback,	 you	 will	 be	asked	 to	 adjust	 your	 breathing	 rate	 to	maintain	 the	 desired	 carbon	 dioxide	 level.	During	 condition	 “c”	 (controlled	 CO2),	 you	 will	 see	 a	 graph	 that	 continuously	displays	 your	 current	breathing	 rate	 in	 reference	 to	 the	 average	breathing	 rate	of	condition	 “b”.	 Based	 on	 this	 feedback,	 you	will	 be	 asked	 to	 adjust	 your	 breathing	rate	 to	 maintain	 the	 desired	 breathing	 frequency.	 During	 these	 periods	 of	hyperventilation,	you	may	feel	slightly	lightheaded.	
Experimental	Measures	and	Recovery		 Following	the	wash-in	period,	the	experimental	measures	will	be	taken	using	identical	 procedures	 as	 outlined	 in	 the	 Baseline	 Measures	 section.	 During	 the	hyperventilation	trials,	you	will	be	asked	to	maintain	the	hyperventilation	protocol	as	outlined	above	(see	Wash-in	Period).	Once	the	experimental	measures	have	been	collected,	you	will	de-instrument	and	will	be	monitored	for	30	minutes	throughout	recovery	to	ensure	that	you	are	symptom	free	from	any	possible	side	effects	caused	by	the	experimental	protocol.	
POTENTIAL	BENEFITS	AND	RISKS	You	 will	 receive	 $100	 for	 completion	 of	 the	 experiment,	 with	 payment	prorated	for	partial	completion.	Your	participation	in	this	project	will	benefit	society	as	your	data	will	provide	more	information	on	the	influence	of	changes	in	CBF	and	cerebral	 alkalosis	 on	 neuromuscular	 function	 that	 occur	 during	 environmental	stress.	 This	 information	 is	 important	 to	 further	 our	 understanding	 of	 the	 central	(relating	 to	 the	 central	 nervous	 system)	 mechanism	 involved	 in	 neuromuscular	fatigue.	 Furthermore,	 results	 from	 this	 study	 may	 provide	 useful	 information	 for	individuals	who	are	exposed	to	conditions	that	lower	cerebral	blood	flow,	either	in	the	 workplace	 (such	 as	 military	 pilots	 and	 industrial	 workers)	 or	 because	 of	pathology	(such	as	chronic	obstructive	pulmonary	disease).	
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There	may	be	risks	associated	with	participation.	There	will	be	at	 least	two	investigators	 trained	 in	 First	 Aid	 and	 CPR	 present	 for	 each	 experiment.	 The	investigators	will	 contact	 you	 later	 in	 the	 day	 following	 each	 session	 to	 check	 on	your	health	 status.	Depending	on	your	health	 status,	 you	may	be	asked	 to	 consult	with	a	physician.	Experimental	sessions	will	be	terminated	if:	1.	 Heart	rate	has	risen	above	95%	of	its	maximum	(220-age)	for	3	min	2.	 Systolic	blood	pressure	drops	below	80	mmHg	for	more	than	1	min.	3.	 Dizziness	or	nausea	precludes	further	experimentation.	4.	 You	decide,	for	any	reason,	to	end	the	experiment.	5.	 The	investigators	determine	that	the	participant	is	unable/unfit	to	continue.		 Although	 humans	 can	 tolerate	 marked	 hypocapnia	 (hyperventilation)	without	 any	 consequences,	 possible	 effects	 can	 include	 brief	 dizziness,	 a	 drop	 in	blood	 pressure,	 visual	 disturbances,	 and	 anxiety.	 Given	 the	 moderate	 level	 of	hypocapnia	 employed	 in	 the	 proposed	 studies	 (15	mmHg),	 it	 is	 unlikely	 that	 any	serious	 symptoms	 would	 arise.	 In	 the	 event	 of	 persistent	 symptoms,	 the	hyperventilation	protocol	would	be	terminated	immediately,	allowing	for	the	quick	return	to	eucapnia	(normal	carbon	dioxide	levels).	Similarly,	 humans	 can	 tolerate	 hypercapnia	 (high	 CO2)	 without	 any	consequences;	 however,	 possible	 side	 effects	 include	 headache,	 confusion	 and	lethargy.	 Given	 that	moderate	 hypercapnia	will	 be	 used	 in	 this	 study	 (~	 45	 –	 50	mmHg),	 it	 is	 unlikely	 that	 any	 serious	 symptoms	 would	 arise.	 In	 the	 event	 of	persistent	 symptoms,	 the	 facemask	 delivering	 the	 air	 with	 high	 CO2	 would	 be	removed	immediately,	allowing	for	the	quick	return	to	eucapnia.	You	should	not	 ingest	 the	 indomethacin	or	placebo	supplement	 if	you	have	any	dietary	or	religious	restrictions	to	the	consumption	of	animal	by	products	as	the	capsule	(for	indomethacin	and	placebo)	and	contents	of	the	placebo	contain	gelatin.	The	 acute	 oral	 dose	 of	 indomethacin	 poses	 minimal	 risk	 to	 otherwise	 healthy	humans.	 Common	 side	 effects	 include	 gastrointestinal	 distress,	 peptic	 ulcers,	headache,	dizziness	and	changes	in	kidney	function;	however,	this	is	more	typically	associated	with	chronic	dosage.	You	should	not	take	indomethacin	if	you	suffer	from	kidney	disease.	The	 incidence	of	other	adverse	reactions	to	 indomethacin	are	very	low	 (<10%)	 however	 may	 include	 myocardial	 infarction,	 stroke,	 high	 blood	pressure,	excessive	fluid	build-up	in	tissue,	worsening	of	heart	 failure,	drowsiness,	tinnitus	 (ringing	 in	 the	 ears),	 rash,	 Stevens-Johnson	 syndrome	 (skin	 condition),	nausea,	shortness	of	breath,	diarrhoea,	anorexia,	flatulence,	bleeding	in	the	GI	tract,	prolonged	 bleeding	 time,	 anemia	 (decreased	 red	 blood	 cells),	 blood	 dyscrasias	(abnormal	 blood	 composition),	 elevated	 liver	 enzymes,	 hepatitis,	 anaphylactic	reactions,	 bronchospasm	 (inflammation	 of	 the	 airway),	 blurred	 vision,	 decreased	kidney	 function,	 kidney	 failure,	 potassium	 build-up,	 bladder	 inflammation	 and	reversible	 female	 infertility.	 Indomethacin	 should	 not	 be	 taken	 if	 you	 take	 ACE	inhibitors,	 angiotensin	 II	 receptor	 blockers,	 beta-blockers,	 cholestyramine,	corticosteroids,	 cyclosporine,	 CYP2C9	 Inhibitors	 (fluconazole,	 voriconazole),	digoxin,	 diuretics,	 drugs	 that	 increase	 the	 risk	 of	 bleeding	 (anticoagulants,	 anti-
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platet	drugs,	heapin),	lithium,	methotrexate,	potassium	supplements,	or	probenecid.	You	should	not	take	indomethacin	if	you	take	the	herbal	supplement	Ginkgo.	To	 counteract	 any	 stomach	 issues	 (such	 as	 ulcers,	 acid	 reflux,	 nausea,	 etc.)	caused	 by	 the	 indomethacin	 drug,	 you	 will	 be	 given	 a	 150	 mg	 antacid	 (such	 as	Zantac).	 Although	 negative	 reactions	 to	 antacids	 are	 extremely	 rare,	 side	 effects	include	 headache,	 general	 discomfort,	 dizziness,	 drowsiness,	 insomnia,	 vertigo,	blurred	 vision,	 mental	 confusion,	 agitation,	 depression,	 and	 hallucinations,	reversible	 involuntary	 movement	 disorders,	 low	 heart	 rate,	 high	 heart	 rate,	irregular	 heart	 beats,	 constipation,	 diarrhea,	 nausea/vomiting,	 abdominal	discomfort/pain,	 hepatitis,	 kidney	 disease,	 muscle	 and	 joint	 pain,	 blood	 count	changes,	rash,	chest	pain,	bronchospasm,	fever,	anaphylaxis,	edema,	and	low	blood	pressure.	 Zantac	 should	 not	 be	 taken	 if	 you	 take	 diazepam,	 lidocaine,	 phenytoin,	propranolol	 and	 theophylline,	 triazolam,	 midazolam,	 ketoconazole,	 atazanavir,	delaviridine,	 or	 gefitnib.	 Zantac	may	 cause	 drowsiness	 therefore,	 you	 should	 take	precaution	when	driving	(etc.)	following	the	trial).	Although	single	pulse	TMS	is	regarded	as	safe,	 the	greatest	acute	risk	 is	the	occurrence	 of	 seizures	 and	 syncope.	 Other	 adverse	 effects	 of	 single	 pulse	 TMS	include	local	discomfort	at	the	site	of	stimulation,	muscle	soreness	caused	by	muscle	contraction,	local	heating	and	temporary	hearing	cause	by	the	rapid	deformation	of	the	 magnetic	 coils,	 headaches,	 dizziness,	 neck	 stiffness	 and	 pain.	 These	 risks	 are	more	prevalent	in	repetitive	TMS,	unlike	the	single	pulse	protocols	employed	in	the	proposed	studies.	On	rare	occasions,	you	may	be	unable	to	tolerate	electrical	stimulation	of	the	nerve.	Although	this	stimulation	is	not	painful,	the	nervous	system	may	perceive	it,	however	brief,	as	harmful.	As	a	result,	there	is	a	potential	for	fainting.	However,	you	will	always	be	lying	down	during	testing	and	therefore,	the	chance	of	injury	will	be	remote.	Furthermore,	 the	 use	 of	 skin	 fold	 calipers	 may	 cause	 a	 slight	 pinching	sensation.	 All	 skin	 fold	 measurements	 will	 be	 taken	 in	 a	 private	 room	 by	 an	investigator	of	the	same	sex.		Adhesive	 tape	 used	 to	 secure	 instrumentation	 may	 cause	 slight	 skin	irritation,	 although	 this	adverse	 response	 is	 rare.	Alternative	adhesive	options	are	available	if	needed.			Additionally,	 alcohol	 and	 light	 scrubbing	 used	 for	 prepping	 the	 skin	 for	electrocardiogram	 and	 EMG	 recordings	 may	 leave	 the	 skin	 red	 and	 irritated.	Moisturizer	will	be	provided	in	such	cases.		Razors	used	for	shaving	skin	area	prior	to	 electrocardiogram	 and	 EMG	 electrode	 placement	 may	 cause	 minor	 bleeding,	although	in	the	history	of	EMG	use	in	the	lab	this	has	not	occurred.	If	bleeding	does	occur,	appropriate	first	aid	will	be	administered.	The	 finger	 cuff	 used	 for	 measuring	 blood	 pressure	 during	 the	 tests	 may	induce	some	discolouring	at	the	end	of	the	finger	during	measurements.	This	is	not	harmful	 to	 you	 and	 colouring	will	 return	within	 1-2	min	 after	 removing	 the	 cuff.	
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Some	 people	 also	 report	 numbness	 of	 the	 finger	 with	 measurement	 durations	exceeding	1-2	hrs.	Upon	removal	of	the	cuff,	this	feeling	will	subside	within	1-2	min.	
CONFIDENTIALITY	Access	to	this	data	will	be	restricted	to	Dr.	Cheung	and	the	principal	student	investigator,	Mr.	Geoff	Hartley.	Your	participation	will	remain	confidential.	The	data	collected	 from	 this	 investigation	 will	 be	 kept	 secured	 on	 the	 premises	 of	 the	Department	of	Kinesiology	at	Brock	University	in	Dr.	Cheung’s	office	or	laboratory,	and	will	not	be	accessed	by	anyone	other	than	the	listed	investigators.		Investigators	will	 require	 disclosure	 of	 your	 name	 and	 contact	 information	(phone,	 email),	 and	 therefore	 your	 participation	 is	 not	 anonymous	 during	 the	conduct	 of	 the	 research.	All	 participants	will	 have	 their	 names	 removed	 from	any	data.	 The	 master	 list	 matching	 participants	 to	 data	 will	 be	 kept	 by	 Dr.	 Cheung	and/or	Mr.	Hartley,	and	will	be	destroyed	following	the	publication	of	data.	All	information	you	provide	is	considered	confidential;	your	name	will	not	be	included	 or,	 in	 any	 other	 way,	 associated	 with	 the	 data	 collected	 in	 the	 study.	Furthermore,	because	our	interest	is	in	the	average	responses	of	the	entire	group	of	participants,	you	will	not	be	identified	individually	in	any	way	in	written	reports	of	this	research.		
VOLUNTARY	PARTICIPATION	Participation	 in	 this	 study	 is	 voluntary.	 If	 you	 wish,	 you	 may	 decline	 to	answer	any	questions	or	participate	 in	 any	 component	of	 the	 study.	 Furthermore,	you	may	decide	to	withdraw	from	this	study	at	any	point	in	time.	Participation,	non-participation,	 or	withdrawal	 from	 the	 study	will	 not	 affect	 your	 standing	at	Brock	University.	
PUBLICATION	OF	RESULTS	Results	of	this	study	may	be	published	in	professional	journals	and	presented	at	 conferences,	 but	 your	 personal	 information	 and	 participation	 will	 remain	confidential.	 Approximately	 one	month	 after	we	 finish	 testing	 all	 participants,	we	will	be	provided	you	with	a	summary	of	your	own	results	and	also	the	overall	group	results.	 Feedback	 about	 this	 study	 will	 be	 available	 from	 Dr.	 Stephen	 Cheung	(stephen.cheung@brocku.ca,	905-688-5550x5662).	
CONTACT	INFORMATION	AND	ETHICS	CLEARANCE	If	 you	 have	 any	 questions	 about	 this	 study	 or	 require	 further	 information,	please	 contact	 the	 Principal	 Investigator	 or	 the	 Faculty	 Supervisor	 (where	applicable)	 using	 the	 contact	 information	 provided	 above.	 This	 study	 has	 been	reviewed	and	received	ethics	clearance	through	the	Research	Ethics	Board	at	Brock	University	(12-167).	 If	you	have	any	comments	or	concerns	about	your	rights	as	a	research	 participant,	 please	 contact	 the	 Research	 Ethics	 Office	 at	 (905)	 688-5550	Ext.	3035,	reb@brocku.ca.		
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CONSENT	FORM	I	agree	to	participate	in	this	study	described	above.	I	have	made	this	decision	based	on	 the	 information	 I	 have	 read	 in	 the	 Information-Consent	 Letter.	 I	 have	 had	 the	opportunity	 to	 receive	 any	 additional	 details	 I	 wanted	 about	 the	 study	 and	understand	that	I	may	ask	questions	in	the	future.	I	understand	that	I	may	withdraw	this	consent	at	any	time.	My	participation,	non-participation,	or	withdrawal	from	the	study	will	not	affect	my	standing	at	Brock	University.			Participant	Name:	 		 	 	Participant	Signature:	 			
Date:			
	 	 	 	Principal	Investigator	Signature:	 	
(Dr.	Stephen	Cheung,	PhD)	
Date:			
Study	Physician	Signature:	 	
(Dr.	Matt	Greenway,	MD,	PhD)	
Date:				Thank	 you	 for	 your	 assistance	 in	 this	 project.	 Please	 keep	 a	 copy	 of	 this	 form	 for	your	records.		 	
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8.2 Informed	Consent:	Project	5.3	
Date:	April	29,	2013	
Project	Title:	The	effects	of	changes	in	cerebral	blood	flow	and	cerebral	alkalosis	on	neuromuscular	function	(EEL	073-1)	
Principal	Investigator:	Dr.	Stephen	Cheung,	Ph.D.	(Professor)	Department	 of	 Kinesiology,	 Brock	 University,	 (905)	 688-5550	 x	 5662,	scheung@brocku.ca		
Principal	Student	Investigator:	Mr.	Geoff	Hartley	(Ph.D.	Candidate)	Faculty	 of	 Applied	 Health	 Sciences,	 Brock	 University,	 (905)	 688-5550	 x	 4901,	geoff.hartley@brocku.ca		
Co-Investigator:	Dr.	Matt	Greenway,	MD,	Ph.D.	(Adjunct	Professor)	Department	of	Kinesiology,	Brock	University,	greenwam@mcmaster.ca	
INVITATION	You	are	invited	to	participate	in	a	study	that	involves	research.	The	purpose	of	 this	 study	 is	 to	 examine	 the	 separate	 and	 combined	 changes	 in	 cerebral	 blood	flow	(CBF)	and	cerebral	alkalosis	 (increased	pH)	on	 the	ability	of	your	muscles	 to	produce	 force	 (neuromuscular	 function)	 with	 high	 body	 temperature	(hyperthermia).	You	may	participate	in	this	study	if	you	are	a	male,	18-45	years	of	age,	with	no	 history	 of	 fainting,	 seizures	 or	 convulsions,	 and	 respiratory,	 cardiovascular,	neuromuscular	or	kidney	disease.	You	should	not	participate	in	this	research	if	you	are	 a	 smoker	or	have	 allergies	 to	non-steroidal	 anti-inflammatory	drugs	 (NSAIDS;	such	as	advil/naproxen/celecoxib).		
WHAT’S	INVOLVED	There	will	 be	 a	 total	 of	 four	 sessions.	 During	 the	 first	 session	 you	will	 be	screened	 for	 participation	 and	 given	 the	 opportunity	 to	 practice	 the	 experimental	protocols.	During	the	second,	third	and	fourth	sessions,	blood	flow	to	your	brain	will	be	reduced	by	either	increasing	your	body	temperature,	your	breathing	rate,	and/or	drug	manipulation.	Prior	to	each	session,	you	will	be	asked	to	refrain	from	alcohol	and/or	heavy	exercise	for	24	hours	prior	to	the	trial	and	caffeine	on	the	day	of	the	trial.	
Health	Screening	Before	being	allowed	 to	participate,	you	will	be	asked	 to	 fill	out	a	standard	screening	questionnaire	detailing	your	current	health	status,	use	of	medications	and	history	 of	 lung,	 heart,	 muscle	 and/or	 kidney	 disease.	 This	 will	 be	 done	 with	 Dr.	Matthew	Greenway,	MD,	Ph.D.		
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Screening	Session	In	the	first	session	you	will	be	introduced	to	all	of	the	equipment	being	used	during	the	experimental	sessions.	The	protocols	for	each	session	will	be	explained	in	detail	 and	any	questions	 regarding	 the	 study	will	 be	answered.	 Subsequently,	 you	will	have	your	height,	weight,	and	the	amount	of	body	fat	measured.	Body	fat	testing	will	 be	 performed	 using	 skinfold	 calipers,	 which	 might	 cause	 a	 slight	 pinching	sensation,	and	will	be	taken	by	someone	of	the	same	sex	in	a	private	room.	During	 this	 session	you	will	be	asked	 to	 lay	down	quietly	while	blood	 flow	through	 your	 internal	 carotid	 artery	 (located	 in	 your	 neck)	 is	 measured	 using	Doppler	 ultrasound.	 Similarly,	 blood	 flow	 velocity	 through	 your	 middle	 cerebral	artery	 (located	within	 your	 skull)	will	 be	measured.	 Previous	 research	 has	 found	that	only	70%	of	 individuals	have	blood	vessels	 that	can	be	 imaged	using	Doppler	ultrasound	 and	 therefore,	 you	 may	 be	 excluded	 from	 the	 study	 if	 viable	measurements	are	not	obtainable.	The	 time	commitment	 for	 the	 familiarization	 session	will	 be	approximately	90	min.	
Experimental	Sessions	There	 will	 be	 a	 total	 of	 three	 experimental	 sessions,	 administered	 in	 a	random	order,	with	the	following	protocol:	
	
Instrumentation	During	all	sessions	you	will	be	required	to	dress	only	 in	a	pair	of	your	own	shorts.	 You	 will	 have	 your	 internal	 temperature	 measured	 by	 wearing	 a	 rectal	temperature	 sensor.	 The	 rectal	 sensor	 consists	 of	 a	 very	 thin	 and	 flexible	 plastic	tube	that	you	insert	15	cm	beyond	the	anus.	Before	and	after	each	session	you	will	have	your	body	weight	measured	and	provide	a	small	urine	sample,	which	we	will	use	to	measure	your	hydration	status.	A	euhydration	threshold	of	≤1.02	will	be	used	as	a	cut	off	value.	If	you	are	above	this	threshold,	we	will	ask	you	to	consume	0.5	L	of	water	and	we	will	reassess	your	hydration	status	30	min	later.	If	you	are	below	the	defined	threshold	at	this	point,	we	will	continue	with	the	study.	 If	not,	we	will	ask	you	 to	 reschedule	 the	 session	 for	 a	 later	 date	 to	 ensure	 your	 safety	 during	 the	experiments.	When	adequate	hydration	is	confirmed,	you	will	be	asked	to	put	on	a	liquid	conditioning	garment	(LCG),	which	is	similar	to	a	diving	wet	suit	lined	with	flexible	PVC	tubing	throughout.	The	garment	consists	of	a	pair	of	pants	and	a	jacket,	leaving	the	head,	hands,	and	feet	uncovered.	During	the	experiments,	hot	(46°C)	water	will	be	run	through	the	tubing	to	 increase	core	temperature.	Skin	temperature	sensors	
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will	 be	 taped	 onto	 the	 body	 surface	 at	 the	 following	 sites:	 forehead,	 abdomen,	forearm,	 hand,	 quads,	 shin	 and	 foot,	 which	 will	 be	 used	 to	 calculate	 mean	 skin	temperature.	A	3-lead	electrocardiogram	will	monitor	your	heart	rate.	A	total	of	three	skin	sites	 on	 your	 chest	 and	 abdomen	 will	 be	 shaved	 and	 swabbed	 with	 alcohol	 to	remove	 any	 oils	 or	 dead	 skin	 cells,	 which	 may	 interfere	 with	 recordings.	Subsequently,	 electrodes	will	 be	 attached	 to	 these	 sites	with	 adhesive	 disks.	 Your	blood	pressure	will	 be	measured	 throughout	 each	experiment	with	 a	 finger	blood	pressure	 cuff	 placed	 on	 your	 left	 hand.	 Similarly,	 the	 oxygen	 saturation	 of	 your	blood	will	be	measured	with	a	pulse	oximeter	placed	over	an	adjacent	 finger.	You	will	 wear	 a	 soft	 silicone	 facemask	 to	 collect	 expired	 gases	 for	 determining	 the	concentration	of	oxygen	and	carbon	dioxide.	Every	time	you	exhale,	the	air	will	pass	through	a	gas	analyzer	to	measure	the	concentration	of	expired	oxygen	and	carbon	dioxide	 from	 your	 lungs.	 A	 computer	 controlled	 system	 will	 then	 adjust	 the	 gas	levels	 appropriately	 for	 your	 next	 breath.	 This	 system	 allows	 the	 investigators	 to	keep	 oxygen	 delivery	 constant	 under	 normal	 or	 hypoxic	 conditions	 while	 either	“clamping”	 carbon	 dioxide	 levels	 at	 your	 resting	 values	 (controlled)	 or	 allowing	them	 to	 fluctuate	naturally	 (uncontrolled)	 throughout	 the	experiment.	You	will	be	permitted	 to	 briefly	 remove	 the	 mask	 and	 drink	 if	 you	 require	 fluid	 during	 the	experimental	 protocol.	 Middle	 cerebral	 artery	 blood	 flow	 will	 be	 measured	 non-invasively	 by	 a	 transcranial	 Doppler	 ultrasound	 probe	 placed	 next	 to	 your	 ear	(temporal	window)	on	either	side	of	the	head.		Surface	electromyography	(EMG)	will	used	to	measure	muscle	activity	in	the	flexor	 carpi	 radialis	 (FCR)	 muscle	 (located	 in	 your	 forearm).	 Initially,	 your	 skin	surface	will	be	shaved,	 lightly	abraded	and	cleansed	with	alcohol.	The	motor	point	(the	most	 electrically	 sensitive	 region)	 of	 the	 FCR	will	 be	 identified	 by	 placing	 an	electrode	to	the	backside	of	the	forearm	and	using	a	metal	probe	to	gently	stimulate	the	front	side	of	the	forearm	(overtop	the	muscle	belly	of	the	FCR)	until	the	point	at	which	 the	 largest	 response	with	 the	 least	 amount	 of	 voltage	 is	 identified	 (i.e.,	 the	motor	point).	Two	 surface	EMG	electrodes	will	 be	placed	on	 the	 skin	 surface,	 one	overtop	the	motor	point	and	the	other	on	the	tendon	located	in	the	palm	of	the	hand.	A	similar	ground	electrode	will	be	placed	on	 the	back	of	 the	hand.	This	apparatus	will	remain	connected	throughout	the	duration	of	the	experiment.	
Baseline	Measures	In	addition	to	the	above	measures,	your	internal	carotid	artery	and	brachial	artery	 blood	 flow	 will	 be	 measured	 during	 the	 baseline	 measurement	 period.	Internal	 carotid	 artery	 blood	 flow	 will	 be	 measured	 non-invasively	 using	 a	 high-resolution	ultrasound	machine.	You	will	lie	on	your	back	with	a	slight	side	tilt	of	the	neck	 away	 from	 the	 side	 being	 scanned.	Measurements	will	 be	 taken	 on	 the	 neck	below	 the	 jaw	 line	 over	 the	 duration	 of	 10	 cardiac	 cycles	 (approximately	 60	seconds).	 Similarly,	 brachial	 artery	 blood	 flow	will	 be	measured	while	 you	 lie	 on	your	 back	 with	 your	 forearm	 extended	 in	 a	 comfortable	 position.	 Blood	 flow	measurements	will	be	taken	in	the	top	1/3	of	the	upper	arm	over	the	duration	of	10	cardiac	cycles	(approximately	60	seconds).		
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Following	 blood	 flow	 measures,	 you	 will	 perform	 the	 neuromuscular	 test	battery.	The	neuromuscular	test	battery	is	comprised	of	the	following	four	tests:	
Motor	 Evoked	 Potential	 Recruitment	 Curve.	 The	 motor	 evoked	 potential	(MEP)	 recruitment	 curve	 represents	 the	ability	of	 the	brain	 to	activate	muscles	at	different	 force	 levels.	MEPs	will	be	evoked	using	a	magnetic	 coil	placed	over	your	scalp.	When	activated,	the	magnetic	coil	will	cause	a	very	brief	muscle	twitch	in	your	forearm.	To	identify	the	area	of	stimulation,	a	tight	lycra	cap	will	be	positioned	over	your	head.	Using	high	stimulus	intensity,	the	coil	will	be	systematically	moved	over	your	scalp	to	determine	the	optimal	location	for	eliciting	a	maximal	amplitude	MEP.	Once	the	optimal	position	of	the	coil	is	established,	it	will	be	marked	on	the	cap	to	ensure	a	constant	coil	placement	throughout	the	experiment.	To	determine	the	MEP	recruitment	 curve,	 stimulator	 intensity	 will	 be	 increased	 incrementally	 from	 the	smallest	 observable	 muscle	 twitch	 by	 10%	 increments	 until	 a	 maximal	 muscle	twitch	is	observed.	
H-Reflex.	 The	 H-Reflex	 is	 a	 measure	 of	 the	 sensitivity	 of	 your	 nerves	 that	attach	 the	 spinal	 column	 to	 the	muscle.	 Initially,	 a	maximal	muscle	 twitch	will	 be	elicited	 by	 electrically	 stimulating	 the	 nerve	 in	 your	 forearm.	 Once	 the	 maximal	twitch	is	established,	the	EMG	activity	following	a	5%	maximal	muscle	twitch	will	be	measured.	
Maximal	 Voluntary	 Contraction.	 A	 maximal	 voluntary	 contraction	 (MVC)	represents	 the	 highest	 amount	 of	 force	 that	 you	 can	 produce	 during	 a	 muscular	contraction.	During	MVC	testing,	your	right	arm	will	be	secured	 in	a	custom	made	device	used	to	isolate	force	production	in	the	wrist.	You	will	be	asked	to	produce	a	5-second	 MVC	 and	 will	 be	 verbally	 encouraged	 to	 maintain	 maximal	 force	production	 throughout	 the	 duration	 of	 the	 contraction.	 EMG	 activity	 and	 force	production	 will	 be	 recorded	 throughout	 the	 duration	 of	 your	 MVC.	 During	 the	contraction,	a	maximal	MEP	will	be	elicited	using	identical	techniques	as	mentioned	above	(see	Motor	Evoked	Potential	Recruitment	Curve)	to	assess	the	capacity	of	your	muscle	to	produce	force,	independent	of	your	brain.	
Sustained	Maximal	 Voluntary	 Contraction:	Using	 similar	 procedures	 as	 the	MVC	(see	Maximal	Voluntary	Contraction),	you	will	be	asked	to	perform	a	sustained,	120-second	 MVC.	 You	 will	 be	 verbally	 encouraged	 to	 maintain	 maximal	 force	production	 throughout	 the	 duration	 of	 the	 contraction.	 EMG	 activity	 and	 force	production	will	be	recorded	throughout	the	duration	of	the	sustained	MVC.	During	the	 contraction,	 a	 maximal	 MEP	 will	 be	 elicited	 using	 identical	 techniques	 as	mentioned	 above	 (see	 Motor	 Evoked	 Potential	 Recruitment	 Curve)	 to	 assess	 the	capacity	of	your	muscle	to	produce	force,	independent	of	your	brain.		Following	 the	 neuromuscular	 test	 battery,	 you	 will	 then	 perform	 the	 One	Touch	Stockings	of	Cambridge	cognitive	test.	During	this	test,	you	will	be	shown	two	displays	 each	 containing	 three	 coloured	 balls.	 There	 is	 a	 row	 of	 numbered	 boxes	along	the	bottom	of	the	screen.	An	investigator	will	demonstrate	how	the	balls	in	the	lower	 display	 can	 be	 moved	 to	 copy	 the	 pattern	 presented	 in	 the	 upper	 display.	You	must	then	complete	three	further	problems	and	determine	(without	moving	the	
	 	 	
	
169	
balls)	 how	many	ball	moves	 are	 required	 to	duplicate	 the	pattern,	 then	 touch	 the	appropriate	box	at	the	bottom	of	the	screen	to	indicate	your	response.	
Wash-in	Period	You	will	then	perform	the	wash-in	phase	of	the	placebo	(visits	“a”	and	“b”)	or	the	 indomethacin	 (visit	 “c”).	 The	 wash-in	 period	 will	 last	 90	 minutes	 allowing	sufficient	 time	 for	 the	drug	concentration	to	peak	 in	 the	blood	stream.	During	this	time,	you	may	de-instrument	and	rest	or	work	quietly	in	the	lab.	
Experimental	Measures	and	Recovery	Following	the	wash-in	period,	you	will	be	subjected	to	(a)	uncontrolled	CO2	+	high	 core	 temperature,	 (b)	 uncontrolled	 CO2	 +	 high	 core	 temperature	 or	 (c)	uncontrolled	CO2	+	high	core	temperature	+	indomethacin	(drug)	condition.	During	each	condition,	your	core	temperature	will	be	passively	increased	from	baseline	to	39.5°C	 or	 until	 thermal	 tolerance.	 Experimental	 measures	 (identical	 to	 baseline	measures)	 will	 be	 conducted	 when	 your	 core	 temperature	 is	 ~38.5°C	(approximately	 half	 way	 through	 the	 passive	 heating	 protocol)	 and	 ~39.5°C	 (or	whenever	 you	 feel	 unbearably	 hot).	 Following	 the	 attainment	 of	 each	 core	temperature	 target	 (38.5°C	 or	 39.5°C),	 the	 LCG	will	 be	 adjusted	 to	maintain	 your	core	temperature	for	the	duration	of	the	experimental	measurements.	Once	all	 the	experimental	 measures	 have	 been	 collected,	 you	 will	 de-instrument	 and	 will	 be	monitored	for	30	minutes	throughout	recovery	to	ensure	that	you	are	symptom	free	from	any	possible	side	effects	caused	by	the	experimental	protocol.	
POTENTIAL	BENEFITS	AND	RISKS	You	 will	 receive	 $100	 for	 completion	 of	 the	 experiment,	 with	 payment	prorated	for	partial	completion.	Your	participation	in	this	project	will	benefit	society	as	you	data	will	provide	more	 information	on	the	 influence	of	changes	 in	CBF	and	cerebral	 alkalosis	 on	 neuromuscular	 function	 that	 occur	 during	 environmental	stress.	 This	 information	 is	 important	 to	 further	 our	 understanding	 of	 the	 central	(relating	 to	 the	 central	 nervous	 system)	 mechanism	 involved	 in	 neuromuscular	fatigue.	 Furthermore,	 results	 from	 this	 study	 may	 provide	 useful	 information	 for	individuals	who	are	subjected	to	hypoxia	and	hyperthermia,	either	in	the	workplace	(such	 as	military	 pilots	 and	 industrial	workers)	 or	 because	 of	 pathology	 (such	 as	chronic	obstructive	pulmonary	disease).	There	may	be	risks	associated	with	participation.	There	will	be	at	 least	two	investigators	 trained	 in	 First	 Aid	 and	 CPR	 present	 for	 each	 experiment.	 The	investigators	will	 contact	 you	 later	 in	 the	 day	 following	 each	 session	 to	 check	 on	your	health	 status.	Depending	on	your	health	 status,	 you	may	be	asked	 to	 consult	with	a	physician.	Experimental	sessions	will	be	terminated	if:	
1. Heart rate has risen above 95% of its maximum (220-age) for 3 min. 
2. Core temperature rises above 39.5 oC. 
3. Systolic blood pressure drops below 80 mmHg for more than 1 min. 
4. Dizziness or nausea precludes further experimentation. 
5. You decide, for any reason, to end the experiment. 
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6. The investigators determine that the participant is unable/unfit to continue. Symptoms	 that	 may	 be	 experienced	 with	 hyperthermia	 include:	 discomfort,	sweating,	 flushing	 and	 redness	 in	 the	 face	 and	 body,	 thirst,	 loss	 of	 fine	 motor	coordination	due	to	sweating,	minor	mental	confusion,	dizziness,	nausea	and	a	drop	in	 blood	 pressure.	 Given	 the	 level	 of	 hyperthermia	 employed	 in	 the	 proposed	studies	(≤	39.5°C),	it	is	unlikely	that	any	serious	symptoms	would	arise.	In	event	of	persistent	 symptoms,	 the	 heating	 protocol	 would	 be	 terminated	 immediately,	followed	by	the	circulation	of	cold	water	through	the	LCGs,	allowing	for	the	return	to	normothermic	levels.		On	 rare	 occasion,	 you	 may	 unable	 to	 tolerate	 electrical	 stimulation	 of	 the	nerve.	Although	this	stimulation	is	not	painful,	the	nervous	system	may	perceive	it,	however	brief,	as	harmful.	As	a	result	there	is	a	potential	for	fainting.	However,	you	will	always	be	in	a	supine	position	during	testing	and	therefore,	the	chance	of	injury	will	be	remote.	Furthermore,	 the	 use	 of	 skin	 fold	 calipers	 may	 cause	 a	 slight	 pinching	sensation.	 All	 skin	 fold	 measurements	 will	 be	 taken	 in	 a	 private	 room	 by	 an	investigator	 of	 the	 same	 sex.	 Adhesive	 tape	 used	 to	 secure	 instrumentation	 may	cause	 slight	 skin	 irritation,	 although	 this	 adverse	 response	 is	 rare.	 Alternative	adhesive	options	are	available	if	needed.			Additionally,	 alcohol	 and	 light	 abrasion	 used	 for	 prepping	 the	 skin	 for	electrocardiogram	 and	 EMG	 recordings	 may	 leave	 the	 skin	 red	 and	 irritated.	Moisturizer	can	be	provided	in	such	cases.		Razors	used	for	shaving	skin	area	prior	to	 electrocardiogram	 and	 EMG	 electrode	 placement	 may	 cause	 minor	 bleeding,	although	in	the	history	of	EMG	use	in	the	lab	this	has	not	occurred.	If	bleeding	does	occur,	appropriate	first	aid	will	be	administered.	The	 finger	 cuff	 used	 for	 measuring	 blood	 pressure	 during	 the	 tests	 may	induce	some	colouring	at	the	distal	end	of	the	finger	during	measurements.	This	is	not	harmful	to	you	and	colouring	will	return	within	1-2min	after	removing	the	cuff.	Some	 people	 also	 report	 numbness	 of	 the	 finger	 with	 measurement	 durations	exceeding	1-2hrs.	Upon	removal	of	the	cuff,	this	feeling	subsides	within	1-2min.	
Indomethacin	You	should	not	 ingest	 the	 indomethacin	or	placebo	supplement	 if	you	have	any	dietary	or	religious	restrictions	to	the	consumption	of	animal	byproducts	as	the	capsule	(for	indomethacin	and	placebo)	and	contents	of	the	placebo	contain	gelatin.	The	 acute	 oral	 dose	 of	 indomethacin	 poses	 minimal	 risk	 to	 otherwise	 healthy	humans.	 Common	 side	 effects	 include	 gastrointestinal	 distress,	 peptic	 ulcers,	headache,	dizziness	and	changes	in	kidney	function;	however,	this	is	more	typically	associated	with	chronic	dosage.	You	should	not	take	indomethacin	if	you	suffer	from	kidney	disease.	The	 incidence	of	other	adverse	reactions	to	 indomethacin	are	very	low	 (<10%)	 however	 may	 include	 myocardial	 infarction,	 stroke,	 high	 blood	pressure,	excessive	fluid	build-up	in	tissue,	worsening	of	heart	 failure,	drowsiness,	tinnitus	 (ringing	 in	 the	 ears),	 rash,	 Stevens-Johnson	 syndrome	 (skin	 condition),	nausea,	shortness	of	breath,	diarrhoea,	anorexia,	flatulence,	bleeding	in	the	GI	tract,	
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prolonged	 bleeding	 time,	 anemia	 (decreased	 red	 blood	 cells),	 blood	 dyscrasias	(abnormal	 blood	 composition),	 elevated	 liver	 enzymes,	 hepatitis,	 anaphylactic	reactions,	 bronchospasm	 (inflammation	 of	 the	 airway),	 blurred	 vision,	 decreased	kidney	 function,	 kidney	 failure,	 potassium	 build-up,	 bladder	 inflammation	 and	reversible	 female	 infertility.	 Indomethacin	 should	 not	 be	 taken	 if	 you	 take	 ACE	inhibitors,	 angiotensin	 II	 receptor	 blockers,	 beta-blockers,	 cholestyramine,	corticosteroids,	 cyclosporine,	 CYP2C9	 Inhibitors	 (fluconazole,	 voriconazole),	digoxin,	 diuretics,	 drugs	 that	 increase	 the	 risk	 of	 bleeding	 (anticoagulants,	 anti-platet	drugs,	heapin),	lithium,	methotrexate,	potassium	supplements,	or	probenecid.	You	should	not	take	indomethacin	if	you	take	the	herbal	supplement	Ginkgo.	To	 counteract	 any	 stomach	 issues	 (such	 as	 ulcers,	 acid	 reflux,	 nausea,	 etc.)	caused	 by	 the	 indomethacin	 drug,	 you	 will	 be	 given	 a	 150	 mg	 antacid	 (such	 as	Zantac).	 Although	 negative	 reactions	 to	 antacids	 are	 extremely	 rare,	 side	 effects	include	 headache,	 general	 discomfort,	 dizziness,	 drowsiness,	 insomnia,	 vertigo,	blurred	 vision,	 mental	 confusion,	 agitation,	 depression,	 and	 hallucinations,	reversible	involuntary	movement	disorders,	low	heart	rate,	high	hear	rate,	irregular	heart	 beats,	 constipation,	 diarrhea,	 nausea/vomiting,	 abdominal	 discomfort/pain,	hepatitis,	 kidney	 disease,	 muscle	 and	 joint	 pain,	 blood	 count	 changes,	 rash,	 chest	pain,	 bronchospasm,	 fever,	 anaphylaxis,	 edema,	 and	 low	 blood	 pressure.	 Zantac	should	 not	 be	 taken	 if	 you	 take	 diazepam,	 lidocaine,	 phenytoin,	 propranolol	 and	theophylline,	 triazolam,	 midazolam,	 ketoconazole,	 atazanavir,	 delaviridine,	 or	gefitnib.	Zantac	may	cause	drowsiness	therefore,	you	should	take	precaution	when	driving	(etc.)	following	the	trial).	
Rectal	Probe	When	 performed	 in	 a	 healthcare	 setting,	 insertion	 of	 the	 rectal	 probe	 is	 a	controlled	act	as	set	out	in	the	Regulated	Health	Professions	Act.	While	this	act	does	not	extend	 to	research	outside	of	a	healthcare	setting,	you	should	be	aware	of	 the	following	potential	risks:	Insertion	of	the	rectal	probe	can	stimulate	the	vagus	nerve	which	can	cause	slowing	of	the	heart	rate	which	may	lead	to	fainting.	This	is	more	likely	to	happen	if	you	have	a	low	resting	heart	rate.	Perforation	 of	 the	 bowel	 can	 lead	 to	 peritonitis,	 a	 serious	 infection	 of	 the	abdominal	cavity.	You	should	not	participate	in	this	research	if	you	are	pregnant,	are	under	the	influence	of	alcohol	or	other	sedating	substances	(tranquilizers,	sleeping	pills,	street	drugs)	or	have	any	history	of	fainting	or	heart	disease.	Rectal	 probes	 are	 classified	 as	 “single	 use	 only”;	 however,	 are	 commonly	used	 multiple	 times	 by	 one	 individual	 without	 any	 issue.	 The	 rectal	 probe	 may	become	slightly	discoloured	during	the	sterilization	process	that	occurs	between	lab	visits.	 Therefore,	 you	 will	 be	 given	 a	 new	 rectal	 probe	 upon	 request	 or	 if	 an	investigator	 believes	 that	 the	 integrity	 of	 the	 probe	 has	 been	 damaged	 in	 the	sterilization	process.	
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Transcranial	Magnetic	Stimulation	Although	single	pulse	TMS	is	regarded	as	safe,	 the	greatest	acute	risk	 is	the	occurrence	 of	 seizures	 and	 syncope	 (occurring	 in	 1	 of	 every	 1000	 studies).	 Other	adverse	 effects	 of	 single	 pulse	 TMS	 include	 local	 discomfort	 at	 the	 site	 of	stimulation,	 muscle	 soreness	 caused	 by	 muscle	 contraction,	 local	 heating	 and	temporary	hearing	cause	by	the	rapid	deformation	of	the	magnetic	coils,	headaches,	dizziness,	neck	stiffness	and	pain.	These	risks	are	more	prevalent	in	repetitive	TMS,	unlike	the	single	pulse	protocols	employed	in	the	proposed	studies.	
CONFIDENTIALITY	Access	to	this	data	will	be	restricted	to	Dr.	Cheung	and	the	principal	student	investigator,	Mr.	Geoff	Hartley.	Your	participation	will	remain	confidential.	The	data	collected	 from	 this	 investigation	 will	 be	 kept	 secured	 on	 the	 premises	 of	 the	Department	of	Kinesiology	at	Brock	University	in	Dr.	Cheung’s	office	or	laboratory,	and	will	not	be	accessed	by	anyone	other	than	the	listed	investigators.		Investigators	will	 require	 disclosure	 of	 your	 name	 and	 contact	 information	(phone,	 email),	 and	 therefore	 your	 participation	 is	 not	 anonymous	 during	 the	conduct	 of	 the	 research.	All	 participants	will	 have	 their	 names	 removed	 from	any	data.	 The	 master	 list	 matching	 participants	 to	 data	 will	 be	 kept	 by	 Dr.	 Cheung	and/or	Mr.	Hartley,	and	will	be	destroyed	following	the	publication	of	data.	All	information	you	provide	is	considered	confidential;	your	name	will	not	be	included	 or,	 in	 any	 other	 way,	 associated	 with	 the	 data	 collected	 in	 the	 study.	Furthermore,	because	our	interest	is	in	the	average	responses	of	the	entire	group	of	participants,	you	will	not	be	identified	individually	in	any	way	in	written	reports	of	this	research.		
VOLUNTARY	PARTICIPATION	Participation	 in	 this	 study	 is	 voluntary.	 If	 you	 wish,	 you	 may	 decline	 to	answer	 any	 questions	 or	 participate	 in	 any	 component	 of	 the	 study.	 Further,	 you	may	decide	to	withdraw	from	this	study	at	any.	Participation,	non-participation,	or	withdrawal	from	the	study	will	not	affect	your	standing	at	Brock	University.	
PUBLICATION	OF	RESULTS	Results	of	this	study	may	be	published	in	professional	journals	and	presented	at	 conferences,	 but	 your	 personal	 information	 and	 participation	 will	 remain	confidential.	 Approximately	 one	month	 after	we	 finish	 testing	 all	 participants,	we	will	 provide	 you	with	 a	 summary	 of	 your	 own	 results	 and	 also	 the	 overall	 group	results.	 Feedback	 about	 this	 study	 will	 be	 available	 from	 Dr.	 Stephen	 Cheung	(stephen.cheung@brocku.ca,	905-688-5550x5662).	
CONTACT	INFORMATION	AND	ETHICS	CLEARANCE	If	 you	 have	 any	 questions	 about	 this	 study	 or	 require	 further	 information,	please	 contact	 the	 Principal	 Investigator	 or	 the	 Faculty	 Supervisor	 (where	applicable)	 using	 the	 contact	 information	 provided	 above.	 This	 study	 has	 been	reviewed	and	received	ethics	clearance	through	the	Research	Ethics	Board	at	Brock	
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University	(12-271).	 If	you	have	any	comments	or	concerns	about	your	rights	as	a	research	 participant,	 please	 contact	 the	 Research	 Ethics	 Office	 at	 (905)	 688-5550	Ext.	3035,	reb@brocku.ca.		
CONSENT	FORM	I	agree	to	participate	in	this	study	described	above.	I	have	made	this	decision	based	on	the	information	I	have	read	in	the	Information-Consent	Letter.	I	have	had	the	 opportunity	 to	 receive	 any	 additional	 details	 I	 wanted	 about	 the	 study	 and	understand	that	I	may	ask	questions	in	the	future.	I	understand	that	I	may	withdraw	this	consent	at	any	time.	My	participation,	non-participation,	or	withdrawal	from	the	study	will	not	affect	my	standing	at	Brock	University.		Please	note	that	Dr.	Greenway	is	responsible	only	for	your	health	screening	and	the	prescription	of	Indomethacin	(drug).	All	other	experimental	procedures	are	the	responsibility	of	the	Principal	Investigator	(Dr.	Cheung).		Participant	Name:	 		 	 	Participant	Signature:	 			
Date:			
	 	 	 	Principal	Investigator	Signature:	 	
(Dr.	Stephen	Cheung,	PhD)	
Date:			
Study	Physician	Signature:	 	
(Dr.	Matt	Greenway,	MD,	PhD)	
Date:				Thank	 you	 for	 your	 assistance	 in	 this	 project.	 Please	 keep	 a	 copy	 of	 this	 form	 for	your	records.		
